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ABSTRACT 
 
Pustular Psoriasis (PP) is a rare and disabling inflammatory skin disorder that is 
associated with an increased risk of plaque psoriasis (also known as psoriasis vulgaris or 
PV). While two PP genes (IL36RN and AP1S3) have been discovered, less than 30% of 
the patients harbour mutations at these loci. Moreover, the main genetic determinant for 
PV susceptibility (HLA-Cw6) is not associated with pustular psoriasis. Therefore, the 
molecular pathogenesis of PP and its clinical association with psoriasis vulgaris remain 
poorly understood. The aim of the current study was to investigate these issues through 
the genetic analysis of extended patient resources.    
In the first part of the project, the possibility that the IL36RN gene may 
contribute to PV susceptibility was investigated by sequencing the gene in 363 
unrelated individuals and re-analysing genome-wide association data. No enrichment of 
IL36RN mutations was detected in cases compared to controls, indicating that this 
important genetic determinant of pustular psoriasis does not confer PV susceptibility. 
Next, the CARD14 locus, which had been previously associated with familial 
PV, was screened in an extended pustular psoriasis cohort (n=205). This revealed a low-
frequency p.Asp176His allele that caused constitutive CARD14 activation in functional 
assays and was significantly enriched in Asian cases compared to controls (P=8.4x10-5; 
OR=6.4).  
In the final part of the project, 17 patients affected by pustular psoriasis were 
exome-sequenced to identify genes that may be involved in the pathogenesis of the 
disease and contribute to the increased PV risk. Stepwise filtering of variant profiles 
uncovered a number of candidate genes that were followed-up in European (n=92) and 
               VI 
Asian validation cohorts (n=94). Although extensive genetic heterogeneity was 
observed, a number of loci deserving further investigation were defined, paving the way 
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1 INTRODUCTION 
1.1 The skin immune system 
The skin is the largest organ in humans. As the outermost layer of the body, it 
confers protection against environmental insults such as temperature changes, solar 
radiation and most importantly, infections. Therefore, the skin has a very important 
immune function (Burns and Breathnach, 2010).  
 
1.1.1 The structure of skin 
The skin consists of two layers, the epidermis and the dermis. Each is further 
divided into sub-layers and contains distinct cell types that are essential to its function. 
 
1.1.1.1 The epidermis 
The epidermis is a rapidly self-renewing tissue that forms the outermost portion 
of the skin. While keratinocytes are its major constituent, immune (e.g. Langerhans 
cells and CD8+ T lymphocytes), sensory (e.g. Merkel cells), and melanin producing 
cells (melanocytes) are also present (Burns and Breathnach, 2010). 
The epidermis encompasses a number of cell layers. The stratum corneum is the 
outermost part of the tissue and is composed of corneocytes (anucleated, nonviable 
keratinocytes) surrounded by a lipid-rich intercellular matrix. This layer represents a 
physical barrier, which protects against water loss, and most importantly, against 
invading microorganisms (Burns and Breathnach, 2010).  
The stratum basale is a single layer of continuously proliferating stem cells from 
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where keratinocytes migrate to the stratum corneum. To further support the structure of 
the epidermis, these basal keratinocytes adhere to each other via their desmosomes and 
to the basement membrane via hemi-desmosomes (Burns and Breathnach, 2010). 
The stratum spinosum and stratum granulosum are both composed of multiple 
cell layers. While the keratinocytes of the stratum spinosum contain thick bundles of 
intermediate filaments in their cytoplasm, the cells of the stratum granulosum are 
characterized by the presence of keratohyalin granules that contain profillaggrin and 
promote the cross-linking of keratin fibres (Burns and Breathnach, 2010). 
Of note, the skin of the palms and soles includes an additional layer (stratum 
lucidum) between the stratum granulosum and stratum corneum (Burns and Breathnach, 
2010).   
 
1.1.1.2 The dermis 
The dermis lies beneath the epidermis and can be divided into papillary dermis, 
which is the uppermost layer, and reticular dermis, which lies between the papillary 
dermis and the subcutaneous fat, and hosts blood vessels, hair follicles, and sweat 
glands (Burns and Breathnach, 2010). The dermis mostly consists of fibroblasts and 
matrix components such as collagen and elastin, which provide mechanical support 
(Nestle et al., 2009; Szun et al., 2014). However, capillary and lymphatic vessels are 
also present and allow the infiltration of immune cells such as dendritic cells, CD4+ T 
lymphocytes, macrophages and mast cells (Nestle et al., 2009; Szun et al., 2014). 
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1.1.2 Innate immunity 
The protective role of the immune system is mediated by two interconnected 
arms known as innate and adaptive immunity. While the former promotes a rapid first 
reaction to pathogens, the latter ensures that the response is antigen-specific           
(Table 1.1.2; Figure 1.1.2). 
The skin, as an anatomical barrier is the first line of protection against invading 
organisms. If a pathogen penetrates through this layer, it will be recognized by germline 
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Table 1.1.2. Comparison between the innate and adaptive immune system 
 Innate immunity Adaptive immunity 
Response time Immediate  Immediate or delayed response  
(3-5 days) 
Memory Absent Present 
Receptors Pattern recognition 
receptors (PRRs) are 
encoded in the germline 
 
B-cell and T-cell receptors are 
generated by somatic 
recombination  
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Figure 1.1.2. Comparison between innate and adaptive immune cells 
Innate immunity is mediated by diverse cell populations including dendritic cells, 
macrophages, mast cells, natural killer cells, granulocytes (basophils, eosinophils and 
neutrophils), as well as soluble factors (complement proteins). The adaptive immune 
response consists of B and T (CD4+ and CD8+) lymphocytes, as well as antibodies. 
There is also an overlap between the two systems, since natural killer T cells and γ δ T 
cells can function at the interface between innate and adaptive immunity.  
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1.1.2.1 Innate immune receptors 
The innate immune system senses pathogens by recognizing evolutionally 
conserved structures called pathogen-associated molecular patterns (PAMPs). These are 
detected by three families of pattern recognition receptors (PRRs): Toll-like receptors, 
RIG-I-like receptors, and NOD-like receptors. The latter can also recognize endogenous 
molecules called damage associated molecular patterns (DAMPs), which are released 
following cell death or tissue injury (Takeuchi and Akira, 2010). 
Toll-like receptors (TLRs) are a family of evolutionary conserved, membrane-
bound proteins located on the cell surface (TLR- 1, 2, 4, 5, 6, 10), or within the 
endosomal membrane (TLR- 3, 7, 8, 9) (Takeuchi and Akira, 2010). TLRs recognize 
features present on the cell walls (e.g. lipoproteins and peptidoglycan recognized by 
TLR-2) or outer membrane (e.g. lipopolysaccharide recognised by TLR-4) of 
pathogens, as well as viral nucleic acids (recognized by TLR-3, -7, -8) (Takeuchi and 
Akira, 2010). Once bound to a ligand, TLRs activate two different pathways known as 
the MyD88-dependent and the TRIF-dependent cascade, leading to the production of 
inflammatory cytokines and type I interferons (IFNs), respectively (Takeuchi and Akira, 
2010). 
RIG-I-like receptors (RLRs) are localized in the cytoplasm and their main role is 
the sensing of viral nucleic acids. RLRs include RIG-I (retinoic acid inducible gene-I), 
MDA-5 (Melanoma Differentiation-Associated protein 5), and LGP2 (laboratory of 
genetics and physiology 2). In the N terminal end of RIG-I and MDA5, there are two 
caspase activation and recruitment domains (CARDs) that mediate signaling toward 
downstream proteins (Wu and Chen, 2014). While RIG-I detects small (<1kB) 
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molecules, MDA5 recognizes longer (>2kB) RNA fragments (Wu and Chen, 2014).  
Upon nucleic acid binding, both receptors signal through the mitochondrial antiviral 
signaling protein (MAVS), leading to IRF3, IRF7, and NF-κB activation, plus the 
production of type I IFNs and pro-inflammatory cytokines (Takeuchi and Akira, 2010; 
Wu and Chen, 2014). As to LGP2, it is involved in MDA5 signaling, and acts as a 
positive regulator (Wu and Chen, 2014). 
Nucleotide oligomerisation domain (NOD)-like receptors (NLRs) are soluble 
cytoplasmic proteins that detect cytoplasmic pathogens and danger-associated 
molecules released during cell damage or stress (Fukata et al., 2009). NLRs can be 
classified in two main families: NOD (nucleotide-binding oligomerization domain) and 
NALP (NACHT, LRR and PYD containing) proteins (Mathews et al., 2008). Although 
they share two common domains (the ligand-sensing LRRs and the NACTH 2 
oligomerization motif), NOD and NALP proteins differ in their effector regions. Upon 
ligand recognition, NOD receptors activate NF-κB and mitogen-activated protein kinase 
(MAPK) signaling, while NALPs cause the cleavage of the pro-inflammatory 
precursors pro-IL-1β and pro-IL-18 into their mature forms, through activation of 
caspase 1 and 5 (Mathews et al., 2008; Fukata et al., 2009).  
 
1.1.2.2 Innate immune cells in the skin 
Keratinocytes are the most abundant cell type in the epidermis, and besides their 
aforementioned role in providing structural support to the skin; they have key functions 
in pathogen detection and host defense. Due to the diverse receptors they express, they 
are able to sense bacterial components trough their TLRs, as well as viral and fungal 
molecules through NLRs (Nestle et al., 2009). As a result, keratinocytes can release a 
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wide-range of cytokines (e.g. IL-1, IL-6, IL-10, IL-18, IL-22 and IL-36), antimicrobial 
peptides (e.g. LL-37 and β-defensin), and chemokines (e.g. IL-8), and attract further 
immune cells to the site of infection (Nestle et al., 2009).  
 Macrophages are professional antigen presenting cells, which express major 
histocompatibility complex (MHC) molecules as well as co-stimulatory ligands such as 
CD80 and CD86 (Bendke and Stenzl, 2010). Macrophages also express many PRRs that 
allow them to sense both pathogen- and damage-associated signals (Szun et al., 2013). 
Once activated, macrophages produce pro-inflammatory cytokines (e.g IL-1) and 
chemokines (e.g Chemikine C-C ligand motif 3, CCL3) (Foss et al., 1999). At the same 
time, macrophages can terminate inflammation by engulfing apoptotic cells (Szun et al., 
2013).  
Under normal conditions, macrophages are the most abundant hematopoietic 
cell type in the skin (Szun et al., 2013). They can be either tissue-resident or bone 
marrow-derived monocytes/macrophages, but the functional difference between these 
two populations remains to be understood (Szun et al., 2013; Nestle et al., 2009). What 
is known is that skin-resident macrophages originate from the yolk sac and are able to 
self-renew during inflammation, while bone marrow-derived monocytes circulate 
through the skin and transport antigens to the lymph nodes (Pasparakis et al., 2014). 
Dendritic cells (DC) are antigen-presenting cells that can migrate to skin 
draining lymph nodes upon pathogen recognition (Szuen et al., 2013). They are a 
diverse population and are able to sense numerous microbial components through their 
pattern recognition receptors (Heath and Carbone, 2013). 
Under homeostatic conditions, Langerhans cells are the only DCs that reside 
within the basal and suprabasal layers of the epidermis, where they can induce Th17 cell 
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responses (Heath and Carbone, 2013), but also activate regulatory T cells. The dermal 
DC population is more heterogeneous and can be subdivided into different subsets, 
based on the expression of surface markers such as Langerin, CD103 and CD11b. These 
DCs are involved in capturing dead cells, presenting antigens to CD4+ and CD8+ T-
cells and inducing Th17 cell response (Heath and Carbone, 2013).   
Mast cells are located in the dermis, close to the blood vessels and are involved 
in wound healing, as well as Th2 activation (Szun et al., 2013).  
Innate lymphoid cells (ILC) are a recently characterized group of effector cells, 
which originate from the lymphoid lineage but do not express antigen-specific surface 
receptors. They are typically found within barrier surfaces (gut, lung and skin) and can 
be classified into different subtypes (ILC1, ILC2 and ILC3) according to the cytokine 
they produce and the immune cells they activate (Pasparakis et al., 2014). Under 
homeostatic conditions, all three subsets are found in skin, where they contribute to the 
fight against intracellular pathogens (ILC1), helminths (ILC2), and extracellular 
bacteria (ILC3) (Pasparakis et al., 2014). 
Neutrophils are also important mediators of early immune responses, but they 
are not found in the dermis or the epidermis, under homeostatic conditions (Nestle et al., 
2009). 
 
1.1.3 Adaptive immunity 
The adaptive immune system is composed of specialized lymphocytes, which 
can mount a humoral or T-cell mediated response. This reaction is antigen-specific and 
is typically stronger after an initial encounter with a pathogen (immunological memory) 
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(Luckheeram et al., 2012).  
T lymphocytes are activated following the presentation of antigens to their T-
cell receptor (TCR) and the engagement of co-stimulatory surface molecules such as 
CD28. Depending on the cytokine milieu, activated CD4+ T cells differentiate into Th 
subsets (e.g. Th1, Th2 and Th17 lymphocytes) or regulatory T-cells (T-regs)  (Figure 
1.1.3) (Luckheeram et al., 2012). While the former can activate additional immune cells 
(e.g. Th1 lymphocytes act on macrophages and NK-cells; Th2 cells act on B-cells), T-
regs modulate the function of the aforementioned T-cell populations through the 
production of IL-10 (Luckheeram et al., 2012). 
CD8+ T cells are also known as cytotoxic-lymphocytes, as they kill infected and 
malignant cells, upon recognising intra-cellular peptides presented by MHC molecules 
(Luckheeram et al., 2012).  
B-lymphocytes express the B cell receptor on their surface and mediate the 
humoral adaptive response. They can become activated through T-cell dependent or T-
cell independent mechanisms, leading to the secretion of antibodies into the 
bloodstream (Egbuniwe et al., 2015). B-lymphocytes can also act as antigen presenting 
cells and produce cytokines (Egbuniwe et al., 2015).  
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Figure 1.1.3. The differentiation of helper T cells is driven by cytokines 
The presence of Interleukin 2 (IL-2) and transforming growth factor-beta (TGF-β), and 
the transcription factor FOXP3 drives the differentiation of the naïve CD4+ T cells into 
Treg cells, while the cytokines IL-4 and TGF-β, and transcription factors T-bet and 
GATA3 induce Th1 and Th2 cell development, respectively. These three T-cell subsets 
regulate the immune response to self, foreign, as well as tumor antigens. IL-6, IL-21, 
TGF-β, and the transcription factor RORγt were implicated in the development of Th17 




               12 
1.1.3.1 Skin-resident adaptive immune cells 
The skin contains twice as many T-cells as peripheral blood (Nestle et al., 2009). 
In the basal- and suprabasal-layer of the epidermis, the majority of these are CD8+ α β 
T lymphocytes (Nestle et al., 2009).  In contrast, the dermal population is a mixture of 
CD8+ and CD4+ T cells, which are found in proximity of the dermal-epidermal 
junction (Nestle et al., 2009). The migration of these cells into the skin is mediated by 
the cutaneous lymphocyte antigen (CLA) (Egbuniwe et al., 2015). 
There are also “innate-like” populations present in the skin, including γ δ T cells 
and NKT cells found within the dermis. While the exact role of the γ δ T cells remains 
poorly defined, they were shown to produce several growth factors (e.g. fibroblast 
growth factor 9 and keratinocyte growth factor) implicated in wound healing. They can 
also release antimicrobial molecules such as cathelicidins (Nestle et al., 2009).   
NKT cells share features with natural killer cells and T-lymphocytes. Upon 
activation, they can produce both Th1 (IFN γ) and Th2 (IL-4) cytokines (Nestle et al., 
2009). 
B-cells are rarely seen in the skin under physiological conditions, and it is still 
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Figure 1.1.3.1. Skin-resident immune cells 
The human skin hosts both innate and adaptive immune cells. Those found in the 
epidermis are keratinocytes, Langerhans cells and CD8+ cytotoxic T cells. The dermis 
contains a more complex immune population, including dendritic cells (dermal DCs 
and, under inflammatory conditions, plasmacytoid DCs), several T cell subsets 
(memory T lymphocytes γδ T cells, NKT cells and under inflammatory conditions 
activated CD4+ T lymphocytes), macrophages and mast cells. Figure retrieved from 
Nestle et al., 2009. 
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1.2 Psoriasis and related phenotypes 
Psoriasis is a non-contagious, chronic inflammatory skin disorder that has a 
profound impact on the well-being of patients. It is estimated to affect up to 2% of the 
population worldwide, but is more prevalent in ethnic groups of European descent 
(Crow, 2012; Nestle et al., 2009). Disease onset shows two peaks, which occur at 15-30 
(early onset disease) and 50-60 years of age (late onset disease) (Mahil et al., 2015). In 
either case, males and females are affected with equal frequency.  
Triggering factors include trauma (e.g, piercings, tattoos), sunburn, chemical 
irritants, as well as systemic drugs (e.g. β blockers) and non-steroidal anti-inflammatory 
agents (Boehncke and Schön, 2015). 
Several clinical variants of psoriasis have been described. These can co-exist or 
more often appear in succession. The subtypes that are relevant to this study are 
described below. 
 
1.2.1 Psoriasis vulgaris and non-pustular disease variants  
1.2.1.1 Clinical features 
The most common type of psoriasis is psoriasis vulgaris (PV, also known as 
chronic plaque psoriasis), which accounts for 90% of disease cases (Boehncke and 
Schön, 2015). PV is characterized by the appearance of red, scaly plaques, which 
mostly affect symmetric sites on the elbows, knees, scalp, and intergluteal cleft (Figure 
1.2.1.1.1). Around 50% of patients also have nail involvement and experience pitting 
and nail-plate thickening (Boehncke and Schön, 2015). 
At the histological level, psoriatic lesions show epidermal hyperplasia and 
increased vascularity of the dermis (Griffiths and Barker, 2007). An inflammatory 
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infiltrate is also present. It includes abundant numbers of CD4+ and CD8+ T cells, 
which underscores the importance of adaptive immunity in disease pathogenesis 
(Griffiths and Barker, 2007).  
The impact of psoriasis can be compounded by several important co-morbidities. 
Approximately 25% of PV patients suffer from a sero-negative form of joint 
inflammation, known as psoriatic arthritis (Naldi and Gambini, 2007). This causes pain 
and swelling in/around the joints, which can lead to occupational or functional disability 
(Naldi and Gambini, 2007; Boehncke and Schön, 2015).  
Epidemiological studies have also demonstrated an increased prevalence of 
cardiovascular disease among psoriatic patients, which is especially noticeable among 
individuals suffering from severe PV (Ryan and Kirby, 2015). Furthermore, PV is 
associated with hypertension and type II diabetes (Ryan and Kirby, 2015). Whether or 
not the association of PV with cardiovascular comorbidities is caused by concurrent 
systemic inflammation remains to be understood (Ryan and Kirby, 2015). 
Less frequent and site-specific subtypes of the disease include flexural (inverse) 
psoriasis, which presents with shiny, red, scale-free lesions in intertriginous sites 
(Griffiths and Barker, 2007; Crow, 2012) (Figure 1.2.1.1.2). Acute forms also exist, 
such as guttate psoriasis, which is characterised by papule eruptions that mostly affect 
the trunk (Griffiths and Barker, 2007; Crow, 2012).  
Finally, the most severe non-pustular variant of the disease is erythrodermic 
psoriasis. This is a rare condition (it accounts for less than 3% of psoriasis cases) that 
can be triggered by severe sunburn, use of systemic steroids or excessive alcohol intake 
(Thomas et al., 2014). It presents with widespread exfoliation, severe itching, pain, and 
fiery redness of the skin (Thomas et al., 2014; Griffiths and Barker, 2007). These 
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symptoms are associated with systemic involvement and increased heart rate. 
Erythrodermic psoriasis is therefore a potentially life-threatening condition, so that 
disease flares require urgent hospitalisation (Griffiths and Barker, 2007; Crow, 2012) 

















Figure 1.2.1.1.1. Clinical presentation of PV 
The incidence (80-90% of psoriasis cases) and typical presentation of PV are shown in 
the lower panels. The anatomical regions that are most often affected are represented as 
red spots in the upper panel diagram. Figure originally published in Crow, 2012; and 
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Figure 1.2.1.1.2. Clinical presentation of further non-pustular variants of psoriasis 
The incidence (% of psoriasis cases) and typical presentation of gutatte psoriasis, 
inverse psoriasis, and Erytrodermic psoriasis are shown in the lower panel, while the 
most often affected anatomical regions are represented as red areas in the upper panel 







               19 
1.2.1.2 Immune pathogenesis 
The effort to elucidate the immune pathogenesis of psoriasis has mostly been 
focused on PV, so that very little is known about the aetiology of other non-pustular 
disease variants.  
PV was first considered to be a Th1-mediated disease, as cytokines like IL-2, IL-
12 and IFN-γ, were found to be highly expressed in psoriatic plaques compared to 
normal skin (Griffiths and Barker, 2007; Di Cesare et al., 2009).  However, more recent 
studies have convincingly implicated the IL-23/Th17 axis in disease pathogenesis (Di 
Cesare et al., 2009; Boehncke and Schön, 2015). Over-activation of the latter immune 
pathway is thought to drive the progression of psoriasis vulgaris and account for most of 
the phenotypic features of psoriatic plaques (Figure 1.2.1.2).  
The cross-talk between innate and the adaptive immunity, which is mediated by 
cytokines such as TNF-α and interleukin 1, is also important in disease pathogenesis 
(Boehncke and Schön, 2015).  
Following injury, keratinocytes produce antimicrobial peptides (e.g. β-defensins 
and cathelicidin) that contribute to host defense by killing pathogens (e.g. Escherichia 
coli) and activating further immune cells (Morizane et al., 2012). One such molecule, 
the cathelicidin LL37, plays a key role in the establishment of psoriatic lesions. In fact, 
the most likely initial step in disease pathogenesis is the binding of host nucleic acid 
(originating from stressed or dying cells) by LL37. The resulting DNA/LL37 complexes 
aberrantly stimulate plasmacytoid dendritic cells (pDCs), a population of DC expressing 
TLR-7 and TLR-9, which infiltrates the dermis under inflammatory conditions 
(Morizane et al., 2012; Ganguly et al., 2009; Lande et al., 2007). The subsequent release 
of interferon α by pDCs activates myeloid DCs, which in turn promote the 
differentiation of CD4+ T-cells into Th1 and Th17 subsets (Figure 1.2.1.2) (Nestle et 
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al., 2009; Morizane et al., 2012; Lande et al., 2007). These lymphocytes migrate to the 
epidermis, where they release a number of pro-inflammatory cytokines, including TNF-
α, IFNγ (Th1 cells), IL-17 and IL-22 (Th17 cells). The resulting pro-inflammatory 
milieu activates keratinocytes to produce chemokines (e.g. IL-8 and CCL20), which 
attract further Th1 and Th17 cells and propagate an abnormal immune response.  
Of note, recent studies demonstrated the presence of LL37 dependent T-cell 
populations in psoriatic skin, indicating that cathelicidin LL37 also acts as an 
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Figure 1.2.1.2.  Immune pathogenesis of PV 
Self nucleic acids released following cell-damage are recognised by LL-37. The 
resulting complexes cause pDCs to release IFNα, which activates myeloid dermal 
dendritic cells.  Myeloid DC-induced IL-12 and IL-23 promotes the differentiation of 
Th1 and Th17 cells, respectively. T lymphocytes migrate into the skin and secrete pro-
inflammatory cytokines, leading to keratinocyte activation. This effect is reinforced by 
the release of keratinocyte growth factor from fibroblasts. Activated keratinocytes 
propagate the inflammatory response by producing chemokines, which attract 
neutrophils, macrophages and further T cells. Figure retrieved from Nestle et al., 2009.  
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1.2.1.3 Genetics 
A genetic component of PV has long been apparent, due to the higher incidence 
of the disease among individuals with affected family members. This is particularly 
noticeable in early onset cases, with almost 70% of patients with childhood psoriasis 
reporting a family history of the condition (Capon et al., 2012; Mahil et al., 2015). 
Several studies have also documented increased disease concordance in monozygotic 
(35-73%) compared to dizygotic twins (12-20%) (Capon et al., 2012; Nestle et al., 
2009; Mahil et al., 2015). Indeed, psoriasis has one of the highest genetic components 
among complex diseases, with heritability estimates ranging between 60% and 90% 
(Mahil et al., 2015).  
In the 1990s, linkage studies identified 9 genomic regions (PSORS1-9) that co-
segregated with the disease in multiplex pedigrees (Capon et al., 2012; Mahil et al., 
2015). Of these, PSORS1, a 220 kB interval of the Major Histocompatibility Complex 
(MHC) class I region, was found to confer the highest risk for the disease (Capon et al., 
2012).  
While the PSORS1 (chromosome 6p21), PSORS2 (chromosome 17q25) and 
PSORS4 (chromosome 1q21) loci were replicated in multiple follow-up studies, the 
remaining genomic regions were not (Mahil et al., 2015), highlighting the lack of 
reproducibility of linkage studies in complex traits.  
In recent years, genome-wide association scans (GWAS) and targeted studies of 
immune loci have led to the identification of over 40 disease susceptibility regions 
(Capon et al., 2012; Tsoi et al., 2012; Mahil et al., 2015). Based on the results of these 
studies, HLA-C (located in PSORS1) is widely regarded as the major genetic 
determinant for the disease, as it account for ~50% of its familial aggregation (Capon et 
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al., 2012).  
The HLA-C gene encodes a class I major histocompatibility molecule that 
mediates antigen presentation to CD8+ T-cells (Mahil et al., 2015). Although the causal 
susceptibility variant at the HLA-C locus has yet to be identified, the HLA-Cw*062 
allele is a prime candidate, as it is strongly associated with psoriasis in several ethnic 
groups and consistently generates the highest odds ratios in GWAS (Capon et al., 2012). 
Of note, fine mapping studies have demonstrated the existence of multiple secondary 
signals within the MHC, implicating other HLA (e.g. HLA-B) and non-HLA molecules 
(e.g. MICA) in disease pathogenesis (Knight et al., 2012; Okada et al., 2014).  
 Although the susceptibility loci identified outside of the MHC typically contain 
several genes, it is noteworthy that the strongest biological candidates cluster to a 
limited number of immune pathways, most notably the IL-23/Th17 and NF-B 
signalling cascades (Capon et al., 2012).  
The IL-23/Th17 pathway has been implicated by the identification of psoriasis-
associated variants in genes such as IL12B, IL23A, and IL23R (Mahil et al., 2015). 
IL23A and IL12B code for the two subunits of IL-23, which signals through the IL-23 
receptor complex (encoded by IL12RB1 and IL23R) and activates Th17 cells (Mahil et 
al., 2015).  
NF-B is a transcription factor for genes involved in apoptosis and innate-
immune responses (Scudiero et al., 2011; Scudiero et al., 2014). It is activated by TLR 
ligands as well as cytokines such as TNF, IL-17 and IL-1 (Scudiero et al., 2011; Mahil 
et al., 2015).  Several genes regulating NF-B activation have been implicated in 
psoriasis pathogenesis. Examples include TRAF3IP2, which encodes an adaptor for IL-
17 mediated NF-B signalling, and NFKBIA, which encodes a molecule inhibiting the 
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formation of NF-B /REL complexes (Hayashi et al., 2012; Harden et al., 2015).  
Another important PV locus involved in the activation of NF-B is CARD14. Its 
gene product (CARD14/CARMA2) belongs to the CARMA family of scaffold proteins, 
which also includes CARD11/CARMA1 and CARD10/CARMA3 (Scudiero et al., 
2014). All three proteins encompass the same conserved functional motifs: a caspase 
activation and recruitment domain (CARD) located at the amino-terminus, a coiled coil 
(CC), a SRC homology 3 (SH3) motif and a guanylate kinase-like domain (MAGUK) at 
the carboxy-terminus of the protein (Scudiero et al., 2014). Although they show 
different expression patterns across human tissues, all three CARMAs are able to 
activate the NF-B transcription factor through an interaction with the BCL10 adaptor 
protein (Scudiero et al., 2014).  CARD14 is predominantly expressed in the skin, and it 
is the only CARMA protein that has several, alternately spliced isoforms (Jordan et al., 
2012; Fuchs-Telem et al., 2012; Scudiero et al., 2011).  
Common CARD14 variants were convincingly associated with PV in GWAS 
(Tsoi et al., 2012). Moreover, the c.349G>A (p.Gly117Ser) and c.349+5G>A mutations 
were shown to underlie rare, monogenic forms of PV linked to the PSORS2 locus 
(Jordan et al., 2014). Functional genomics demonstrated that the above disease alleles 
are gain-of-function mutations, which cause abnormal NF-B activation (Jordan et al., 
2014). 
Very little is known about the genetic determinants underlying other non-
pustular forms of psoriasis. Guttate psoriasis shows a very strong association with the 
HLA-Cw*0602 allele, but no other susceptibility loci have been identified (Asumalhti et 
al., 2003). Likewise, no disease alleles have been associated with erythrodermic 
psoriasis, as the rarity of the condition has prevented the ascertainment of adequately 
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powered patient resources. 
1.2.1.4 Treatment 
An important criterion in determining the most appropriate treatment for a 
patient is disease severity. This can be measured using the Psoriasis Area and Severity 
Index (PASI), which ranges from 0 (not affected) to 72 (severely affected) and is 
calculated based on the severity of psoriatic lesions and the percentage area of affected 
skin (Boehncke and Schon, 2015).   
For mild disease (PASI <7), topical therapies (e.g. gluco-corticosteroids) and/or 
vitamin D derivatives are usually prescribed, while moderate (PASI: 7-12) and severe 
(PASI >12) disease can often be managed with systemic treatment, either alone or in 
combination with photo-therapy (Boehncke and Schon, 2015).  
In recent years, disease treatment has been improved by the availability of 
biologics that directly target disease associated pathways (Boehncke and Schon, 2015) 
(Figure 1.2.1.4). These drugs can be used when patients do not show a durable response 
to topical treatment or conventional therapies.  Such therapeutics include TNF-α 
inhibitors (e.g. infliximab, which is a monoclonal anti-TNF-α antibody), IL-12 and IL-
23 blocking agents (e.g. ustekinumab, which blocks the p40 subunit shared by IL-12 
and IL-23) and IL-17 inhibitors (e.g. secukinumab, which targets IL-17A) (Mease, 
2015). Although their long-term usage does not cause organ toxicity - an advantage of 
these agents compared to other systemic drugs such as cyclosporin and acitretin-, 
biologics can have many side effects, most notably a decreased ability to fight serious 
infections (http://www.bad.org.uk). Hence, patients are required to have regular blood 
tests and clinical assessments. 





Figure 1.2.1.4. The IL-23/Th17 pathway as a therapeutic target in psoriasis 
GWAS have greatly helped the understanding of psoriasis pathogenesis and have 
identified key inflammatory cytokines, which have been successfully targeted for 
disease treatment. The diagram shows a schematic representation of the IL-23/Th17 
axis, with the names of selected disease associated genes in yellow. The names of 
biologics that target this pathway are highlighted in red. Figure retrieved from Mahil et 
al., 2016. 
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1.2.2 Pustular Psoriasis 
1.2.2.1 Clinical features 
The term pustular psoriasis refers to a group of inflammatory skin diseases 
which present with sterile pustules on erythematous background and are associated with 
an increased risk of psoriasis vulgaris (Burns et al., 2010). 
At the histological level, pustular psoriasis presents with marked infiltration of 
neutrophils in the epidermis, which gives rise to characteristic Kogoj’s spongiform 
pustules (Augey et al., 2006). Other histological findings are similar to those observed 
in PV and include parakeratosis, elongation of the rete ridges, as well as thinning of the 
supra-papillary epidermis (Augey et al., 2006). 
At the clinical level, the disease can manifest as generalised or localised pustular 
psoriasis.    
Generalised Pustular psoriasis (GPP) is the most rare and severe form of the 
disease. It affects 1-2 individuals per million, with a sex bias towards females (the 
estimated male female ratio is 0.7) (Augey et al., 2006).   
GPP is a potentially lethal condition, characterized by episodes of systemic 
inflammation and skin pustulation (Figure 1.2.2.1) (Augey et al., 2006). During disease 
flares the skin becomes red and numerous small pustules appear all over the body 
(Naldi and Gambini, 2007). The pustules might coalesce to form lakes of pus, but 
eventually dry out ad peel off (Naldi and Gambini, 2007). During these attacks, the 
patients often show signs of systemic upset, such as fever, malaise, neutrophilia and 
increased levels of acute phase reactants. GPP flares are therefore considered a 
dermatological emergency, requiring the immediate hospitalisation of the patient. 
The impact of GPP can also be complicated by co-morbidities as a significant 
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proportion of cases suffer from concurrent PV and/or psoriatic arthritis (Naldi and 
Gambini, 2007).  
GPP triggers include recurrent infections, hypocalcaemia, pregnancy (impetigo 
herpetiformis is a form of GPP triggered by pregnancy), high stress, and ultrapotent 
tropical therapies (Griffiths and Barker, 2007; Augey et al., 2006). However, many 
patients are not exposed to any of these agents, which underscores the need for further 
studies of disease pathogenesis (Griffiths and Barker, 2007; Augey et al., 2006).  
There are two main subtypes of localised pustular psoriasis: acrodermatitis 
continua of Hallopeau and palmoplantar pustulosis.  
Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic condition 
characterised by pustular eruptions on the tips of fingers and toes (Naldi and Gambini, 
2007). These lesions may also spread to the dorsal surface of the hands and forearms 
(Naldi and Gambini, 2007) (Figure 1.2.2.1). Importantly, the pustulation of patients’ 
nail-bed is often associated with onychodystophy (the malformation of the nail), 
osteolysis (dissolution of the bone), and arthritis (Naldi and Gambini, 2007). 
  Patients with palmoplantar pustulosis (PPP) experience hyperkeratosis and 
sterile pustulation on the palms and the soles (Naldi and Gambini, 2007). The pustules 
appear in crops on red skin, which is prone to develop painful cracks (fissures). The 
lesions later turn brown and then scaly (Naldi and Gambini, 2007) (Figure 1.2.2.1).   
PPP accounts for approximately 1% of psoriasis cases and shows a very robust 
sex-bias, with a female to male ratio of 9:1. Of note, the vast majority of patients 
(~90%) are smokers (95%) (Griffits and Barker, 2007).  Both PPP and ACH manifest 
with a chronic disease course. While this is not life threatening, both conditions have a 
profound effect on quality of life and often cause occupational or functional disability. 
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Figure 1.2.2.1. Clinical presentation of Generalised Pustular Psoriasis (GPP; left); 
Acrodermatitis continus of Hallopeau (ACH; middle) and palmaplantar pustulosis (PPP; 
right) 
The photos illustrate the presence of widespread pustulation in GPP patients and 
localized lesions in individuals affected by ACH and PPP.   
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1.2.2.2 Genetics and immune pathogenesis 
Although the rarity of pustular psoriasis has hindered the implementation of 
case-control studies, it has long been apparent that the disease is not associated with 
HLA-Cw*0602, the major genetic determinant of PV (Asumalahti et al., 2003) 
In more recent years, the advent of next-generation sequencing has greatly 
helped the study of GPP, enabling the discovery of two disease genes. 
The first genetic determinant to be robustly associated with the disease was the 
IL36RN locus. Bialleleic IL36RN mutations were first uncovered in Tunisian 
consanguineous pedigrees and in unrelated British patients with GPP (Marrakchi et al., 
2011, Onoufriadis et al., 2011). Further disease alleles have been subsequently 
identified in German, Japanese and Malaysian cases, with a total of 17 deleterious 
variants identified so far (Sugiura et al., 2013; Farooq et al., 2012; Setta-Kaffetzi et al., 
2013; Kanazawa et al., 2013).  
The most prevalent mutations in the Asian population are the c.115+6T>C and 
p.Arg10X variants, which are null alleles causing early protein truncation. In Europe 
and North-Africa, the most frequent disease alleles are the p.Ser113Leu and p.Pro27Leu 
amino acid changes; respectively, and both affect highly conserved amino acid residues 
(Marrakchi et al., 2011; Setta-Kaffetzi et al., 2013). 
Of note, a small but significant number of individuals carrying a single 
p.Ser113Leu allele has been reported, indicating that the mutation may under certain 
circumstances, be pathogenic in the heterozygous state (Setta-Kaffetzi et al., 2013).  
 IL36RN is mostly expressed in skin and it codes for an anti-inflammatory 
protein (IL-36 receptor antagonist or IL-36Ra) that antagonizes the effects of IL-36α, -
β, and –γ (Gabay and Towne, 2015). While the binding of the latter cytokines to the IL-
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36 receptor drives NF-B and MAPK signalling, IL-36Ra blocks the recruitment of the 
IL-1Rrp2 accessory protein and therefore hinders the activation of downstream 
pathways (Marrakchi et al., 2011; Onoufriadis et al., 2011).  
In individuals carrying IL36RN mutations, the IL-36Ra protein no longer 
functions as an antagonist, resulting in increased production of NF-B induced pro-
inflammatory cytokines (Figure 1.2.2.2) (Marrakchi et al., 2011; Onoufriadis et al., 
2011). In these subjects, activated keratinocytes secrete IL-36 cytokines that can 
activate dermal DCs, and in the absence of a functional antagonist, induce the increased 
production of TNF-α and IL-17α (Gabay and Towne, 2015), leading to the recruitment 
of T cells, neutrophils, and DCs (Gabay and Towne, 2015). An association was also 
observed between the expression of IL-36 cytokines in psoriatic skin and that of IL-17, 
IL-23, and TNF, further supporting the notion that IL-36 cytokines govern the 
pathogenesis of psoriasis in patients with IL36RN mutations (Gabay and Towne, 2015).  
The second locus to be associated with pustular psoriasis is AP1S3. This gene 
encodes a small subunit of the AP-1 adaptor complex, a cytosolic tetramer that regulates 
vesicular trafficking between the trans-Golgi network and the endosomes (Setta-
Kafettzi et al., 2014). Two founder AP1S3 mutations (p.Phe4Cys and p.Arg33Trp) were 
found in the heterozygous state in all subtypes of pustular psoriasis, but only in patients 
of European origin (Setta-Kafettzi et al., 2014). The mechanisms whereby AP1S3 alleles 
cause skin inflammation are still under investigation. 
Finally, a p.Asp176His CARD14 substitution has been tentatively associated 
with GPP in a small Japanese study (Sugiura et al., 2014) but the pathogenic potential of 
this change remains to be understood.  
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Importantly IL36RN and AP1S3 mutations have been observed in patients 
affected by all forms of pustular psoriasis, demonstrating a common genetic basis for 
common localized and acute generalized variants of the disease (Setta-Kaffetzi et al., 
2013; Setta-Kaffetzi et al., 2014) 
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Figure 1.2.2.2. Mutations in IL36RN lead to increased NF-B and MAPK signalling 
As a result of IL36RN mutations, the IL-36Ra protein is not able to function as an 
antagonist and prevent the binding of IL-36α, -β, and –γ, to the IL-36 receptor. This 
leads to increased activation of the NF-B and MAPK signalling and abnormal 
production of pro-inflammatory cytokines. DITRA: Deficiency of Interleukin Thirty-six 
Receptor Antagonist. Figure retrieved from Marrakchi et al., 2011. 
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1.2.2.3 Treatment 
The biologics that have transformed the treatment of plaque psoriasis show 
limited efficiency in the pustular forms of the disease, indicating that the latter are likely 
to have a distinct aetiology. In fact, the results of genetic studies suggest that blocking 
IL-1 signalling downstream of the IL-36 receptor might be a more efficient therapeutic 
approach than targeting the IL-23/Th17 axis. Of note, pilot studies of Anakinra (a 
recombinant form of the IL-1 receptor antagonist) have given promising results in GPP 
(Rossi-Semeraro et al., 2015; Huffmeier et al., 2014). However, larger trials or case 
series will be required to rigorously assess the efficacy of IL-1 blockade. 
In the context of a limited efficiency of biologics, the use of retinoids, either 
alone or in combination with PUVA appears to be more effective compared to other 
systemic therapies (Augey et al., 2006; Marsland et al., 2006).  However, therapeutic 
options are extremely limited overall, highlighting the need for an improved 
understanding of disease pathways. 
 
1.2.3 Pityriasis Rubra pilaris 
1.2.3.1 Clinical features 
Pityriasis Rubra pilaris (PRP) is a chronic inflammatory skin disorder of 
unknown etiology which affects 1:5,000 patients with dermatological conditions 
(Griffiths, 1980). The disease is characterized by keratotic follicular papules, reddish, 
scaly plaques, and palmoplantar keratoderma, that may progress to erytroderma with 
distinct islands of uninvolved skin (Griffiths, 1980) (Figure 1.2.3.1). Compared to PV, 
the major differences are the prominent involvement of the face and the absence of 
psoriasis-like nail changes (Fuchs-Telem et al., 2012). 
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At the histological level PRP lesions also have a distinctive appearance 
characterised by parakeratosiss, orthokeratosis, hypergranulosis, and follicular 
hyperkeratosis (Fuchs-Telem et al., 2012). 
At the clinical level, PRP can be classified into five subtypes based on age of 
onset, clinical presentation, and prognosis: classic adult type (type I, accounting for 
50% of cases); atypical adult type (type II, 5% of cases); classic juvenile (type III, 10% 
of cases); circumscribed juvenile (type IV, 25% of cases), and atypical juvenile (type V, 
10% of cases) (Griffiths, 1980). Familial PRP is part of the type V group and accounts 
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Figure 1.2.3.1. Clinical presentation of Pityriasis Rubra Pilaris 
The picture illustrates the presence of widespread, erythematous plaques surrounded by 
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1.2.3.2 Genetics and immune pathogenesis 
The only known genetic determinant of the disease is CARD14, with a small 
number of heterozygous gain-of function mutations detected in familial forms of PRP 
(Fuchs-Telem et al., 2012). Interestingly, these variants do not overlap with those 
identified in familial PV, suggesting that mutations are disease-specific. 
 Immunostaining of patient skin   showed an abnormal accumulation of the p65  
NF-B subunit compared to healthy controls. Furthermore, the expression of NF-B 
target genes (CCL20, IL1B, and NOS2) was increased in lesional skin, supporting the 
notion that the CARD14 mutations associated with PRP lead to increased NF-B 
signaling (Fuchs-Telem et al., 2012). 
 
1.2.3.3 Treatment 
There are no efficient treatments against the disease, with modest improvements 
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1.3 Gene identification by next-generation sequencing 
1.3.1 Traditional approaches to gene discovery 
Understanding the genetic background of a disease has great translational 
impact, as it enables early diagnosis, prenatal testing and appropriate counselling for 
high-risk individuals. The identification of disease genes can also provide mechanistic 
insights into the aetiology of the condition, which has the potential to inform the 
development of targeted therapies.  
Historically, gene discovery was pursued by positional cloning or mutational 
analysis of candidate loci. The former approach was based on the linkage analysis of 
extended pedigrees and the subsequent sequencing of genes located within the critical 
disease interval. This hypothesis-free approach allowed the identification of genes 
underlying important Mendelian disorders (e.g. spinal muscular atrophy and cystic 
fibrosis) and monogenic forms of cancer (e.g. early onset breast cancer). 
The analysis of candidate genes, on the other hand, relied on previous 
knowledge of disease processes or assumptions on likely pathogenic mechanisms.   
 The cornerstone of both approaches was Sanger sequencing, a method that 
defines the order of nucleotides in a DNA sequence through the incorporation of 
labelled, chain-terminating di-deoxynucleotides. The reaction is carried out in-vitro by 
DNA-polymerase and the sequence is determined upon electrophoretic size-separation 
of the DNA fragments (Venter et al., 2001) (Figure 1.3.1).  
Sanger sequencing – also termed capillary sequencing- has been a commonly 
used technology since its discovery. Importantly, it underpinned the completion of the 
Human Genome Project in 2001, which derived the entire sequence of the first reference 
human genome (Venter et al., 2001).  
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Although the method has been automated, it was still too time-consuming and 
expensive for the systematic analysis of extended genomic regions. This hindered gene 
identification efforts for conditions where linkage studies had defined large linkage 
intervals and/or the knowledge of the underlying pathway was insufficient to priorities 
candidate genes for analysis. 
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Figure 1.3.1. Sanger sequencing workflow 
In a sequencing reaction, a primer is first annealed to a single-stranded DNA template, 
upon which the DNA polymerase incorporates both deoxy-nucleotide triphosphates 
(dNTPs) and labelled di-deoxynucleotides (ddNTPs). Given that ddNTPs lack a 
hydroxyl group, their random insertion terminates the DNA synthesis at various stages 
of elongation, generating a mixture of labelled DNA fragments of differing lengths. 
These products are then separated by capillary gel electrophoresis. Finally the 
fluorescent signals are captured by a detector, and an imaging system shows the identity 
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1.3.2  Next-generation sequencing 
In the last few years, the field of gene discovery has been revolutionised by the 
advent of next-generation sequencing methods, which allow the rapid and cost effective 
analysis of entire genomes. The use of these technologies has transformed Mendelian 
genetics, with hundreds of disease causing genes identified since the first proof of 
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Figure 1.3.2. The use of whole-exome sequencing accelerated our understanding of 
Mendelian disease  
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1.3.2.1 Sequencing platforms 
` Next-generation sequencing is currently implemented in one of three major 
platforms: Roche 454 (which, however, is going to be discontinued in mid-2016), ABI 
Solid, and the Illumina HiSeq System (Liu et al., 2012). 
The key steps in the underlying protocols are fundamentally similar. These 
include the preparation of libraries by DNA shearing and adaptor ligation, the massively 
parallel sequencing of short DNA fragments, the alignment of reads to a reference 
genome, and the variant calling (Liu et al., 2012).   
The Roche 454 platform employs the pyrosequencing technology where a 
pyrophosphate is released during nucleotide incorporation and the number of 
incorporated nucleotides is derived from the signal intensity (Liu et al., 2012). The main 
advantages of this system are the long read length (700 bp) and the high sequencing 
speed (a run can be completed in less than a day) (Table 1.3.2.1) (Liu et al., 2012).  
However, the cost-per base is high compared to other technologies and the error rate at 
homo-polymer detection is high (Liu et al., 2012).  
The ABI SOLiD System determines the DNA sequences by ligating 
fluorescently labeled probes (two bases long) to the template. What makes this platform 
to stand out from the rest is its accuracy. However, sequence runs are more time-
consuming compared to the other platforms (they can take up to 14 days) and the reads 
that are generated are shorter  (85bp), which complicates the alignment process (Liu et 
al., 2012).  
Illumina introduced the cheapest technology (Table 1.3.2.1). This technique 
applies a sequencing-by-synthesis approach and reads one incorporated nucleotide per 
sequencing cycle (Liu et al., 2012). The read length is relatively short, but is increasing 
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with the latest models, supporting the generation of 300 bp reads in a paired-end 
arrangement. The error rate remains significant, though (2%). 
  A number of “third-generation sequencing” approaches have also been emerging 
in recent years. An example is the Single Molecule sequencing in Real Time (SMRT) 
system devised by Pacific Biosciences, which can generate very long reads (10-15kb) 
and has allowed scientists to sequence the E. Coli genome with 99.9999% accuracy 
(Chin et al., 2013). Another example is the Nanopore sequencing method that is being 
developed by Oxford Nanopore Technologies (Schmidt, 2016). This is based on single-
use DNA sequencing devices that can generate 5-10kb long reads. Although this 

















Table 1.3.2.1. Comparing traditional and next-generation sequencing platforms that 
differ in read length, accuracy, times needed to complete a sequence run, and required 
informatics for data analysis.  Figure retrieved from Liu et al., 2012. 
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1.3.2.2 Next-generation sequencing applications 
The use of NGS technologies in gene discovery includes different applications.  
Targeted sequencing is performed when the analysis can be focused on a discrete 
genomic region or a relatively small number of candidate genes (Rehm, 2013). This is 
the case when linkage data are available or previous knowledge of disease mechanisms 
can be leveraged to define a panel of candidate genes. In either case, probes that 
hybridise the target genomic regions are designed, so that the relevant genomic 
segments can be captured and then sequenced (Rehm, 2013).  
Whole-exome sequencing (WES) is currently the most popular NGS application 
in gene discovery. It allows researchers to focus on the coding portion of the genome 
(i.e. the exome), based on the assumption that it is more likely to harbour disease-
causing mutations. As coding regions only represents 1% of the human genome, whole-
exome sequencing can be more cost- and time-effective than whole-genome sequencing 
(WGS) (Singleton, 2011).  
The underlying protocol of WES is similar to those described in the earlier 
section. The difference is that upon library preparation, the coding regions are captured 
by hybridization with complementary probes (Figure 1.3.2.2.1) (Singleton, 2011). The 
latter are commercially available as reagents are provided by Agilent (SureSelect 
Human All Exon kits), Roche/Nimblegen (SeqCap EZ Exome Library), and Illumina 
(TruSeq Exome Enrichment system).  
The above products differ in various aspects of probe design. While Nimblegen 
relies on overlapping baits and provides the highest coverage among the three suppliers, 
Agilent uses longer oligonucleotides that are adjacent to each other. Finally, Illumina 
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sequencers generate paired-reads that are extended from the baits (Figure 1.3.2.2.2) 
(Singleton, 2011). 
 Another dissimilarity between these platforms are their target regions, given 
that the capture probes are designed on the basis of information provided in different 
repositories, such as RefSeq, Ensembl, and UCSC Knonw Genes. Thus, Illumina probes 
cover the most untranslated regions, Nimblegen provides better coverage of micro-
RNAs and Agilent was the most specific platform for the analysis of Ensembl genes 
(Figure 1.3.2.2.2) (Singleton, 2011).  
The platforms also differ in their target specificity, with Nimblegen probes 
performing best on this parameter (98.6% of target bases covered at least once; 96.8% 
covered  at >10X) (Clark et al., 2011).  
Despite their success, it is important to bear in mind that WES studies suffer 
from some significant limitations. The most important is uneven coverage of target 
regions. In a typical experiment, 5-10% of exonic sequences are not captured or 
sequenced at a sufficient depth (Rehm, 2013). This is due to numerous factors, most 
importantly, probes that fail to tile their targets either due to repetitive sequences, GC-
richness, or low mapping quality (Rehm, 2013).  
Whole-genome sequencing does not suffer from the above limitations but is 
more expensive. As the protocol generates a very substantial volume of data, the costs 
associated with data storage and data analysis are also much higher.  
  
. 




Figure 1.3.2.2.1. Overview of the experimental procedure for whole-exome sequencing 
Figure retrieved from Singleton et al., 2011.  





Figure 1.3.2.2.2 Performance comparison of exome sequencing technologies 
Commercially available platforms for exome enrichment differ in the length and density 
of oligonucleotide baits (a) and composition of their target regions (b). While the 
coverage of coding exons represented  in RefSeq (c) and Ensembl (d) is comparable 
across platforms, Illumina probes performs better in targeting UTR regions (e).   
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1.3.2.3 Data analysis 
The most challenging part of the whole-genome/whole-exome sequencing 
workflow is the computational analysis of the data (Figure 1.3.2.3).  
Next-generation sequencing instruments generate FASTA/FASTAQ files that 
include the sequence itself and its quality scores (Pabinger et al., 2013). After the reads 
have been aligned to a reference genome, this information is converted to a Sequence 
Alignment Map (SAM) file, in a tab-delimited text format (Olson et al., 2015).  There 
are different programs available for this conversion step; one of them is the Burrows-
Wheler Aligner (BWA).  
For easier storage, SAM files are converted to a BAM binary format (Olson et 
al., 2015). Read qualities are recalculated as Phred scores, which provide base-calling 
error probabilities on a logarithmic scale (Olson et al., 2015). Phred scores typically go 
from 10 (1:10 probability of incorrect base call, 90% accuracy) to 40 (1 in 10,000 
probability of incorrect base call, 99.999% accuracy). In a typical analysis pipeline, a 
minimum Phred score is specified (e.g. Phred ≥ 20) and bases that are below this 
threshold are excluded from further consideration.  
The next step is SNP annotation from BAM files. This can be achieved using 
software packages such as the Genome Analysis Tool Kit (GATK), which identify sites 
that show differences compared to the reference genome and generate output files in the 
variant call format (vcf) (Pabinger et al., 2013; Olson et al., 2015). The latter lists the 
exact genomic position of the base change, the reference and the alternative base at that 
position as well as the quality score of the variant.  
Further downstream analyses can be completed using this format as input. For 
instance, the sequence changes can be annotated with the ANNOVAR software, to 
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determine their frequency in the relevant population. Information on the gene and amino 
acid affected by the variant can also be retrieved. This data is extremely valuable for the 
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Figure 1.3.2.3. The general workflow for next-generation sequencing 
Once the library preparation is completed, the samples are sequenced on the chosen 
platform. The quality of the reads is assessed, and those passing this QC are aligned 
against a reference genome. Finally, variants are annotated and filtered to identify the 
most likely disease-causing changes. 
Figure retrieved from Pabinger et al., 2013. 
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1.3.2.4 Data filtering 
The sequence analysis of typical Caucasian exome identifies more than 20,000 
nucleotide changes (Ng et al., 2009). Thus, variant profiles need to be carefully filtered 
to find disease causing mutations among the numerous variants that have been detected.  
First, all synonymous variants are removed. Next, one needs to define the most 
likely mode of disease inheritance, in order to establish whether the mutation is likely to 
occur in the heterozygous or homozygous/compound heterozygous state.  
The expected penetrance and prevalence of the disease allele also need to be 
estimated, so that a Minor Allele Frequency (MAF) threshold can be defined and 
changes that exceed it can be filtered out, using publicly available datasets (e.g. the 
1000 Genome Project, 1000 Genomes Project Consortium, 2012) and in-house 
reference panels. Given that the frequency of rare alleles can vary widely among 
populations and that some variants may only be found in certain ethnic groups, it is 
important that the origin of the patient(s) is taken into consideration and appropriate 
control sequences are used during the filtering process. Fortunately, exome data is now 
available for several non-European populations, thanks to the efforts of the 1000 
Genomes Consortium and the NHLBI Grand Opportunity (GO) Exome sequencing 
project, among others (1000 Genomes Project Consortium, 2012; Johnston and 
Biesecker, 2013). 
Further filtering steps can be introduced at this stage, depending on the design of 
the study. If multiple family members are being examined, the variants that are not 
shared by all affected individuals are filtered out. Likewise, in the analysis of multiple 
isolated cases, the genes that are only mutated in a small number of patients can be 
excluded from further consideration.  
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Finally, variants can be prioritized for follow-up, based on in-silico 
pathogenicity predictions. These can be implemented by a variety of algorithms that 
take into account the biochemical properties and evolutionary conservation of the amino 
acid residues that are affected by sequence variants. Given that none of these methods is 
completely accurate, it is advisable to use multiple programs and look for consensus 
predictions rather than rely on the output of a single tool (Miosge et al., 2015).  
Of note, the studies that originally identified IL36RN and AP1S3 as GPP genes 
were executed in our lab, showing that rigorous filtering of exome sequencing data has 
the power to detect disease-causing alleles for pustular psoriasis (Onoufriadis et al., 
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1.4 Aims of the study 
While genetic studies have identified more than 40 susceptibility loci associated 
with plaque psoriasis, our understanding of pustular psoriasis (PP) genetics is still very 
limited. Of note, the identification of the IL36RN and AP1S3 genes in PP has suggested 
that the disease is driven by innate rather than adaptive immune mechanisms, indicating 
a distinct etiology. 
Hence the aim of the current study was to further investigate the above issues by 
comparing and contrasting the genetic basis of plaque and pustular psoriasis. This was 
achieved by investigating the genetic overlap between PV and GPP, as well as by 
identifying novel genetic determinants for pustular psoriasis: 
The first two parts of the study focused on the candidate genes IL36RN and 
CARD14 and on their in depth examination: 
To address the possibility that IL36RN loss-of-function alleles may contribute to 
PV susceptibility, the locus was systematically screened in 363 unrelated patients with 
familial forms of the disease and genetic data extracted from large-scale association 
studies was re-analysed. 
To validate the involvement of CARD14 in monogenic forms of PV and explore 
the gene contribution to pustular psoriasis, the locus was screened in large datasets of 
patients with familial psoriasis vulgaris (n=159) and pustular psoriasis (n=205).  
The last part of the study sought to further characterise the molecular pathogenesis 
of pustular psoriasis:  
Since the majority (almost 70%) of PP patients do not carry mutations in IL36RN 
or AP1S3, whole-exome sequencing was undertaken in twelve carefully selected 
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individuals with generalised pustular psoriasis and five unrelated cases of 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 General reagents and buffers 
Reagent Supplier 
2-Mercaptoethanol Sigma-Aldrich 
Acetic Acid BDH 
Adenosine triphosphate (ATP)  Fermentas 
Amersham ECL Western Blotting Detection Reagent GE Healthcare 
Bovine Serum Albumin (BSA) Cell Signalling  
Bromophenol Blue Sigma-Aldrich 
Complete Protease Inhibitor Cocktail Tablet Roche 
Deoxynucleotide Triphosphates (dNTPs) Thermo Scientific 
Dimethyl Sulphoxide (DMSO) Sigma-Aldrich 
Dried Skimmed Milk Marvel 
Dithiothreitol (DTT) Invitrogen 
Ethanol BDH 




Magnesium Chloride (MgCl2) BDH 
Methanol BDH 
Nonidet-P40 Sigma-Aldrich 
Normal Goat Serum Cell Signalling 
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Paraformaldehyde, 4% Alfa Aesar 
Potassium Chloride (KCl) Sigma-Aldrich 
Ponceau S Sigma-Aldrich 
RNaseZap RNase Decontamination Solution Life Technologies 
Sodium Acetate (NaOAc) Sigma-Aldrich 
Sodium Chloride (NaCl) VWR 
Sodium Dodecyl Sulphate (SDS) Sigma-Aldrich 




Urea Life Technologies 
 
2.1.2 Enzymes, buffers and supplements 
Reagent Supplier 
10X PCR Buffer Thermo Scientific 
Agencourt AMPure XP beads Beckman Coulter 
Big Dye 5X Sequencing Buffer Applied Biosystems 
Bovine Serum Albumin (BSA) New England Biolabs 
DreamTaq Polymerase Thermo Scientific 
Magnesium Sulfate (MgSO4)   Novagen 
Taq Polymerase Thermo Scientific 
TaqMan Universal Master Mix II Applied Biosystems 
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2.1.3 Gel Electrophoresis Reagents 
Reagent Supplier 
5X DNA Loading Buffer Bioline 
10X Tris-Borate-EDTA (TBE) Geneflow 
Agarose  VWR 
Ammonium Persulphate (APS) Sigma-Aldrich 
Ethidium Bromide Sigma-Aldrich 
GeneScan 500 TAMRA Size Standard Life Technologies 
HiDi Formamide Applied Biosystems 
HyperLadder I Molecular Weight Marker Bioline 
HyperLadder II Molecular Weight Marker Bioline 
Precision Plus Dual Colour Protein Marker Biorad 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Ultra PureProtoGel 30% Acrylamide Mix National Diagnostics 
 
2.1.4 Bacterial culture reagents  
Reagent Supplier 




Bacto-Yeast Extract BD 
SOC Outgrowth Medium New England Biolabs 
XL10-Gold ultracompetent cells Agilent Technologies 




pcDNA3-CARMA2-sh.1 Prof. Pasquale Vito 
(Università del Sannio, 
Italy) 
 
2.1.6 Tissue culture reagents 
Reagent Supplier 
Dulbecco's Modified Eagle's Medium (DMEM) Life Technologies 
Foetal Calf Serum (FCS)  LabTech 
Lipofectamine2000 Life Technologies 
Penicillin-Streptomycin (P/S) Life Technologies 
Phospate Buffer Saline (PBS) Life Technologies 
ProLong Diamond Antifade Reagent Life Technologies 
Tryple Life Technologies 
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2.1.7 Antibodies 
Reagent Supplier Dilution 
Alexa Fluor® 488 Goat Anti-Rabbit IgG  Invitrogen 1 : 800 
Donkey monoclonal anti-rabbit IgG GE Healthcare 1 : 10000 
DYKDDDDK Tag Antibody  Cell-Signalling 1 : 600 
Goat polyclonal  anti-mouse IgG Dako 1 : 10000 
Monoclonal ANTI-FLAG M2, Clone M2 Sigma-Aldrich 1 : 3000 
Rabbit polyclonal anti-β–actin 
Cell-Signalling 1 : 1000 
 
2.1.8 Molecular biology kits 
Reagent Supplier 
Agilent Sure SelectXT Kit Agilent Technologies 
Agilent Sure Select Human All Exome Kit v.4 Agilent Technologies 
Big Dye Terminator v3.1 Cycle Sequencing Kit Life Technologies 
Herculase II Fusion DNA Polymerase Kit Agilent Technologies 
High-Capacity cDNA Reverse Transcription Kit Life Technologies 
HiSpeed Plasmid Midi Qiagen 
IllustraExoStar 1-Step GE Healthcare 
KAPA SYBR FAST qPCR kit KAPA Biosystems 
MycoSensor PCR Assay Kit  Agilent Technologies 
Oragene DNA kit DNA Genotek 
QIAprepMiniprep Kit Qiagen 
QIAshredder Columns Qiagen 
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QuikChange Lightning Kit Agilent Technologies 
Rneasy Plus Mini Kit Qiagen 
SureSelect Library Prep Kit Agilent Technologies 
 
 
2.1.9 Stock solutions 
Solution Composition 
Denaturing Cell Lysis / HU Buffer 5%SDS 
200Mm Tris-HCL (pH6.8) 
1mM EDTA 
1.5% β -Mercaptoethanol 
8M Urea 
Immunofluorescence Antibody Dilution Buffer   1% BSA 
0.3% TritinX-100 
1X PBS 
Immunofluorescence Blocking Buffer  5% Goat Serum 
0.3% TritinX-100 
1X PBS 
Laemmli Buffer (6X) 0.375 M Tris-HCl (pH 6.8) 
9% (v/v) SDS 
50%(v/v)  Glycerol 
5% (w/v) β-Mercaptoethanol 
0.03% Bromophenol Blue 
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LB Agar 1% (w/v) NaCl 
1% (w/v) Bacto-Tryptone 
0.5% (w/v) Bacto-Yeast 
1.5% (w/v) Bacto-Agar 
Luria Broth (LB) 1% (w/v) NaCl 
1% (w/v) Bacto-Tryptone 
0.5% (w/v) Bacto-Yeast 
Non-denaturing buffer 50mM Tris-HCl (pH 7.4) 
50mM NaCl 
10% (v/v)  Glycerol 
5mM EDTA 
0.03% Bromophenol Blue 
1% (v/v) NP-40 
Poly-Acrylamide Gel Electrophoresis Running 
Buffer (10X) 
0.25 M Tris-base 
1.92 M Glycine 
1% (v/v) SDS 
Sanger Sequencing Precipitation Solution 95% (v/v) Ethanol 
0.12 M NaOAc (pH 4.6) 
Tris-buffered Saline (TBS)(pH 7.6, 10X)  1.5 M NaCl 
0.2 M Tris-base  
Tris-EDTA (pH.8.0, 1X) 0.1 mM EDTA 
10 mMTris-HCl 
Western Blot Transfer Buffer (10X) 0.25 M Tris-base 
1.92 M Glycine 
20% (v/v) Methanol  
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2.2 Study Resource 
This study was performed in accordance with the principles of the Helsinki Declaration. 
Ethical approval was granted by St Thomas Hospitals’ ethics research committee (ref 
06/Q0702/7; 11th May 2006) and all patients gave their written informed consent for the 
use of their DNA. 
 
2.2.1 Patients with familial psoriasis vulgaris and eryhtrodermic psoriasis 
Patients were recruited through St John`s Institute of Dermatology (London, UK) and 
Glasgow Western Infirmary (Glasgow, UK), based on the standard diagnostic criteria 
reported by Griffiths and Barker (Griffiths and Barker, 2007). Individuals who had at 
least one first degree relative affected by plaque psoriasis were considered cases of 
familial PV. The cohort recruited on this basis consisted of 349 unrelated probands (175 
females, 174 males) (Table 2.2.1), while the erythrodermic psoriasis dataset included 23 
unrelated cases (5 females and 18 males).  All subjects were of British (white) European 
descent. 
 
2.2.2 Pityriasis Rubra Pilaris patients 
Twenty-nine unrelated individuals (13 females and 16 males) with sporadic pityriasis 
rubra pilaris were ascertained by Professor John McGrath from the records of St John’s 
Institute of Dermatology  (London, UK) and classified based on the criteria listed by 
Griffiths (Griffiths, 1975) (Table 2.2.2.).  
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Table 2.2.1. Disease recurrence in the familial PV resource 
Number of affected individuals in the pedigree 
>5 5 4 3 2 Total 
15 11 33 121 169 349 
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Table 2.2.2. Pityriasis Rubra Pilaris resource 
PRP Type  Ethnicity 





Type 3, classic juvenile type (n=2) North-European 
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2.2.3 Sporadic pustular psoriasis cases 
This cohort consisted of 194 unrelated cases (8 Acrodermatitis continua of Hallopeau, 
94 Generalised Pustular Psoriasis, and 92 Palmoplantar pustulosis patients; Table 2.2.3), 
who did not carry mutations within the IL36RN or AP1S3 genes. Participants were 
recruited from St. John’s Institute of Dermatology (London, UK) by Professor 
Catherine Smith and Jonathan Barker, Glasgow Western Infirmary (Glasgow, UK) by 
Professor David Burden, University of Manchester (Manchester, UK) by Professor 
Chrisopher Griffits, Hospital Sultanah Aminah (Johor Bahru, Malaysia) by Professor 
SE Choon, Singapore National Skin Center (Singapore) by Professor Siew-Eng Tan, 
Our Lady's Children's Hospital and St Vincent University Hospital (Dublin, Ireland) by 
Professor Allan Irvine, Helsinki University Central Hospital  (Helsinki, Finland) by Dr 
Annamari Ranki, Hopital Necker-Enfants Malades (Paris, France) by Professor Asma 
Smahi, Geneva University Hospital and Zurich University Hospital (Switzerland) by Dr 
Alexander Navarini, Radboud University Nijmegen Medical Centre (Nijmegen, The 
Netherlands) by Professor Marieke Seyger. Clinical data were collated in the Case 
Report Form (CRF) attached in Appendix I and patients were classified according to the 
standard diagnostic criteria reported by Griffiths and Barker, (Griffiths and Barker, 
2010). The screening of IL36RN and AP1S3 genes was undertaken prior to the onset of 
the study (Onoufriadis et al., 2011; Setta-Kaffetzi et al., 2014).  
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Table 2.2.3. Sporadic pustular psoriasis cases 
Disease N. of Cases Gender Concomitant PV Mean Age of onset Ethnicity 
Acrodermatitis Continua of Hallopeau 8 3M, 5F 4/8  
(50%) 
53+/-19 North-European 










Palmar Plantar Pustulosis 92 31M, 61F 14/92 
(15.21%) 
49+/-26 North-European 
M: male; F: female; PV: psoriasis vulgaris
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2.2.4 Familial GPP cases  
Six affected relative pairs were recruited from Sultanah Aminah Hospital in Johor 
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Table 2.2.4.  Familial GPP cases 
Sample 
ID 





Chinese Female 25 Yes 
Aunt and niece 
16GPP2 
T014369 
Chinese Female 3 No 
38GPP1/ 
T014395 
Malay Female 25 Yes 
Father and daughter 
38GPP2/ 
T014394 
Malay Male 27 Yes 
23GPP1/ 
T014376 
Malay Female 31 Yes 
Great aunt and niece 
23GPP2/ 
T020702 
Malay Female 12 Yes 
8GPP1/ 
T012409 




Chinese Female 21 No 
41GPP1/ 
T14398 




Malay Female 35 No 
PV: psoriasis vulgaris 
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2.2.5 Controls 
Several control panels of European and Asian descent were analysed at various stages 
of the study. The following populations were represented: North-American (n=5,548), 
British (n=4,098), European (n=54,658), Chinese (n=416), Japanese (n=424), Malay 
(n=96), and Indian (n=340). The individual datasets are described in Table 2.2.5. 
 
2.2.6 DNA extraction and sample storage 
DNA was isolated by technical employees at St John’s Institute of Dermatology, either 
from 2 ml saliva or 10 ml blood, using the Oragene DNA kit or the “salting out” method 
(Miller Dykes et al., 1988), respectively. DNA concentrations were quantified with a 
NanoDrop ND-1000 Spectrophotometer and samples were stored as duplicate aliquots 
at -20°C. Working dilutions (25 ng/μl in 1X TE) were aliquoted in skirted 96-well 
plates and stored at -20°C. 
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Table 2.2.5. Control datasets 
Origin Dataset Reference Application 
American 
(White European) 
Controls genotyped by the International 
Psoriasis Genetics Consortium (n=5,548) 
 IL36RN association analysis 
British 
(White European) 
1000 Genomes GBR sample (n=91) 
Exomes sequenced in-house (n=2,222) 
Exomes sequenced by collaborator (n=1,785)  
Abecasis et al., 2012. 
Setta-Kaffetzi et al., 2014. 
Filtering of variant profiles 
ARFGAP2 association analysis 
 
Chinese 1000 Genomes project CHB (n =206) and CHS 
(n =210) samples 
Abecasis et al., 2012. Filtering of variant profiles 
CARD14 association analysis 
CYP1A1 association analysis 
European Exome Aggregation Consortium European 
(Non-Finnish) sample (n=33,000) 
Controls genotyped by the International 
Psoriasis Genetics Consortium  (n=21,658) 
 ARFGAP2 association analysis 
 
IL36RN association analysis 
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Japanese 1000 Genomes project JPT sample (n=104) 
Population controls analysed in the literature 
(n=100) 
Population controls genotyped in-house 
(n=220)1 
Abecasis et al., 2012. 
Sugiura et al., 2014. 
CARD14 association analysis 
Indian 1000 Genomes project GIH (n=103), ITU 
(n=102), STU (n=102), and PJL (n=96) samples 
Singapore sequencing Indian project, SSIP 
(n=38) 
 
Abecasis et al., 2012. 
Wong et al., 2014. 
 
Filtering of variant profiles (SSIP only) 
CYP1A1 association analysis 
Malay Singapore sequencing Malay project (n=96) Wong et al., 2013. Filtering of variant profiles 
CYP1A1 association analysis 
 
1 Recruited at National Cerebral and Cardiovascular Center, Osaka. Abbreviations are as follows: GBR, British in England and Scotland; CHB, Han 
Chinese in Bejing China; CHS, Southern-Han Chinese, JPT, Japanese in Tokyo Japan; GIH, Gujarati Indian from Houston Texas; ITU, Indian Telegu 
from the UK; STU, Sri Lankan Tamil from the UK; PJL, Punjabi from Lahore Pakistan. 
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2.3 Sanger sequencing and genotyping 
2.3.1 Polymerase Chain Reaction (PCR) 
2.3.1.1 Primer design and storage 
PCR primer pairs were designed with Primer3Plus (Untergrasser et al., 2012), in order to 
amplify the relevant exons and intron/exon junctions. All oligonucleotides were aligned to 
their target region on the Ensembl genome browser in order to avoid, wherever possible, an 
overlap with single nucleotide polymorphisms. The primer sequences were also analysed with 
BLAST (Zhang et al., 2000) to verify their specificity. For highly polymorphic or GC rich 
regions, oligonucleotides were designed manually, based on the following criteria: GC 
content: 45-55% Tm: 54-64°C; oligonucleotide length:18-24 bases; product size: 300-700 bp. 
Oligonucleotides were purchased from Eurofins MWG Operon, diluted in RNAse/DNAse free 
water to a 100pmol/l concentration and stored at -20°C. Stock solutions were subsequently 
diluted to a 10pmol/μl working concentration. 
All primer sequences are listed in Appendix II. 
2.3.1.2 PCR conditions 
After optimising annealing temperatures by gradient PCR, target regions were amplified 
under the following cycling conditions: 5 min initial denaturation at 95 °C; 30 replication 
cycles at 95 °C for 30 sec, 52-68°C for 30 sec (Appendix II) , 72 °C for 30 sec, followed by a 
final extension at 72 °C for 10 min. Each 15 μl reaction contained the components listed in 
Table 2.3.1.2.  For primers encompassing GC-rich regions, PCR reactions were also 
supplemented with 10%v/v DMSO. 
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Table 2.3.1.2. PCR reaction components 
Component Volume [μl] 
10X Polymerase Buffer  1.5 
10 μM Forward Primer  0.5 
10 μM Reverse Primer  0.5 
25 ng/l DNA Template  2 
2 μM dNTPs 1.5 
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2.3.1.3 Agarose gel electrophoresis 
The outcome of PCR reactions was determined by agarose gel electrophoresis.  PCR products 
(3.5μl) were diluted in 5X DNA loading buffer (1.5μl), and loaded on a 2% agarose gel 
supplemented with 0.5 mg/ml ethidium bromide. Hyper ladder II was used as a molecular 
weight marker. Amplification products were separated at 200 Volts for 15 minutes, and 
visualized under UV light (UVP, GelDoc-It310 Imaging Syetem). 
 
2.3.2 Sanger sequencing 
2.3.2.1 PCR Product purifications 
In order to remove unincorporated dNTPs and primers, 2 μl of each PCR product were 
transferred into a non-skirted 96-well plate, treated with 3 μl of IllustraExoStar 1 solution 
(0.125μl of Illustra ExoStar1 diluted in 2.875 μl ddH2O), and incubated at 37°C for 30 min 
and 80 °C for 15 min.  
 
2.3.2.2 Sequencing reaction 
One point twenty five microliter of 5X BigDye Terminator sequencing buffer, 0.25 μl of 
BigDye Terminator v3.1, and 0.25 μl of 10μM sequencing primer were added to each purified 
sample. Sanger sequencing reactions were performed under the following cycling conditions: 
30 cycles at 96 °C for 30 sec, 50°C for 15 sec, and 60°C for 1 min. For sequencing plasmid 
DNA, 1μl of 5X BigDye Terminator sequencing buffer, 2 μl of BigDye Terminator v3.1, and 
0.32 μl of 10 μM sequencing primer were added to 3 μl of 30 ng/μl plasmid DNA, and diluted 
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in water to a final volume of 10 μl. 
 
2.3.2.3 Purification of sequencing reaction 
Sequencing reaction products were treated with 26 μl of precipitation solution (50ml of 95% 
ethanol solution mixed with 2ml of 3M NaOAc, pH=4.6), incubated at room temperature for 
10 min, and then centrifuged at 3000 rpm for 30 min at room temperature. Supernatants were 
removed by inverting the plates and centrifuging them for a few seconds at 300 rpm. Pellets 
were resuspended in 100 μl 70% ethanol solution and centrifuged at 3000 rpm for 15 min at 
room temperature. Supernatants were removed as described above, and pellets were air dried 
for at least 15 min at room temperature. Dried pellets were resuspended in 10 μl of HiDi 
formamide and denatured at 96 °C for 2 min. The samples were run on a 3730xl 
ABIsequencer (Applied Biosystems). 
 
2.3.3 Microsatellite genotyping 
Primer sequences were obtained from the GeneLoc database (Appendix III). After optimising 
annealing temperatures by gradient PCR, the region spanning the microsatellite was amplified 
by standard PCR , using a forward primer that was labelled with 5’-FAM. Gel electrophoresis 
was performed to confirm target amplification. PCR products were diluted 1:20 to 1:80 
depending on band intensity.  Next, 1 μl of diluted sample was supplemented with 8.75 μl 
HiDi and 0.25 μl of TAMRA Sizing Standard. Reactions were run on a 3730xl AB Sequencer. 
Fragments were analysed with Peak Scanner (v1.0). 
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2.4 Whole-exome sequencing 
2.4.1 Sample selection for whole-exome sequencing 
The samples were selected to provide a phenotypically homogeneous cohort of patients.  
The foremost criterion was the presence of a severe disease, manifesting at an early age (<35 
years old), with signs of systemic inflammation. To obtain the relevant clinical information, 
all available CRFs were systematically interrogated. Once a small number of cases were 
selected for analysis, the accuracy of the data reported in the CRF was validated by contacting 
the dermatologist who had recruited the patient. Individuals with a family history of 
generalised pustular psoriasis were further prioritised,. 
 
2.4.2 Sample preparation for whole-exome sequencing 
Genomic DNA samples were diluted in 130 μl TE to a final concentration of 30 ng/μl. Sample 
concentration was determined by using a Qubit 2.0 Fluorometer. 
 
2.4.3 Whole-exome sequencing 
Sequencing libraries were prepared by the personnel of Guy’s and St Thomas Hospital 
Biomedical Research Centre (BRC) core genomics facility. Briefly, 3 μg DNA were diluted in 
130 ml 1X TE and sheared into150-200 bp fragments with a Covaris M220 ultrasonicator. 
Libraries were prepared using the SureSelect Library Prep Kit. DNA fragments were purified 
with Agencourt AMPure XP beads and repaired to produce blunt-ended 5’-phosphorylated 
ends. 3’-dA overhangs were added to these repaired fragments, and indexing-specific paired-
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end adapters were ligated. Each library was amplified with a Herculase II Fusion DNA 
Polymerase Kit under the following cycling conditions:  98°C for 2 minutes, (98°C for 30 
seconds, 65°C for 30 seconds, 72°C for 60 seconds) x 5, 72°C for 10 minutes. The quality and 
concentration of amplification products were determined using an Agilent 2100 Bioanalyzer 
and a Qubit 2.0 Fluorometer, respectively. 
 The BRC technicians also undertook the exome capture procedure, using the Agilent Sure 
Select Human All Exome Kit v.4, according to the manufacturer’s protocol. Briefly, libraries 
were hybridised for 24h at 65C, purified on a Dynal magnetic separator, and amplified under 
the following cycling conditions: 98°C for 2 minutes, (98°C for 30 seconds, 57°C for 30 
seconds, 72°C for 60 seconds) x 10, 72°C for 10 minutes. After index tags were added, the 
quality and concentration of the preparation were assessed with the Agilent 2100 Bioanalyzer 
High Sensitivity DNA assay. Following that, samples were pooled for multiplex sequencing 
and prepared for cluster amplification.  
 
2.5 Plasmid DNA manipulation 
2.5.1 Plasmid transformation and propagation 
Thirty nanograms of wild-type pcDNA3-CARMA2-sh.1 plasmid were added to 50 μl of NEB 
5-alpha competent E.coli cells thawed on ice. The cells were incubated on ice for at least 45 
minutes, heat shocked at 42°C for 45 seconds, and incubated on ice for another 5 minutes. 
Five hundred microliters of pre-warmed SOC medium was added to the bacteria and the 
culture was incubated at 37°C for at least one hour. The cultures were centrifuged for 3 
minutes at 6000 rpm and 400 μl of the supernatant was discarded. The bacteria were re-
suspended in the remaining 100 μl medium and the cell suspension was spread on LB agar 
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plates containing 100 μg/ml ampicillin. The plates were incubated at 37°C overnight;, single 
colonies were picked next day and used for the inoculation of 5 ml LB broth supplemented 
with 100 μg/ml ampicillin. The small cultures were grown in a Barnstead SHKE6000 shaker 
incubator, at 37°C and 180 rpm for 8 hours. Plasmid DNA was isolated by using the QIAprep 
Miniprep Kit, while 500 μl of culture was used to inoculate 50 ml of LB broth supplemented 
with 100μg/ml ampicillin. Large cultures were incubated overnight as described above and 
plasmid DNA was isolated using the HiSpeed Midi Kit according to the manufacturer’s 
protocol. The concentration of the plasmid DNAs was assessed with a NanoDrop ND-1000 
Spectrophotometer and the sequence of the insert was verified by Sanger sequencing. 
Plasmids were stored as glycerol stocks (750ml overnight culture supplemented with 250 ml 
80% glycerol) and recovered by streaking 30 μl bacteria on an LB agar plate supplemented 
with 100 μg/ml ampicillin. Single colonies were picked the next day and processed as 
described above. 
 
2.5.2 Site-directed mutagenesis 
Mutagenic primers were designed with the QuikChange Primer Design tool, according to the 
manufacturer’s instructions (Table 2.5.2, Figure 2.5.2). The mutagenesis reactions were set up 
in a final volume of 50 μl, using 30 ng plasmid DNA and the reagents provided by the 
QuikChange Lightning Site-directed Mutagenesis Kit. The protocol provided by the 
manufacturer was used with minor modifications. In particular, the DpnI digestion time was 
extended from 5 to 15 min and the reaction products were concentrated by ethanol 
precipitation. Briefly, 1/10 volume of NaOAc and 3 volumes of 95% ethanol were added to 
the reaction. After a 15 minute incubation on ice, the reactions were centrifuged for 30 
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minutes at 13,000 rpm, at 4°C. The supernatants were discarded and the pellets were rinsed 
with 70% ethanol before a 15 minute centrifugation at 13,000 rpm. After discarding the 
supernatant, the pellets were air-dried for 5 minutes and re-suspended in 10 μl water. The 
mutagenised constructs were transformed into E.coli XL-10 Gold ultracomptent cells, 
according to the manufacturer’s guidelines. Cells were propagated as described in 2.5.1 and 
constructs were validated by direct sequencing of the entire CARD14 coding sequence, pCMV 
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Figure 2.5.2. Plasmid used for site-directed mutagenesis 
The position of the FLAG tag and CARD14 cDNA within the multiple cloning site is 
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Table 2.5.2. Primers used for site directed mutagenesis 
Target change Primer ID Primer sequence (5’ to 3’) 
p.Gly117Ser G117S F GCT TGG ATG TCT CCA TGA GAC TGC TAA 
AGT TAC TGA AGT C 
G117S R GAC TTC AGT AAC TTT AGC AGT CTC ATG 
GAG ACA TCC AAG C 
p.Glu138Ala E138A F CCT TTT CCT GGT TCA GCG CCT CCT GCA 
GGC TGC C 
E138A R GGC AGC CTG CAG GAG GCG CTG AAC CAG 
GAA AAG G 
p.Leu156Pro L156P F AGG TGC TCC TGC GGC TGC TGG CAC C 
L156P R GGT GCC AGC AGC CGC AGG AGC ACC T 
p.Asp176His D176H F CAT GCG GCT GTG GTG AGC CTC CAG CTG 
GT 
D176H R ACC AGC TGG AGG CTC ACC ACA GCC GCA 
TG 
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2.6 Cell culture 
2.6.1 Cell lines 
Human embryonic kidney (HEK293) cell cultures were handled under aseptic conditions, in a 
laminar flow hood contained in a designated tissue culture room. Cell lines were grown at 
37°C, in a NuAir Air-Jacketed Automatic CO2 Incubator (NU-5500) providing humidified 
atmosphere with 5% CO2. Cultures were tested for mycoplasma contamination once every 3 
months, using the MycoSensor PCR Assay Kit according to the manufacturer’s instructions. 
Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
Foetal Calf Serum (FCS), 2mM L-Glutamine, 50 U/ml of penicillin and 50 μg/ml of 
streptomycin (complete medium). Cultures were stored in liquid nitrogen. When thawing 
aliquots, cryo-vials were hand warmed and sequentially diluted in 1 ml of FCS and 9 ml of 
pre-warmed complete medium. Next day, at passage no.1, the medium was removed; cells 
were washed with 3 ml of PBS, and then trypsinised by adding 3 ml of TrypLE. After 5 min 
incubation at room temperature, detached cells were diluted in pre-warmed complete medium 
to stop trysinisation, and then centrifuged at 1500 rpm for 5 minutes. Supernatants were 
discarded, cell pellets re-suspended in 10 ml of complete medium, and plated in a T75 flask. 
These steps were repeated every time the cells reached ~80-90% confluency, when cultures 
were passaged by transferring 1 ml of cell suspension to a new T75 flask. 
For storage in liquid nitrogen, 2x106 cells were diluted in 1ml of chilled, freshly prepared and 
filter-sterilised freezing medium consisting of 90% FCS and 10% of DMSO. The cryo-vials 
were immediately placed in a MrFrosty container at -80°C for ~24hours and then transferred 
to a liquid nitrogen tank.  
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2.6.2 Transfection 
To investigate the impact of CARD14 variants on protein expression, 2.5x105 HEK293 cells 
were seeded in 1 ml of DMEM supplemented with 10% of FCS, in 12-well plates. The 
following day, 1.6 μg of plasmid DNA was transfected using the Lipofectamine2000 
Transfection reagent according to the manufacturer’s guidelines. The medium was changed 6 
hours after transfection to 1 ml of DMEM supplemented with 10% FCS per well. Cells were 
harvested for protein extraction 48 hours after transfection.  
For immunofluorescence microscopy, HEK293 cells were seeded on poly-D-lysin coated 
coverslips (Becton Dickinson) in a 24-well plate, at a density of 1.25x105 cells per well, in 
500 ml of DMEM supplemented with 10% FCS. The following day, 0.8 μg of plasmid DNA 
was transfected using the Lipofectamine2000 Transfection reagent according to the 
manufacturer’s guidelines. Media was changed 5 hours after transfection to 500 ml of DMEM 
supplemented with 10%FCS per well. 
 
2.6.3 Immunofluorescence microscopy 
Twenty-four hours after transfection, the medium was aspirated and cells were carefully 
washed in 500 μl PBS for two times. Coverslips were covered with 350 μl of 4% 
paraformaldehyde freshly diluted in PBS and cells were fixed for 15 min at room temperature. 
The formaldehyde solution was aspirated and cells carefully rinsed in 350 μl of PBS for 5 
minutes. After the washing step was repeated three times, specimens were incubated in 350 μl 
Blocking Buffer for 1 hour at room temperature. The blocking solution was aspirated and 0.6 
μl DYKDDDDK Tag primary antibody (targeting FLAG) diluted in 350 μl Antibody Dilution 
Buffer was directly applied to each well. After an overnight incubation at 4°C, the primary 
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antibody was aspirated and coverslips were rinsed three times in PBS, for 5 min per wash. 
Specimens were incubated in Alexa Fluor® 488 Goat Anti-Rabbit IgG diluted in 350 μl 
Antibody Dilution Buffer for 1 hr and 10 min at room temperature, in the dark. Coverslips 
were carefully rinsed three times in PBS for 5 min and mounted onto slides using ProLong 
Diamond Antifade reagent containing 4', 6-diamino-2-phenylindole (DAPI). Coverslips were 
sealed with transparent nail polish to prevent drying out of the samples. Slides were stored in 
the dark at 4°C and imaged at least 24 hours later, using immunofluorescence microscopy 
(ZEISS, AxioCAM MRm microscope and ZEISS Axiovision Software Version 4). A 
minimum of 25 cells per coverslips were examined for the presence of CARD14 oligomers in 
their cytoplasm. 
 
2.7 Transcript analysis 
2.7.1 RNA extraction 
The procedure was performed under hood, using filter tips. Prior to RNA extraction, all 
surfaces and pipettes were treated with RNaseZap Decontamination Solution. Cell pellets 
were homogenised using the QIAshredder columns and RNA was extracted with the RNeasy 
Mini Kit according to the manufacture’s guidelines. RNA was eluted in 30μl of RNase-free 
water and quantified with a NanoDrop ND-1000 Spectrophotometer. Samples were stored in 
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2.7.2 cDNA synthesis 
One microgram of total RNA was reverse-transcribed using the High Capacity cDNA Reverse 
Transcription Kit, according to the manufacturer’s protocol. The reactions were incubated at 
25°C for 10 minutes, 37°C for 120 minutes, and 85°C for 5 minutes. After the reverse 
transcription was completed, the cDNAs were diluted by adding 30 μl of nuclease-free water 
to each reaction. Skin, CD4+T lymphocyte, and RNAs used in the ARFGPA2 study were 
generously provided by Prof. Nestle’s group at KCL. The remaining samples were generated 
by other members of the Capon group. 
 
2.7.3 Real-time PCR 
PPIA transcript levels were measured using a fluorescent, VIC labelled TaqMan probe 
purchased from Life Technologies (see Table 2.7.3). Reactions were set up in duplicate, in a 
final volume of 20μl containing 1 μl probe, 1X TaqMan Universal Master Mix II, and 2μl of 
diluted cDNA.  
ARFGAP2 transcript levels were measured with the KAPA SYBR FAST qPCR kit, using 
primers designed in house and purchased from Eurofin Genomics. Reactions were set up in 
duplicate, in a final volume of 20μl containing 1X KAPA SYBR FAST Universal qPCR 
Master Mix, 45 nM primers (Table 2.7.3, Appendix II), and 2 μl of cDNA. Samples were 
loaded on a 7900HT Fast Real Time PCR System and run under the following cycling 
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2.7.4 Gene expression analysis 
Relative gene expression was quantified with the ΔΔCt method (Livak et al., 2001).  PPIA 
was used as endogenous control. The average detection threshold cycle (Ct) of each duplicate 
sample was calculated and the ΔCt was derived with the following formula:                           
ΔCt  = Ct[sample] – Ct[PP1A] 
ΔCt values were then normalized to those of a calibrator sample: 
                                 ΔΔCt  = ΔCt[sample] – ΔCt[calibrator] 
Finally, relative gene expression levels (RQ) were calculated using the following formula:                                               
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Table 2.7.3. Primers and probe used for real-time PCR 
Primer ID Transcript target 
ARFGAP2 Main ARFGAP2 full length transcript (ENST000000524782)  
ARFGAP2 2nd Main ARFGAP2 isoform lacking exon 5 (ENST000000426335)  
4310883E  PPP1A (ENST00000312989) 
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2.8 Protein analysis 
2.8.1 Sample preparation  
Cells were trypsinized as described in 2.6.1, centrifuged at room temperature for 5 minutes at 
5000 rpm, and washed twice with 500 μl PBS. The pellets were stored at -20°C overnight. 
For the preparation of whole-cell extracts, pellets were thawed and re-suspended in 70 ml of 
HU buffer. Suspensions were incubated for 5 min at room temperature, centrifuged for 15min 
at 65°C, and sonicated for 45 sec with a W-375 ultrasonic sonicator (Heat Systems 
Ultrasonics) to reduce their viscosity. Following that, samples were ready to load on a gel or 
store at -20 °C. 
For the separation of the soluble and insoluble cell fraction, pellets were thawed on ice and 
initially re-suspended in 70 μl of ice-cold, non-denaturing cell lysis buffer, freshly 
supplemented with 10μl 7X protease inhibitors. Cell suspensions were incubated on ice, in a 
4°C cold room, for at least 40 minutes, and centrifuged at 13000 rpm at 4°C for 15 minutes. 
Supernatants were transferred to new, pre-chilled Eppendorf tubes and stored at -80°C or 
immediately loaded on a gel. Pellets were re-suspended in denaturing buffer, and processed as 
described above. 
 
2.8.2 Gel preparation 
The 8% separating gel contained 2.7 ml Ultra PureProtoGel 30% Acrylamide Mix, 2.5 ml 
1.5M Tris pH 8.8, 100 μl 10% SDS, 100 μl 10% Ammonium Persulfate, and 6 μl TEMED, in 
a final volume of 10 ml.  To create a straight, clear cut junction between the stacking and 
separating gel, 500 ml of isopropanol was applied to the top of the gel.  After the separating 
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gel had polymerized (~5-10 min), the isopropanol was removed, and 2 ml of stacking gel (330 
μl acrylamide mix, 250 μl Tris pH 6.8, 20 μl 10% SDS, 20 μl 10% Ammonium Persulfate, 2 
μl TEMED) was poured on top. The gel was stored at 4°C overnight, soaked in 1X Running 
buffer. 
 
2.8.3 Western Blotting 
Thirty five microliters of lysate were mixed with 10 ul 6X Laemmli buffer, denatured at 95-
98°C for 5 minutes and loaded on the polyacrylamide gel, alongside 7 l of Precision Plus 
molecular weight marker.  The gel was electrophoresed in 1X running buffer for at least 60 
minutes at 150 Volt. Wet transfer to a nitrocellulose membrane (brand) was carried out in a 
Biorad Mini Trans-Blot Electrophoresis transfer cell apparatus at 200 mA for 1 hour 45 min, 
at 4°C. To evaluate transfer efficiency, the membrane was stained with Ponceau S red dye. To 
inhibit unspecific antibody binding, the membrane was incubated in 5% milk-1X TBS-0.1% 
Tween 20 for at least one hour at room temperature. After blocking, the membrane was 
incubated overnight at 4°C with the primary antibody (Monoclonal ANTI-FLAG M2, Clone 
M2, or Rabbit polyclonal anti-β–actin, see 2.1.7 for dilutions). The membrane was then 
washed 6 times in 1X TBS-0.1% Tween 20 for 5 minutes. For the secondary antibody 
staining, the membrane was incubated at room temperature with a peroxidase-linked species-
specific antibody (Goat polyclonal  anti-mouse IgG or Donkey monoclonal anti-rabbit IgG) 
diluted in 5% skimmed milk/1X TBS-0.1% Tween 20 (see 2.1.7 for dilutions). After 1 hour, 
the antibody was discarded and the membrane was washed 6 times as described above. For 
signal detection the membrane was treated with the Amersham ECL Western Blotting System 
for 1 minute. Fujifilm Super RX autoradiography films were exposed to the ECL-treated 
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membrane and developed using an automated film developer (KONICA MINOLTA SRX-
101A). 
 
2.8.4 Densitometric analysis  
Autoradiographs were scanned with a Canon CanoScanLiDE 25 device and densitometric 
analysis was performed with the ImageJ software, according to the manufacturer’s directions. 
The densities of both the protein of interest and loading control (β -Actin) were determined.  
 
2.9 Bioinformatics 
2.9.1 Sanger sequence data analysis 
Reference sequences were obtained from the Ensembl genome browser (Flicek et al., 2014, 
Genome assembly: GRCh38) and chromatograms were analysed with the Sequencher 
software (v4.9, Genecodes). Variants were detected by visual inspection of contigs. 
 
2.9.2 Pathogenicity predictions 
The SIFT/PROVEAN (Ng and Heinkoff, 2003), Align GVD (Tavtigian et al., 2005) and 
Polymorphism Phenotyping v2 (PolyPhen-2, Adzhubei et al., 2010) online tools were used to 
analyse the likely impact of single nucleotide changes and small (~up to 6 basepairs) 
deletions/insertions. The effects of splice site variants were investigated with SROOGLE 
(Schwartz et al., 2009) and MaxEntScan (Yeo and Burge, 2004), while Mutation Taster 
(Schwartz et al., 2014) and CADD (Kircher M, 2014) were used for both class of changes. 
The ClustalW2 program was used to estimate whether a variant affected an evolutionarily 
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conserved residue (Thompson, 1994). Reference sequences for all tools mentioned above 
were obtained from the Ensemble Genome browser (Flicek et al., 2014, Genome assembly: 
GRCh38). 
 
2.9.3 Coiled-coil prediction 
The following tools were used to assess what portions of the CARD14 protein were more 
likely to form coiled-coil domains and to assess the impact of mutations lying in such regions: 
COILS (Lupas, 1991), MultiCoil (Wolf, 1997), NCOILS (Lupas, 1996) and STRAP project 
(Gille, 2008). Reference DNA and protein sequences were obtained from Ensembl (Flicek et 
al., 2014). 
 
2.9.4 Haplotype analysis of the CARD14 locus 
Haploview (v4.2, Barrett et al., 2005) (Appendix III) was used to visualize linkage 
disequilibrium blocks within the CARD14 locus and to identify informative SNPs (rs4889991, 
rs2044103, rs3829612, rs8068433; Sugiura et al., 2014) tagging common CARD14 haplotypes 
in the Chinese population. The analysis was carried out on the CHB (Han Chinese from 
Beijing) genotypes generated by International HapMap Project Consortium (The International 
HapMap Consortium, 2007). Primers were designed according to Sugiura et al, for genomic 
regions spanning the above four SNPs. The relevant regions were sequenced in the four 
patients harbouring the p.Asp176His variant.  
2.9.5 Exome sequence data processing 
The raw sequence data generated by an Illumina HiSEq1000 sequencer was processed 
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through a software pipeline, originally established by Prof Michael Simpson and currently 
managed by Guy’s and St Thomas’ Hospitals BRC Bioinformatics core. Briefly, 100 bp 
paired-end reads were aligned to the reference hg19 genome with Novoalign (Novocraft 
Technologies), duplicates and poor quality reads were removed with MarkDuplicates and 
SAMtools (Li et al., 2009), while capture efficiency was assessed with BEDtools (Quinlan et 
al., 2010). Changes that were covered by more than four reads were called with SAMtools, 
and annotated to known genes with Annovar (Wang et al., 2010).  
 
2.9.6 Exome sequence data filtering 
Annovar annotated files were imported and analysed in Microsoft Excel. Variant profiles were 
initially filtered by removing synonymous substitutions and common alleles occurring with a 
minor allele frequency (MAF) > 0.015 in 2,222 exomes sequenced in-house or the 1000 
Genomes Project CEU dataset. Rare changes were further filtered based on the predicted 
mode of inheritance of the disease allele: 
A) In the analysis of cases born into consanguineous marriages, sequencing profiles were 
filtered to exclude all heterozygous changes. Homozygosity clusters were determined 
by the manual analysis of variant profiles around rare variants. Stretches of 
homozygous markers spanning at least 2 Mb were considered as most likely 
autozygous, based on the observations of Alsalem et al., and McQuillan et al. Hence 
variants lying in such regions were prioritised.  
B) In the analysis of familial GPP cases, the predicted mode of inheritance was inferred 
from the pedigree structure and variant profiles were filtered by excluding single 
heterozygous (for recessive pedigrees) or homozygous changes (for dominant 
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pedigrees), as appropriate. 
C) In the isolated cases, both homozygous and heterozygous changes were studied, as it 
was not possible to infer the most likely mode of disease inheritance. 
 
Filtered profiles were allocated to different analysis groups according to the predicted mode of 
inheritance of the disease allele. Genes that were mutated in multiple families were prioritised 
for analysis and the variants they harboured were assessed for pathogenicity, using the online 
tools described in 2.9.2. Changes that were predicted to be deleterious by four out of five 
algorithms were followed-up, the rest were filtered out. In individuals of Asian descent, allele 
frequencies in relevant control populations were also taken into account, and variants with 
frequencies of higher than 0.015 were removed from the list of possible candidates (Table 
2.2.5). Given the numerous candidates in the dominant group, putative mutations were further 
prioritised by ranking them on the basis of their CADD scores.  
 
2.9.7 Quality control of exome sequence reads  
The accuracy of all variant calls that passed the above filtering steps was verified using the 
Integrative Genomic Viewer (IGV) tool (Robinson et al., 2011). Changes supported by a 
small number of reads (n<6) and variants surrounded by numerous mismatches were deemed 
to be artifacts and excluded from further analyses (Figure 2.9.7).  
If the sequence change was validated by the IGV analysis, reads spanning the relevant gene 
were also inspected in samples that did not appear to present any damaging alleles. This was 
to make sure that the lack of mutation was not the consequence of poor coverage. 
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Figure 2.9.7. Examples of high confidence (a) and low confidence (b) variant calls using 
IGV. The IGV program aligns sequence reads to a reference genome. In case of complete 
sequence homology only reference bases are shown. Variants covered by many reads are 
considered high confidence calls (a), whereas the presence of numerous mismatches around 
the base change indicates that the reads have probably been misaligned. The calls are 
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2.9.8 Analysis of Copy Number Variants (CNV) 
The occurrence of CNVs was assessed by using the ExomeDepth tool (Plagnol et al., 2012) to 
analyse read counts. The frequency of CNVs in the general population was determined by 
querying the Ensembl genome browser (Flicek et al., 2014).  
 
2.10 Statistical analyses 
2.10.1 Power calculations 
In order to measure the probability of detecting variants with varying MAFs, a power 
calculation was performed with an online binomial calculator (Appendix III). The Genetic 
Power Calculator (Purcell et al., 2003) was used to estimate the probability of identifying 
disease associated SNPs occurring with varying frequencies and effect sizes. Power ≥80% 
was considered adequate. 
 
2.10.2 Association testing 
Because there is a very strong expectation that rare deleterious variants will be enriched and 
not reduced in frequency among affected patients, all analyses were implemented as one-
tailed association tests. Depending on the sample size, Fisher’s exact test or Chi-square tests 
with Yates correction were used to assess the association between individual gene variants 
and disease phenotypes. In the study of ARFGAP2, and CYP1A1, burden tests were used to 
assess the cumulative effects of deleterious changes in the relevant gene region. All tests were 
performed using Graphpad and cases were always compared to controls of similar ethnicity. 
 In the investigation of CARD14 and CYP1A1, a meta-analysis of different association studies 
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was performed by using the RevMan 5.2 software to calculate a weighted pooled odds ratio 
and Z score (Cochrane Collaboration, 2012). 
For the study of common IL36RN alleles in PV, genome-wide association data was available 
for 2,622 patients with psoriasis and 5,667 controls (Strange et al., 2010). Genotype data was 
extracted for a 26 kb interval (2:113,806,215- 113,832,325 , GRCh37) spanning the IL36RN 
gene and 10 kb of flanking regions. Experimental genotypes were integrated by imputing 
additional SNPs with IMPUTE v2 (Howie et al., 2009), using the 1000 Genome haplotypes as 
a reference set. Imputed SNPs showing minor allele frequencies < 0.01, info scores < 0.5, or 
extreme deviations from Hardy-Weinberg equilibrium (P <1x10-6) were excluded from further 
analyses. Association tests accounting for the uncertainty in the imputed genotypes were 
implemented under additive and recessive models using SNPTEST (Marchini et al., 2007).  
For the analysis of rare IL36RN variants in PV, genotypes were extracted from a large case-
control dataset (11,801 cases and 27,233 unrelated controls), which had been typed by the 
International Psoriasis Consortium, using Illumina’s HumanExome Beadchip. Combined 
allele counts were compared in cases vs. controls, using Fisher’s exact test.  
 
2.10.3 Multiple testing and significance thresholds 
For candidate gene studies, P values smaller than 0.05 were considered to be nominally 
significant. No correction for multiple testing was required for the IL36RN analysis (no P 
values < 0.05 were observed) or the CARD14 study (only one SNP was examined). For the 
follow-up of WES, the issue of multiple statistical testing was addressed by adopting an 
exome-wide significance threshold of P<1.5 x10-6 (Kiezun et al, 2012).  
 
               99 
2.10.4 Densitometry data analysis 
The densitometry data were analysed with GraphPad Prism 6.0 (GraphPad Software, La Jolla, 
CA) using one-way ANOVA, followed by a Dunnett’s post-test. P values < 0.05 were 
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3 GENETIC ANALYSIS OF IL36RN ALLELES IN PSORIASIS VULGARIS 
 Generalised pustular psoriasis often presents with concomitant psoriasis vulgaris, 
suggesting the existence of shared genetic determinants between the two conditions (Sugiura 
et al., 2014). In this context, the possibility that IL36RN alleles may confer susceptibility to 
plaque psoriasis looks particularly plausible given that IL-36 cytokine levels are elevated in 
the lesional skin of PV patients (Blumberg et al., 2007; Carrier et al., 2011; Johnston et al., 
2011), and that il36rn knockout exacerbates psoriasis-like skin inflammation in il36a 
transgenic mice (Blumberg et al., 2007; Carrier et al., 2011; Tortola et al., 2012). Therefore, 
the aim of this project was to investigate in association studies whether IL36RN variation 
contributes to PV susceptibility.  
 
3.1 Common variant analysis 
Single nucleotide polymorphisms in IL36RN detected in a previous genome-wide 
association study were re-examined first (Strange et al., 2010). 
 
3.1.1 Power calculations 
The study included 2,600 PV patients and 5,700 controls of British origin. Calculations 
were undertaken by assuming a 2% population prevalence of psoriasis and indicated that the 
study had 80% power to detect disease associated alleles occurring with a frequency ≥1.5%, 
provided the Genotype Relative Risk (GRR) exceeded 1.4. Variants with a GRR ≥1.1 could 
also have been detected (80% power), if their frequency was above 40% (Figure 3.1.1). 
 
 





Figure 3.1.1. Required Genotype Relatives Risk and Minor Allele Frequency values to reach 
80% power. Calculations were performed by the online Genetic Power Calculator (Purcell et 
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3.1.2 Analysis of IL36RN genotypes from genome-wide association data  
The genotypes generated by Strange et al. were supplemented by imputing additional 
markers with IMPUTE v.2 (Howie et al., 2009), using the 1000 Genomes haplotypes as a 
reference. The resulting dataset included a total of 130 single-nucleotide polymorphisms 
spanning the IL36RN locus and 10 kb of flanking regions (the latter were included in the 
analysis so as to cover likely regulatory regions lying in proximity of the gene). The 
genotypes were examined under a recessive model, using SNPTEST. No markers generated a 
P-value <0.05, indicating that common IL36RN variants are unlikely to confer a substantial 
PV risk.  
 
3.2 Rare variant analysis 
3.2.1 Case selection 
IL36RN mutations are highly penetrant in GPP (Capon, 2013). Therefore, it was 
assumed that IL36RN alleles associated with psoriasis vulgaris would result in familial 
recurrence of the disease, or lead to very severe phenotypes. On this basis, 349 probands (175 
females, 174 males) with a family history of PV (Table 2.2.1 in methods) and 14 individuals 
(10 females, 4 males) with severe erythrodermic psoriasis were selected for analysis.  
 
3.2.2 Power calculations 
Power calculations were undertaken at the outset of the study. The first analysis was 
performed with an online binomial calculator and demonstrated that Sanger sequencing the 
patient resource (726 chromosomes) would have 80% power to detect alleles occurring with a 
frequency of at least 0.25% (Figure 3.2.2/A), while variants with lower frequencies might 
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have been missed.  
A further analysis was carried out with the Genetic Power Calculator (Purcell et al., 
2003), assuming a PV prevalence of 2%. This showed that the dataset consisting of 363 
patients and 2,313 controls could reveal disease associations with 80% power in the presence 
of allele frequencies as low as 0.10%, as long as the Genotype Relative Risk (GRR) was 
higher than 5 (Figure 3.2.2/B). Of note, the p.Ser113Leu variant has a minor allele frequency 
of 0.28% in the British population and has been associated with a GRR of 4.9 in pustular 
psoriasis (Setta-Kaffetzi et al., 2013). Thus, the study would have 80% power to detect an 
association with this change, which represents the most common GPP allele in European 
populations (Setta-Kaffetzi et al., 2013). Smaller effect sizes (GRR ≥2.75) could have been 
also detected, provided the frequency of the risk allele was higher than 0.5%, although those 


















Figure 3.2.2. Power to identify rare disease alleles (A) and to detect disease associations (B) 
The power was estimated using the online binomial calculator (A) and the Genetic Power 
Calculator (B) (Appendix III; Purcell et al., 2003). The calculations were performed on 363 
patients and 2,313 controls. 
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3.2.3 Sanger sequencing of IL36RN coding exons in familial psoriasis vulgaris 
Sequencing of the IL36RN coding sequence (exons 2-5) and proximal promoter region 
(1,070 bp) did not identify any rare alleles in the homozygous or compound heterozygous 
state, indicating that bialleleic IL36RN mutations did not underlie the onset of PV or 
erythrodermic psoriasis, in the examined cases. 
  One PV patient harboured a Threonine to Isoleucine substitution (p.Thr77Ile). The 
change; however, was predicted to be tolerated by five different algorithms and as a result was 
not studied any further (Table 3.2.3.1). Two additional individuals with psoriasis vulgaris 
carried a copy of the p.Ser113Leu mutation, which is the most frequent pustular psoriasis 
allele in European populations (Setta-Kaffetzi et al., 2013). To further investigate the 
pathogenic potential of the Ser113Leu variant in these subjects, the segregation of the 
substitution was analysed in the relevant two pedigrees.  
In one family (upper panel in Figure 3.2.3), the affected children inherited the 
mutation from their unaffected mother, while their affected father carried a wild-type allele. In 
the second pedigree (lower panel in Figure 3.2.3), two affected siblings harboured the 
p.Ser113Leu substitution, but a third brother did not. These observations demonstrate that 
p.Ser113Leu does not segregate with PV in the families.   
To complement these findings, the frequency of the p.Ser113Leu in the PV cases was 
compared with that observed in 2,313 unrelated controls of British origin. This failed to 
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 Table 3.2.3.1. Pathogenicity predictions for the rare variants detected in the study 
Variant PROVEAN SIFT PolyPhen-2 Mutation Taster CADD1 
p.Thr77Ile Tolerated Neutral Benign Polymorphism 1.2 
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Table 3.2.3.2. Distribution of the p.Ser113Leu allele in PV cases and controls 
Variant Location rs number Allele frequencies (allele counts) P value 
Cases Controls 
p.Ser113Leu Exon 5 rs144478519 0.003 (2/726) 0.0035 (16/4626)1 0.76 
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Figure 3.2.3. Segregation of the p.Ser113Leu variant in the families of the two patients who 
were originally Sanger sequenced. Grey symbols represent individuals affected by PV. 
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3.2.4 Analysis of IL36RN genotypes from exome-wide association data 
The study described in 3.2.3 had < 80% power to detect association with very rare 
variants (MAF<0.25%). Therefore, a larger resource was also examined. Data on IL36RN 
coding variants was extracted from a collaborative study of 11,801 PV cases and 27,233 
controls (Table 3.2.4.1), which had been typed on Illumina’s HumanExome Beadchip. 
Genotypes were available for six rare, single nucleotide changes lying within IL36RN. Three 
were known disease alleles (p.Pro27Leu, p.Arg48Trp, p.Ser113Leu) (Marrakchi et al., 2011; 
Onoufriadis et al., 2011), whereas the remaining three (p.Lys35Arg, p.Asn47Ser, p.Pro82Leu) 
were predicted to be benign by multiple algorithms (Table 3.2.4.2) and were therefore 
excluded from further analyses. 
 A comparison of allele counts between patients and controls detected no statistically 
significant differences for any of the three pathogenic alleles (Table 3.2.4.3). A burden test 
based on the combined frequency of deleterious alleles in each group was also undertaken, but 
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Table 3.2.4.1. Participants in the study 
 
Origin Cases Controls Total 
UK 2,431 5,892 8,323 
Estonia 1,264 1,252 2,516 
Germany 2,508 14,541 17,049 
USA 5,598 5,548 11,146 
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Table 3.2.4.2. Changes with predicted neutral outcome 
 
AA Change Pathogenicity Predictions 
PROVEAN SIFT Polyphen-2 Mutation Taster CADD1 
p.Lys35Arg Neutral Tolerated Benign Polymorphism 22.7 
p.Asn47Ser Neutral Tolerated Possibly 
damaging 
Polymorphism 22 
p.Pro82Leu Neutral Deleterious Benign Disease causing 23.2 
1The CADD algorithm returns a quantitative prediction, with scores above 15 considered 
pathogenic. Variants that were deemed to be pathogenic are highlighted in bold. Abbreviation 
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Table 3.2.4.3. Frequency of deleterious IL36RN alleles in cases vs. controls 






















Abbreviation is as follows: AA, amino acid. The differences in total allele counts are 
due to slight variations in SNP genotyping rates. P values were calculated with Chi-
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3.3 Analysis of IL36RN mutations in GPP patients with concurrent psoriasis vulgaris 
To further investigate the pathogenic role of IL36RN in psoriasis vulgaris, the 
prevalence of disease alleles was compared in individuals affected by GPP only or GPP 
presenting with concomitant PV.  
Data on IL36RN mutation status and PV concurrence was first collated by Safia 
Hussain through a thorough review of the literature, based on the terms “IL36RN” and 
“generalised pustular psoriasis”. This generated a dataset including 177 unrelated patients of 
African, Asian, and European origin. A further 56 cases were screened in-house specifically 
for this study (the work was partly undertaken by Safia Hussain, under Dorottya Berki’s direct 
supervision)-, so that genotype and phenotype information was available for a total of 233 
GPP patients, 136 of which also had PV (Tables 3.3.1 and 3.3.2).  
A total of fourteen rare IL36RN variants were detected in this resource. Four of these 
changes - p.Arg10X, p.Arg10Argfs*1, p.Leu27Pro, and p.Ser113Leu - have well established 
deleterious consequences (Farooq et al., 2013; Sugiura et al., 2012; Marrakchi et al., 2011;  
Onofriadis et al., 2011). The pathogenic potential of the remaining alleles was assessed by 
online tools, and six further rare variants were predicted to be damaging (Table 3.3.3).  
Patients harbouring bi-allelic (homozygous or compound heterozygous, n=36) or 
single heterozygous IL36RN changes (n=15) were classified as IL36RN-positive, whereas 
individuals who had a wild-type gene sequence were labelled as IL36RN-negative. A 
comparison of these two groups revealed that the prevalence of PV was significantly lower in 
individuals carrying mutations in IL36RN (43.14% vs. 68.67%, P= 0.0009, Table 3.3.4), 
further supporting the notion that IL36RN-deficiency does not confer an increased risk of PV.  
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Table 3.3.1. Key demographics of patients included in the analysis of 
genotype phenotype correlations  
 
Sex Ethnicity 






6 Male, 6 Female 
172 (73.8%) 
71 Male, 101 Female 
49 (21%) 















               115 
 
Table 3.3.2. The resource underpinning genotype-phenotype correlations   
Study  Number of GPP patients 
(with concomitant PV) 
Abbas et al., 2013 1 (0) 
Farooq et al., 2013 14 (5) 
Kanazawa et al., 2013 1 (1) 
Körber et al., 2013 17 (6) 
Li et al., 2013 10 (1) 
Marrakchi et al., 2011 9 (2) 
Onoufriadis et al., 2011 5 (0) 
Rossi-Semerano et al., 2013 1 (0) 
Renert-Yuval et al., 2014 1 (0) 
Setta-Kaffetzi et al., 2013 85 (65) 
Song et al., 2014 1 (0) 
Sugiura et al., 2013 28 (19) 
Sugiura et al., 2014 4 (1) 
This study 56 (36) 
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Table 3.3.3. Pathogenic potential of rare IL36RN changes  
Mutation Pathogenicity Prediction 
PROVEAN SIFT PolyPhen-2 Mutation 
Taster 
CADD1 
p.His32Arg Neutral Tolerated Benign Polymorphism 14.0 
p.Lys35Arg Neutral Damaging Benign Polymorphism 21.5 
p.Asn47Ser Neutral Damaging Probably 
Damaging 
Polymorphism 21.8 





p.Glu94X n/a n/a n/a Disease 
Causing 
37.0 
p.Arg102Gln Neutral Tolerated Probably 
Damaging 
Polymorphism 25.1 















p.Gly141Metfs*29  n/a n/a n/a Disease 
Causing 
n/a 
1The CADD algorithm returns a quantitative prediction, with scores above 15 considered 
pathogenic. These varinats were collected from the literature; none of them were detected upon 
sequencing 56 cases in-house. Variants with at least two neutral predictions were deemed to be 
tolerated, the rest were deemed to be deleterious and highlighted in bold. Abbreviation is as follows: 
n/a not applicable.  
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Table 3.3.4. Prevalence of concomitant PV in IL36RN positive vs. IL36RN 
negative patients.  
 Number of cases (%) 
Clinical Phenotype IL36RN positive1 IL36RN negative 
Isolated GPP 29 (56.86%) 52 (31.33%) 
GPP with concomitant PV 22 (43.14%) 114 (68.67%) 
1Homozygous, compound heterozygous, or heterozygous mutations 
Participants with unknown PV status (n =16) were excluded from the analysis. 
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3.4 Discussion 
The prevalence of PV among GPP patients markedly exceeds that observed in the 
general population, while no overlapping genetic factors have been identified between these 
disease phenotypes (Capon et al., 2012). However, experimental evidence - mostly obtained 
from animal studies - indicates that IL-36 cytokines contribute to the pathogenesis of PV. 
Blumberg et al. were the first to report that transgenic mice over-expressing Il36a in their 
keratinocytes show a psoriasis-like skin disorder, characterised by acanthosis, hyperkeratosis, 
and infiltration of inflammatory cells in the dermis and the epidermis. Importantly, the disease 
phenotype was more severe in animals that were deficient for Il36rn. Consistent with these 
results, Tortola et al. showed that Il36rn -/- mice experienced exacerbated symptoms of skin 
inflammation in an Imiquimod-induced model of psoriasis. Finally, a recent study by Milora 
et al. highlighted  IL36α as a key driver of psoriasiform skin inflammation.  
On the basis of the above observations, it was suggested that IL-36 blockade could be 
a novel therapeutic approach to the treatment of psoriasis (Tortola et al., 2012). This is not just 
a theoretical possibility, as an antibody targeting the IL-36 receptor had now been developed 
(Wolf and Ferris, 2014).  
At the same time, it is important to bear in mind that the pathogenic role of IL-36 
cytokines has not been investigated in human PV, as the only findings that are available are 
expression data indicating that the pathway agonists (IL-36α, IL-36β, IL-36γ) and antagonist 
(IL-36Ra) are up-regulated in psoriatic lesions (Blumberg et al., 2007; Carrier et al., 2011). 
Therefore, the goal of this study was to establish whether loss-of-function mutations of 
IL36RN confer PV susceptibility in humans. 
This objective was pursued through case-control studies, which were specifically 
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designed to detect associations with common and rare variants. 
The role of common alleles was investigated by re-examining the genotypes generated 
in a previous genome-wide association study of 2,600 PV patients and 5,700 controls. Despite 
evidence for adequate power and locus coverage, this analysis did not reveal any IL36RN 
changes that would confer risk for PV. Importantly, a number of GWAS have been carried out 
in recent years in various European and Asian populations (Yin et al., 2014; Tsoi et al., 2015), 
but none has generated evidence for association at the IL36RN locus. Thus, common IL36RN 
variants are unlikely to confer PV susceptibility. 
The role of rare variants was initially examined in a re-sequencing study, where the 
coding and proximal promoter region of IL36RN were screened in 363 unrelated psoriasis 
cases, selected on the basis of a positive family history. No homozygous or compound 
heterozygous mutations were detected in any of these individuals. The p.Ser113Leu allele, 
which is the most frequent GPP mutation in Europeans, was the only deleterious change 
observed among the PV patients. It was found in the heterozygous state in two patients, but 
the allele frequency of the variant was not different in psoriasis cases compared to controls, 
nor was the change segregating with the disease in the relevant pedigrees. Therefore, it can be 
concluded that IL36RN mutations are not highly penetrant in PV. Importantly, the power 
calculations indicated that the lack of association between rare variants and PV was most 
likely not the consequence of limited sample size, although the possibility of coding changes 
with small GRR could not be excluded. 
The issue of power was addressed by interrogating the results of a larger exome-wide 
study, including a total of 11,801 cases and 27,233 controls. When the frequency of rare 
IL36RN changes with pathogenic potential, was compared between PV cases and controls, no 
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significant differences were observed. While an association with variants that were not part of 
the genotyping platform cannot be formally ruled out, the likelihood that such markers were 
missed during the chip design is low, given that SNPs were selected based on the analysis of 
>12,000 exomes.    
Of note, the association findings were complemented by a study of genotype-
phenotype correlations, demonstrating that GPP patients with IL36RN mutations are at low 
risk of developing PV.  
Taken together, the data presented in this chapter demonstrate that the most frequent 
disease gene for GPP is not associated with PV susceptibility. It is important to bear in mind, 
however, that the study only focused on IL36RN and was not designed to address the 
possibility that mutations in related genes (e.g. IL36R, encoding the IL-36 receptor) could be 
responsible for the up-regulation of IL-36 cytokines in psoriatic plaques. Alternatively, this 
phenomenon could be explained by the abnormal IL-23/Th17 signalling that underlies chronic 
inflammation in PV. In fact, IL-17 produced by Th17 cells can induce IL-36 secretion by 
keratinocytes (Carrier et al., 2011).   
While the above hypotheses are both interesting, the current study shows that the 
mechanism whereby IL-36 signalling is disrupted in pustular psoriasis is specific to this 
disease. Further investigations will therefore be required to clarify whether IL-36 up-
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4 GENETIC ANALYSIS OF CARD14 ALLELES IN DIFFERENT SUBTYPES OF 
PSORIASIS 
A pathogenic role of CARD14 has been demonstrated in familial PV by detecting 
mutations that segregated with the disease in two large pedigrees (Jordan et al., 2012). 
Deleterious changes within this locus were also found in patients with pityriasis rubra pilaris 
(PRP) (Fuchs-Talem et al., 2012), a skin disorder that has a similar presentation to PV (Fuchs-
Talem et al., 2012). Finally, a small Japanese study revealed an association between 
generalised pustular psoriasis and a non-synonymous CARD14 substitution (p.Asp176His) 
(Sugiura et al., 2014).  
While these observations suggest the presence of an allelic series underlying the 
pathogenesis of various inflammatory dermatoses (Figure 4.1), most of the above findings had 
been subject to very limited follow-up at the time of the start of the study. Therefore, the aim 
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Figure 4.1. Localisation of the main CARD14 mutations in the protein and cDNA sequence 
Mutations were identified by Jordan et al., 2012; Fuchs-Telem et al., 2012; and Sugiura et al., 
2014. The D176H mutation described in this chapter is indicated by an asterisk. The protein 
and cDNA sequences were obtained from Ensembl, while the diagram of the domain structure 
has been adapted from Scudiero et al., 2014.  
Abbreviations are as follows: EP: erythrodermic psoriasis; GPP: Generalised Pustular 
Psoriasis; PRP: pityriasis rubra pilaris; PV: psoriasis vulgaris; G117S: p.Gly177Ser; E138A: 
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4.1 Case selection  
A total of 416 unrelated patients were selected for the study. These individuals were 
affected by psoriasis vulgaris (n=159), pityriasis rubra pilaris (n=29), erythrodermic psoriasis 
(n=23), acral pustular psoriasis (Acrodermatitis Continua of Hallopeau, n=8; Palmar Plantar 
Pustulosis, n=92), or generalised pustular psoriasis (n=105) (Table 4.1.1). Importantly, all PV 
patients (Table 4.1.2) and six individuals with GPP (Methods section, Table 2.2.4) reported a 
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  Table 4.1.1. Patient resource summary 
1Including Palmar Plantar Pustulosis (n=92) and Acrodermatits continua of Hallopeau (n=8)  






Disease N. of Cases screened 
Exons 3 and 4  Entire coding region  
Acral Pustular Psoriasis 1001 262 
Erythrodermic Psoriasis 23 20 
Familial Psoriasis Vulgaris 159 16 
Generalised Pustular Psoriasis 105 15 
Pityriasis rubra pilaris 29 20 
Total 416 97 
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Table 4.1.2. Familial PV cases screened for CARD14 variants 
 
Number of affected individuals in the family 
 
 
>5 5 4 3 2 Total 
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4.2 Power calculations 
Given that all published CARD14 mutations map to exons 3 and 4 (Fuchs-Talem et al., 
2012; Jordan et al., 2012), these genomic segments were screened in the entire study resource, 
while the rest of the coding region (exon 2, exons 5-23) was only examined in representative 
patient subsets (Table 4.1.1). 
The power to detect rare sequence changes in the above datasets was estimated with an 
online binomial calculator. This demonstrated that in all patient resources, the analysis of 
exons 3 and 4 had sufficient power (>80%) to uncover mutations accounting for >5% of 
disease cases (Figure 4.2.1.A). Of note, power exceeded 95% in the acral pustular psoriasis, 
familial PV, and generalised pustular psoriasis datasets.  
The samples screened for the entire CARD14 coding region had sufficient power 
(>80% in erythrodermic psoriasis, generalised pustular psoriasis, psoriasis vulgaris, pityriasis 
rubra pilaris; >90% in acral pustular psoriasis) to detect changes presenting in >11% of 
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Figure 4.2.1. Power calculations for the analysis of exons 3-4 (top panel) or for the study of 
the whole coding region (lower panel) 
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4.3 Sanger sequencing of the CARD14 coding region 
4.3.1 Patients with familial PV, erythrodermic psoriasis, and pityriasis rubra pilaris  
No bialellic (loss of function) mutations were detected in these patients, but three rare 
heterozygous variants were found (Table 4.3.1.1). The first was a novel p.Met119Arg 
substitution that was located just two amino acids away from the mutation (p.Gly117Ser) 
originally observed by Jordan et al. in familial PV. The second allele, a p.Ser200Asn change, 
was detected in four PV patients. Both amino acid changes however, were predicted to be 
tolerated by multiple algorithms (Table 4.3.1.1). 
The third variant was a p.Gln136Lys substitution that was observed in one PRP patient 
and was predicted to have a pathogenic outcome (Table 4.3.1.1). A closer inspection of the 
case notes revealed that a differential diagnosis of erythrokeratoderma had been considered, 
and a p.Cys169Trp substitution had been detected in the GJB4 gene (Common et al., 2005). 
Since the latter variant was also predicted to be deleterious (Table 4.3.1.2), it was not possible 
to draw any conclusion on the pathogenic role of the CARD14 substitution. 
Taken together, the above observations indicate that CARD14 alleles are unlikely to 
account for a significant number of familial PV, pityriasis rubra pilaris or erythrodermic 
psoriasis cases. 
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 Pathogenicity prediction 



















Tolerated Benign Neutral Polymorphism Neutral NEUTRAL 
1 CADD scores >15.0 are considered as evidence of pathogenicity. PRP: pityriasis rubra pilaris; PV: psoriasis vulgaris 
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p.Cys169Trp  Damaging Probably damaging Deleterious Disease Causing 18.6 DAMAGING 
1 CADD scores >15.0 are considered as evidence of pathogenicity 
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4.3.2 Patients with pustular psoriasis 
No bialellic mutations were detected in the patients with pustular phenotypes, but six 
rare heterozygous changes were observed (Table 4.3.2.1 and 4.3.2.2). These included two 
novel substitutions (p.Glu168Lys and p.Ala216Thr), two splice site variants (c.2283+11A>C 
and c.2569+4T>C), and the p.Ser200Asn allele that had been previously detected in the 
genome of four PV patients. Pathogenicity predictions however, indicated that all changes 
were likely to be neutral (Tables 4.3.2.1 and 4.3.2.2).  
An Asparagine to Histidine substitution (c.526G>C; p.Asp176His) was detected in 
three unrelated cases of Chinese origin (Figure 4.3.2.1; Table 4.3.2.3). One of the patients 
(T014369) had a positive family history of the disease and the analysis of her maternal aunt 
(T014368), who was also affected by GPP, revealed that the variant was segregating with the 
phenotype. The frequency of the p.Asp176His allele was also increased in Chinese cases 
compared to population-matched controls (6.2% vs.1.0%; P=0.03). 
Interestingly, the same p.Asp176His allele was described by Sugiura et al. in their 
analysis of a small GPP dataset ascertained in Japan. Thus, the association between 
p.Asp176His and generalised pustular psoriasis was further investigated in a meta-analysis of 
the Chinese sample examined here and the published Japanese resource. To increase the 
power of the study, CARD14 sequence data was obtained for a further 322 Japanese healthy 
individuals (218 subjects analysed in house and 104 sequenced by the 1000 Genomes 
Consortium, JPT data set), which increased the size of the published control cohort by 4-fold.  
The meta-analysis revealed that the Chinese and Japanese datasets were genetically 
similar (I2=0%), and that CARD14 mutations were associated with GPP in both samples 
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(P=8.4x10-5; OR:6.4; 95% CI: 2.5-16.1) (Table 4.3.2.4). 
In the Japanese population, the c.526G>C (p.Asp176His) base change occurs on the 
background of a specific CARD14 ancestral haplotype (Sugiura et al., 2014). To investigate 
whether this also applied to the Chinese GPP cases described here, four CARD14 tagging 
SNPs were typed in these patients (Methods 2.9.4). This showed that three of the subjects 
were homozygous, and one likely heterozygous for the same intragenic haplotype that was 
reported in the Japanese individuals with the p.Asp176His allele (Table 4.3.2.5). This suggests 
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SIFT Polyphen-2 PROVEAN 
Mutation 
Taster 


























Tolerated Benign Neutral Polymorphism Neutral NEUTRAL 
1 CADD scores >15.0 are considered as evidence of pathogenicity. GPP: generalised pustular psoriasis; PPP: palmar plantar pustulosis  
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Neutral Neutral Neutral Disease Causing Neutral  NEUTRAL 
1 CADD scores >15.0 are considered as evidence of pathogenicity PPP: palmar plantar pustulosis 
 




Figure 4.3.2.1. The NM_0204110.4:c.526G>C (NP_077015.2: p.Asp176His) change  
The chromatogram was obtained after Sanger sequencing the coding region of CARD14 in the 
DNA of case T014369. The Asp176His (c.526G>C) mutation is indicated by an asterisk, 
while the wild-type sequence can be seen below the chromatogram. The same change was 
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Table 4.3.2.3. Clinical features of GPP patients harbouring the p.Asp176His substitution 
Patient ID Sex Age of onset PV PsA Systemic involvement 
T0143681 F 25 Yes Yes Fever >38C; neutrophil count >13x109/L 
T014369 F 3 No No Fever >38C 
T022932 F 13 No No - 
T022956 M 38 Yes Yes CRP >100mg/L; neutrophil count >15x109/L 
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Table 4.3.2.4. Genetic analysis of the p.Asp176His variant 
Ethnicity Allele counts (%) P value 
Cases Controls 
Japanese 4/42 (9.5%) 14/844 (1.7%) 0.008 
Chinese 3/48 (6.2%) 4/400 (1.0%) 0.030 
Meta-analysis   8.4 x 10-5 
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Table 4.3.2.5. Intragenic SNP haplotypes of patients bearing the p.Asp176His allele 
SNP ID 
Patient ID 
T0143681 T014369  T0229322 T022956 
rs4889991 G G G G G A G G 
rs2044103 A A A A A G A A 
rs3829612 C C C C C T C C 
rs8068433 C C C C C T C C 
1Maternal aunt of T014369; 2genotypes are also compatible with an alternative  
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4.4 In-silico characterization of the p.Asp176His allele 
Prior to functional studies, the pathogenic potential of the p.Asp176His change was 
further assessed and compared with that of representative mutations, previously associated 
with familial PV (p.Gly117Ser), pityriasis rubra pilaris (p.Leu156Pro), and erythrodermic 
psoriasis (p.Glu138Ala) (Jordan et al., 2012; Fuchs-Telem et al., 2012).  
An initial sequence alignment indicated that the evolutionary conservation of 
Asparagine 176 is comparable to that of other residues that are affected by deleterious 
changes (Figure 4.4.1).  
Since exon 4 encodes the CARD14 coiled-coil (CC) domain, the NCOILS software 
was subsequently used to assess the potential effects of the various mutations. The amino acid 
change from a negatively charged Asparagine to a positively charged Histidine was predicted 
to decrease the likelihood of CC formation in the region surrounding residue 176 (Figure 
4.4.2). Importantly a similar effect was observed for the p.Leu156Pro and p.Glu138Ala 
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               ___Exon3__   _________Exon 4_________ 
                  G117S      E138A    L156P    D176H 
Human            NFSGLME   LQEELNQ..CQQLQEH..LEADHSR    
Chimpanzee       NFSGLME   LQEELNQ..CQQLQEH..LEADHSR    
Mouse            TFSGLME   LQEELAQ..CQQLKER..LEVDHSR 
Xenopus(frog)    SFSKLID   LHEELMQ..LRKMREK..MEHENQR   
Medaka(fish)     TFSGLIK   MQKELQE..CASLESE..LQSENDR  




Figure 4.4.1. Evolutionary conservation of the p.Asp176His substitution and representative 
CARD14 mutations  
Conservation was assessed with ClustalW. Symbols are as follows: asterisks (*) indicate 
positions which have a single, fully conserved residue; colons (:) indicates conservation 
between groups of residues with strongly similar properties. G117S: p.Gly177Ser; E138A: 
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Figure 4.4.2. Predicted effects of CARD14 mutations on coiled coil formation  
Wild-type (WT) and mutant (E138A: p.Glu138Ala; L156P: p.Leu156Pro; D176H: 
p.Asp176His) CARD14 sequences were analysed with NCOILS to estimate the likelihood of 
CC formation along sliding windows of seven amino acids. This showed that all mutations 
were predicted to affect CC formation. 
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4.5 Experimental characterization of the p.Asp176His allele  
4.5.1 Analysis of CARD14 aggregates by Western blotting 
While it has been shown that CARD14 mutations can up-regulate NF-B signalling 
(Jordan et al., 2012), the mechanism whereby they result in such an outcome has not been 
investigated.  
Of interest, gain-of-function mutations causing diffuse large B-cell lymphoma have 
been detected in the CC domain of CARD11, a CARD14 paralogue (Lenz et al., 2008; 
Scudireo et al., 2013). Since these disease alleles cause spontaneous protein oligomerisation 
leading to constitutive NF-B activation (Lenz et al., 2008), the possibility that CARD14 
mutations may act in a similar fashion was investigated.  
Since the aim of the experiment was to investigate the aggregation of wild-type and 
mutant proteins (rather than dissecting the consequences of disease alleles on keratinocyte 
signalling), all the assays were carried out in HEK293 cells. Cultures were transfected with 
wild type and mutant FLAG-CARD14 constructs and the accumulation of recombinant protein 
was measured by western blotting, using an anti-FLAG antibody. An initial assessment of 
whole-cell extracts confirmed that all constructs were expressed at comparable levels (Figure 
4.5.1.1). After that, the soluble and insoluble factions of the cell lysates were examined in 
separate experiments. The analysis of soluble extracts showed that the p.Asp176His change 
was associated with a statistically significant decrease in the accumulation of free CARD14 
(Figure 4.5.1.2). A similar effect was observed for the p.Leu156Pro and p.Glu138Ala 
mutations. Conversely, the analysis of the insoluble fraction demonstrated that the 
transfection of mutant cDNAs caused a marked increase in the accumulation of CARD14 
aggregates, compared to the over-expression of wild type constructs (Figure 4.5.1.3).  




Figure 4.5.1.1. Western blotting of total cell lysates  
HEK293 cells were transfected with wild-type or mutant FLAG-CARD14 constructs and the 
expression of recombinant proteins was visualised with an anti-FLAG antibody. The image is 
representative of the results obtained in two independent experiments. . The densitometry data 
(mean ±SD of measurements obtained in two independent experiments) were analysed using 
one-way ANOVA, followed by a Dunnett’s post-test. WT: Wild-type; E138A: p.Glu138Ala; 
L156P: p.Leu156Pro; D176H: p.Asp176His. 
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Figure 4.5.1.2. Western blotting of soluble proteins 
HEK293 cells were transfected with wild-type and mutant FLAG-CARD14 constructs and the 
soluble fraction of whole-cell lysates was isolated by centrifugation. The accumulation of 
recombinant proteins was visualised with an anti-FLAG antibody and quantified by 
densitometry, normalising the intensity of each band to the expression of β-actin.   The image 
is representative of the results obtained in four independent experiments. WT: Wild-type; 
E138A: p.Glu138Ala; L156P: p.Leu156Pro; D176H: p.Asp176His. Asterisks represent the 
following P values: *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001 (one-way ANOVA, 
followed by Dunnett’s post-test, error bars represent standard deviations).  
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Figure 4.5.1.3. Western blotting of insoluble proteins 
HEK293 cells were transfected with wild-type and mutant FLAG-CARD14 constructs an the 
insoluble fraction of whole-cell extracts was isolated by centrifugation. The accumulation of 
recombinant proteins was visualised with an anti-FLAG antibody and quantified by 
densitometry, normalising the intensity of each band to the expression of of β-actin. The 
image is representative of the results obtained in three independent experiments. WT: Wild-
type; E138A: p.Glu138Ala; L156P: p.Leu156Pro; D176H: p.Asp176His. Asterisks represent 
the following P values: *P≤0.05; **P≤0.01; ***P≤0.001 (one-way ANOVA, followed by 
Dunnett’s post-test, error bars represent standard deviations). 
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4.6 Discussion 
CARD14 belongs to a family of three proteins: CARMA1/CARD11; 
CARMA2/CARD14 and CARMA3/CARD10 that promote NF-B signalling downstream of 
TRAF2 (Scudiero et al., 2014). CARMAs show high sequence similarities given that they all 
consist of a caspase activation and recruitment domain (CARD), Coiled-coil domain, Post 
synaptic density Drosophila disc large tumor suppressor Zonula occludens-1 protein  (PDZ), 
SRC Homology 3 (SH3), and guanylate kinases (GUK) domains (Scudiero et al., 2014). 
Although CARD14 is the least studied among the three CARMA proteins, the function of the 
above motifs has been investigated in CARMA1 and 3: 
PDZ domains play an important role in organizing multiprotein signalling complexes, while 
the SH3, GUK, and CARD motifs are required for the oligomerisation of CARMA proteins 
(Baruch and Wendell, 2011; Hara et al., 2015; Scudiero et al., 2011; Scudiero et al., 2014). 
The Coiled-coil part is also of crutial importance for signal transduction given that it is 
involved in binding to downstream signalling molecules (Scudiero et al., 2014; Bertin et al., 
2014; Lamason et al., 2011).  
Inflammatory stimuli - e.g. TNF or T Cell Receptor engagement- cause the 
phosphorylation of these proteins by phospholipase C or protein kinase C, and their 
subsequent oligomerisation. Such modifications enable the recruitment of Bcl10, MALT1, 
and TRAF2/6 leading to the formation of a multi-protein complex that drives NF-B 
signalling (Bertin et al., 2001; Scudeiro et al., 2011; Xie, 2013). Recent studies showed that 
the latter two molecules activate the pathway independently, through a distinct mechanism, 
likely upon different stimuli such as the yeast cell-wall derived zymosan in case of MALT1, 
and TNF-α in case of the TRAFs (Afonina et al., 2016; Scuediero et al., 2011). Of note, 
CARD14 and the complex described above also regulate the p38/JNK axis (Afonina et al., 
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2016).  
The association of common CARD14 variants with PV is well established and was 
confirmed in several large-scale studies (Tsoi et al., 2012; Chen et al., 2014).  Rare gain-of-
function CARD14 mutations were also detected in familial forms of PV and PRP (Jordan et 
al., 2012; Fuchs-Telem et al., 2012). Moreover, Sugiura et al. described a recurrent 
Asparagine to Histidine substitution (p.Asp176His) in a number of IL36RN-negative GPP 
patients. However, the size of the latter study was limited, and the observations made in PV 
and PRP datasets were only followed-up in small samples of non-European descent (Ammar 
et al., 2013; Eytan et al., 2014). 
Hence, the aim of this study was to further assess the prevalence of CARD14 
mutations in the above phenotypes and in erythrodermic psoriasis, one of the most severe 
subtypes of the disease (Griffiths and Barker, 2008). Given that all previously described 
CARD14 mutations map to exons 3 and 4 (Jordan et al., 2012; Fuchs-Telem et al., 2012), 
these coding regions were prioritised in the project. Importantly, Bertin et al. reported that the 
domains encoded by these exons (CARD region and coiled-coil) are necessary for cell 
signalling by CARMA proteins, unlike the C-terminal motifs, which are not required for NF-
B activation. 
No disease alleles were detected in individuals affected by familial PV (n=159). Of 
note, these patients were not screened for HLA-Cw6, which is the major susceptibility 
determinant for psoriasis vulgaris (Nair et al., 2006). Given that the two mutation bearing 
families originally described by Jordan et al. were Cw6-negative, it is possible that the 
inclusion of Cw6-positive cases may have affected the outcome of this study. It is also 
theoretically possible that disease-causing mutations may reside outside of exons 3-4, in the 
regions that were only examined in a subset of cases. It has to be emphasised, however, that 
               148 
even this smaller dataset had sufficient power (>80%) to detect changes accounting for more 
than 10% of cases.  
The data presented here are in accordance with the results of a recent study, which 
also failed to detect an association between deleterious changes in CARD14 and the 
progression of PV in European patients (Ammar et al., 2015). Of note, the same authors 
identified various CARD14 mutations (p.Gly117Ser; p.Arg69Trp; p.Glu197Lys; 
p.Glu197Lys; c.1356+5G>A; p.Leu350Pro; p.Thr420Ala) in PV cases of Tunisian descent, 
suggesting that CARD14-driven familial psoriasis may be more prevalent in non-Caucasian 
populations (Ammar et al., 2015). 
The mutation screen was also negative in Acral pustular psoriasis (APP), 
Erythrodermic psoris (EP), Pityriasis rubra pilaris (PRP), although it has to be emphasised 
that the patient resource was smaller in the latter two disease types (n=29 and n=23; 
respectively).  
The PRP patients were all sporadic cases, so that the lack of disease alleles in this 
dataset is in keeping with the results of other studies (Eytan et al., 2014; Hong et al., 2014) 
and indicates that the gene is specifically mutated in familial forms of the disease.  
The analysis of the generalised pustular psoriasis resource identified the same 
p.Asp176His substitution previously described in a small Japanese sample (Sugiura et al., 
2014) and demonstrated that the change was significantly associated with the disease in Asian 
populations. The p.Asp176His allele was not found in any of the patients with acral pustular 
psoriasis, but these were all of European descent, so that the lack of association could simply 
reflect the very low allele frequency of the substitution (MAF=0.0006) among Caucasians. In 
fact, Mössner et al. recently described 2 out of 34 individuals with palmar plantar pustulosis, 
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who harboured the p.Asp176His mutation. Of note, these cases had all been recruited within 
the Estonian population, which is characterised by significant degree of Asian admixture 
(Kasperavicute et al., 2004). Thus, the association between CARD14 and pustular disease 
would seem specific to the p.Asp176His allele, as it is only observed in those ethnic groups 
where this change is present.  
The functional impact of the p.Asp176His allele was assessed in the subsequent phase 
of the study. Of note, the pathogenic potential of previously detected CARD14 mutations has 
been extensively investigated. For instance, Jordan et al. showed that the transfection of 
CARD14 mutant constructs into HEK293 cells caused an increase in the expression of several 
NF-B driven, pro-inflammatory genes - e.g CCL20, IL8 and IL36G. These observations were 
in keeping with those made in the keratinocytes of mutation bearing patients, where the same 
loci were found to be up-regulated (Jordan et al., 2012). Fuchs-Telem et al. also investigated 
CARD14 mutations in PRP and reported that individuals harbouring deleterious changes 
showed up-regulation of IL1B and CCL20 in their skin lesions.  However, the mechanism 
whereby CARD14 disease alleles lead to such consequences has not been studied. Thus, the 
additional aim of the project was to elucidate the nature of this process.    
Since the other two CARMA proteins had been more thoroughly investigated, a 
working hypothesis was generated, based on observations obtained in the analysis of CARD11 
mutations. Lamason et al. showed that the coiled-coil (CC) and CARD domains of CARD11 
keep the protein in a closed, inactive state through intra-molecular binding. Upon receptor 
signalling - e.g TCR or BCR engagement-, the protein is phosphorylated, which disrupts the 
CC-CARD interaction, and leads to a conformation change. The protein opens up, and 
becomes active by exposing the CARD and CC regions. While the CARD domain mediates 
the interaction with downstream signalling molecules such as Bcl10, the CC enables the 
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formation of protein oligomers. Most importantly, Lamason et al. showed that oncogenic 
mutations in the CC domain of CARD11 prevented intra-molecular interactions with the 
inhibitory region, leading to spontaneous protein oligomerisation and constitutive NF-B 
activation. Given the high degree of structure homology between CARD14 and CARD11 
(Scudiero et al., 2011), it was hypothesised that CARD14 mutations may also result in 
abnormal protein oligomerisation. 
This hypothesis was tested in western blot which demonstrated that the p.Asp176His, 
p.Leu156Pro and p.Glu138Ala mutations were all associated with increased accumulation of 
CARD14 aggregates, indicating that mutant CARD14 proteins tend to spontaneously 
oligomerise. The impact of the p.Asp176His substitution is also comparable to that of 
previously characterised mutations. Of note, this outcome was consistent with the results of 
bioinformatic predictions, which validates the accuracy of the NCOILS software and suggests 
that the pathogenic potential of further CARD14 mutations could be assessed in-silico, using 
this effective tool. In fact, Howes et al. also reported recently that disease causing CARD14 
mutations led to spontaneous NF-B activation. Although the p.Asp176His change was not 
included in their, overall their findings supported the above observations.  
 What remains to be understood is how the various mutations can have the same 
immediate consequences – spontaneous protein oligomerisation leading to abnormal NF-B 
signalling – but lead to different diseases. Further studies will be needed to uncover whether 
patients affected by clinically distinct conditions also harbour additional deleterious changes 
in their genomes – e.g. in genes encoding molecules that act downstream of CARD14.  
The analysis of larger datasets will also be needed to investigate the correlation 
between CARD14 mutations and PV concurrence in GPP, and more broadly to define 
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genotype-phenotype correlations, so that the analysis of CARD14 alleles can aid the 
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5 IDENTIFICATION OF NOVEL CANDIDATE GENES BY WHOLE-EXOME 
SEQUENCING 
5.1 Case selection 
In order to find additional genes – besides IL36RN, AP1S3, and CARD14 – underlying 
pustular psoriasis, whole-exome sequencing was undertaken in a small number of patients 
who did not carry mutations in the aforementioned loci. To maximise the likelihood of 
identifying recurrent disease alleles, cases were selected to form a phenotypically 
homogeneous cohort. The foremost criterion was the presence of severe disease manifesting 
at an early age (<35 years old). Patients also had to satisfy at least one of the following 
conditions: a) originate from a consanguineous union; b) have a positive family history of 
GPP; c) demonstrate multiple episodes of systemic inflammation. Such criteria defined a 
panel of twelve individuals, including ten females and two males (Table 5.1.1), a composition 
that is consistent with a well-documented sex bias in the incidence of GPP (Griffiths and 
Barker, 2007; Naldi and Gambini, 2007). Two of the selected patients were born into 
consanguineous marriages (Figure 5.1.1), while eight had a positive family history of GPP 
(Figure 5.1.2). 
All selected cases had concomitant PV or close relatives that were affected by the 
disease. Therefore, they were screened for the rs4406273-A allele, which is a surrogate of 
HLA-Cw6 (Stuart et al., 2015), the major genetic determinant of psoriasis vulgaris. All twelve 
individuals harboured the rs4406273-G variant in the homozygous state, which demonstrated 
that their disease was not associated with HLA-Cw6.  
 In the most informative pedigree  (23GPP; Figure 5.1.2. b) the involvement of the 
MHC region was further excluded by genotyping a chromosome 6p21 microsatellite  
(D6S273; Figure 5.1.3).   
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Table 5.1.1. Cases selected for whole-exome sequencing 
ID Gender Ethnicity Age of onset PV PsA Markers of systemic inflammation 
T009425 Female Romany 9 Yes No Fever>38°C; CRP>100mg/l; ESR> 50mm/hr 
2GPP1 Male Indian 28 Yes No Fever > 38°C; Neutrophiliaa  
T002229 Female British 19 Yes No Fever>38°C; CRP>100mg/l; ESR> 50mm/hr; Neutrophiliaa 
T003673 Female British 29 Yes No Fever>38°C; CRP>100mg/l; ESR> 50mm/hr; Neutrophiliaa 
8GPP1 Female Chinese 30 Yes Yes ESR> 50mm/hr 
8GPP2 Female Chinese 21 No Yes none 
41GPP1 Female Malay 25 Yes No none 
41GPP2 Female Malay 35 No No Fever > 38°C; CRP>100mg/l; ESR> 50mm/hr 
23GPP1 Female Malay 31 Yes Yes Fever > 38°C; Neutrophiliaa  
23GPP2 Female Malay 12 Yes No Fever > 38°C; CRP>100mg/l 
38GPP1 Male Malay 27 Yes Yes Fever > 38°C; Neutrophiliaa  
38GPP2 Female Malay 25 Yes No Fever > 38°C; CRP > 100mg/l; ESR> 50mm/hr; Neutrophiliaa 
Abbreviations are as follows: CRP. C-Reactive Protein; ESR. Erythrocyte Sedimentation Rate; PsA. Psoriatic arthritis; PV. Psoriasis vulgaris. 
aNeutrophilia: neutrophil count >15x109/L. 
 










Figure 5.1.1. Pedigrees of patients born into consanguineous marriages  
Individual 2GPP1 (a) and T009425 (b) were selected for whole-exome sequencing. Grey 
symbols refer to family members who were only affected by PV. DNA was only available for 
patients indicated with T numbers. 
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Figure 5.1.2. Pedigrees of patients with a family history of psoriasis 
Individuals 8GPP1 and 8GPP2 (a), 23GPP1 and 23GPP2 (b), 38GPP1 and 38GPP2 (c), 
41GPP1 and 41GPP2 (d) were selected for whole-exome sequencing. Grey symbols refer to 
family members who were only affected by PV. DNA was only available for patients 
indicated with PV or GPP numbers. 
c) 
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Figure 5.1.3. Family 23GPP is not linked to the Major Histocompatibility Complex 
Marker D6S273 (AFM142xh6) does not segregate with the disease, as can be deduced by 
comparing the genotypes of the individuals from the fourth generation. Black symbols 
represent GPP, while grey symbols refer to family members who were only affected by PV. 
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To maximise the power, the study resource was expanded to include five severe cases 
of acrodermatitis continua of Hallopeau that had been whole-exome sequenced prior to the 
onset of the project (Table 5.1.2). These patients, who did not carry any deleterious changes at 
known disease genes, were analysed together with the generalised pustular psoriasis subjects, 
based on the well-documented genetic overlap between GPP and ACH (Setta-Kaffetzi et al., 
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Table 5.1.2. Previously whole-exome sequenced samples that were included in the analysis 
of variant profiles. 
ID Gender Ethnicity Age at onset PV PsA 
S0655 F Polish       57 Y N 
S0657 F Swiss 82 N  N 
S0658 M Swiss 49 N  N 
S0660 F Swiss 56 N  Y 
S0661 F British 39 N  N 
Abbreviations are as follows: PsA. Psoriatic arthritis; PV. Psoriasis vulgaris.  
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5.2 Coverage statistics 
For the GPP cases, the mean sequence coverage across the exome ranged from 79.3x to 
150.4x, with more than 85% of CCDS bases covered at a depth of at least 20x (Table 5.2.1). 
An average of 25,185 variants per sample (range: 24,169 to 25,861) were identified (Table 
5.2.2). 
In the previously sequenced ACH cases, the mean sequence coverage across the exome 
ranged from 115.8x to 175.3x, with more than 90% of CCDS bases covered at a depth of at 
least 20x (Setta-Kafetzi et al., 2014). The average number of variants was 24,446 per sample 
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Table 5.2.1. Coverage of target exons 
  2GPP1 T009425 T00229 T003673 8GPP1 8GPP2 
Mean Coverage (%) 79.30 132.43 138.41 150.38 100.96 109.78 
CCDS bases >1 98.08 98.3 98.4 98.44 98.9 98.92 
CCDS bases >5 95.79 96.72 96.88 96.81 98.06 98.14 
CCDS bases >10 92.92 95.3 95.6 95.45 97.11 97.28 
CCDS bases >20 85.57 91.8 92.38 92.3 94.26 94.84 
   23GPP1 23GPP2  38GPP1 38GPP2 41GPP1 41GPP2 
Mean coverage (%) 127.45 94.63 107.48 100.74 112.85 112.9 
CCDS bases >1 98.42 98.86 95.38 98.11 98.93 98.92 
CCDS bases >5 96.8 97.98 100.03 96.27 98.15 98.15 
CCDS bases >10 95.34 96.93 99.51 94.22 97.32 97.33 
CCDS bases >20 91.69 93.78 99.39 89.02 94.98 94.98 
Abbreviation: CCDS; Consensus coding sequences. 
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Table 5.2.2. Number of sequence variants detected in each GPP patinet 
2GPP1 T009425 T002229 T003673 8GPP1 8GPP2 
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Abbreviations are as follows: HOM, homozygous; HET, heterozygous; CH, possible compound heterozygous; NS, not 
synonymous. The term “rare” refers to variants with a minor allele frequency< 0.015. 
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Table 5.2.3. Number of sequence variants detected in each ACH patient 
 
 
S0655 S0657 S0658 S0660 S0661 




















































Abbreviations are as follows: HOM, homozygous; HET, heterozygous; CH, possible compound heterozygous; NS, not 
synonymous. The term “rare” refers to variants with a minor allele frequency< 0.015. 
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5.3 Allocation of samples to distinct analysis groups 
The whole-exome sequenced samples were allocated to two analysis groups, dominant 
and recessive, based on disease recurrence and/or parental relatedness (Table 5.3).  
The variant profiles of the two individuals born into consanguineous marriages were 
studied under a recessive model, based on the hypothesis that they harboured autozygous 
disease alleles. The four patients originating from families 23GPP and 38GPP were examined 
assuming dominant inheritance, which was inferred based on the pedigree structure.  
Conversely, the pattern of disease segregation in families 8GPP and 41GPP was compatible 
with recessive inheritance but also with the presence of a dominant allele showing reduced 
penetrance (Figure 5.1.2). Thus, the sequence data was analysed with both models. The same 
approach was applied to the isolated cases, which could have arisen as the result of recessive 
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Patient classification ID 
Analysis group  
Recessive                               Dominant 







T002229 ✔ ✔ 
T003673 ✔ ✔ 
S0655 ✔ ✔ 
S0657 ✔ ✔ 
S0658 ✔ ✔ 
S0660 ✔ ✔ 
S0661 ✔ ✔ 
Familial case 
8GPP1 ✔ ✔ 
8GPP2 ✔ ✔ 
41GPP1 ✔ ✔ 
41GPP2 ✔ ✔ 
     23GPP1 
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5.4 Analysis of recessive cases 
5.4.1 Analysis of the entire dataset 
The sequence variant profiles were filtered for rare (MAF ≤ 0.015), bialellic changes 
that were classified as deleterious by at least four out of five pathogenicity prediction tools. 
The haplotypes spanning homozygosity regions >2Mb were considered identical by descent 
(autosygous) as opposed to identical by status (Methods 2.9.6) (Alsalem et al., 2013; 
McQuillan et al., 2008). Hence, variants lying in such regions were further prioritised. The 
sequence changes that met these criteria were then compared across samples, searching for 
genes that were mutated in multiple individuals (Figure 5.4.1). 
This process uncovered a variant in ARHGAP11A (rs140472511, p.Asp333His), which 
was found in the homozygous state in case T009425 and in the heterozygous state in S0658 
(Table 5.4.1). The Asparagine to Histidine substitution was predicted to be deleterious by all 
online tools used in the study, and its frequency in the British control population was < 0.1%.   
A closer inspection of the ARHGAP11A locus revealed that four of the coding exons 
were not covered by exome sequence reads, in any of the samples. Therefore, it was 
hypothesised that S0658 may harbour a second, as yet undetected mutation. 
To explore this possibility and uncover additional pathogenic changes at this locus, 
exons 4-7 of ARHGAP11A were Sanger sequenced in all the samples from the recessive 
analysis group. No further mutations were observed in S0658, or in any of the other subjects, 
arguing against the notion that ARHGAP11A may be a recessive locus for the disease, 
although the possibility of a second mutation in non-coding regions cannot be excluded. 
No other gene harboured bialellic mutations in more than one affected individual, 
indicating the presence of substantial genetic heterogeneity. 
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Figure 5.4.1. Filtering steps in the analysis of recessive cases  
The filtering process is described in detail in section 2.9.6 of the Methods. The numbers of 
rare, biallelic changes detected in the patients are summarised in Tables 5.2.2 and 5.2.3. 
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Table 5.4.1. The ARHGAP11A variant emerging from the initial recessive analysis  
         Sample ID Variant Pathogenicity predictions Outcome 
of follow-up 
 
SIFT PROVEAN PolyPhen-2 MutationTaster CADD1 
T009425 (HOM)                         
p.Asp333His 
rs140472511 





1The CADD algorithm returns a quantitative prediction and scores above 15 are considered pathogenic. Abbreviations are as follows: HOM, 
homozygous; HET, heterozygous. 
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5.4.2 Analysis of patients born into consanguineous marriages 
Given that no genes were found to harbour biallelic mutations in multiple cases, 
candidates were next selected from individual pedigrees. The power to detect disease alleles 
was highest in the offspring of consanguineous unions; therefore, individuals T009425 and 
2GPP1 became the focus of these analyses.  
Based on the hypothesis that the probands had inherited autozygous disease allele, an 
additional filtering step was introduced by prioritising variants that lie in regions of 
homozygosity. 
In individual T009425, who originated from a Roma community where 
consanguineous unions were reported on many occasions, there were numerous homozygosity 
clusters. Thus the number of damaging changes lying in these regions was elevated (Table 
5.4.2), making it difficult to prioritize any candidate for further examination. 
The filtering strategy was more successful in individual 2GPP1, as rare variants with 
deleterious potential were only identified in MAPKBP1, DOCK8, and STOX1 (Table 5.4.2). 
Importantly, all three genes are expressed in disease relevant cell types (skin and/or in 
immune cells) and participate in inflammatory processes. STOX1 encodes a transcription 
factor regulating TNSF10/TRAIL (Rigourd et al., 2008), while DOCK8 is a disease gene for 
the immune deficiency known as hyper-IgE syndrome (Aydin et al., 2015), and MAPKBP1 
contributes to JNK signaling (Arasa et al., 2015).  
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Table 5.4.2. Filtering of variant profiles in individuals born into consanguineous marriages  
 Sample ID 
2GPP1 T009425 
Total n. of  variants 24,169 24,336 
Rare, non-synonymous/splice site variants 859 746 
 Homozygous changes 45 54 
Located in homozygosity clusters > 2Mb 17 31 
Predicted to be deleterious 3 6 
Candidate Genes DOCK8, MAPKBP1, STOX1* ARHGAP11A,  EVI5*, FMN1, GLI2, NR3C2*, 
SLC45A4*,  
*Gene mapping to a homozygosity block larger than 10Mb 
 
               171 
5.4.3 Candidate gene follow-up   
Given that patient 2GPP1 was of Indian origin, the three candidate genes were 
followed up in an Asian patient cohort including 86 cases of Indian (n=17), Malay (n=48) and 
Chinese (n=21) descent (Table 2.2.5 in Methods).  
The adopted strategy was to first check the recurrence of the variant detected by 
whole-exome sequencing. If the change was observed in additional samples, then the 
mutation screening was extended to include the whole coding region of the candidate gene. 
Since the majority of pustular psoriasis alleles are accounted for by recurrent mutations 
(Onoufriadis et al., 2012, Setta-Kaffetzi et al., 2013 Setta-Kaffetzi et al., 2014), this approach 
was deemed to be the most cost-effective.  
While screening the p.Glu385Lys allele originally found in STOX1, two additional 
Indian patients were identified, who harboured the change in the heterozygous state. The 
remaining 3 coding exons of the gene were therefore screened in the Asian patient cohort. 
However, no further deleterious variants could be identified, excluding the possibility that the 
two p.Glu385Lys patients may have been compound heterozygotes. Of note, an analysis of 
Indian control datasets that have only recently become available (Table 2.2.5 in Methods) 
revealed an overall MAF of 5.6% for the p.Glu385Lys allele, arguing against the notion that 
this may be pathogenic mutation.  
The follow-up of DOCK8 and MAPKBP1 uncovered no additional patients bearing the 
changes detected by whole-exome sequencing. Therefore, the rest of the genes were not 
sequenced. 
Thus, the analysis of the recessive cases could not identify a strong candidate gene for 
the disease. 
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Table 5.4.3. Follow-up of candidate genes emerging from the analysis of consanguineous pedigrees  
Sample ID Gene Variant Pathogenicity Predictions Outcome of follow-up 
(chr) SIFT PROVEAN PolyPhen-2 MutationTaster CADD1 




Delterious Damaging Probably 
Damaging 
Disease Causing 21 Locus excluded 
MAPKBP1 
(chr15) 
p.Glu259Lys Delterious Damaging Probably 
Damaging 




p.Asp224His Delterious Damaging Probably 
Damaging 
Disease Causing 27 Recurrent mutation 
exlcuded 
1The CADD algorithm returns a quantitative prediction, with scores above 15 considered pathogenic. 
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5.5 Analysis of dominant cases 
The variant profiles were filtered for rare (MAF ≤ 0.015), heterozygous changes that 
were shared by affected relatives and classified as deleterious by at least four out of five 
pathogenicity prediction tools. The sequence changes that passed these criteria were then 
compared across samples, searching for genes that were mutated in multiple pedigrees or 
isolated cases (Figure 5.5.1). Finally, the candidate genes harbouring the changes with the 
highest CADD scores were prioritised for follow-up. The latter step was introduced, as the 
number of potential candidate genes was much larger than that observed in the recessive 
analysis.  
Given that AP1S3 and CARD14 are only mutated in specific ethnic groups (Setta-
Kaffetzi et al., 2014; Chapter 4 of this thesis), the Asian and European cases were initially 
analysed as separate datasets to maximise the power to detect population-specific disease 
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Figure 5.5.1. Filtering steps in the analysis of dominant cases 
The filtering process is described in detail in section 2.9.6 of the Methods. The number of all 
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5.5.1   Analysis of the Asian cohort 
5.5.1.1  Analysis of the entire dataset 
The analysis of the eight Asian subjects uncovered four candidate genes, each 
harbouring rare deleterious changes in two affected relative pairs (Table 5.5.1.1). The variants 
with the strongest pathogenic potential (CADD>30) were found in MEGF11, a gene that 
regulates the spacing of different neuron subtypes in the retina (Kay et al., 2012). Deleterious 
changes were also observed in HKR1, which functions as a UV-light sensor in the retina 
(Luck M et al., 2012.), FRAS1, a disease gene for a developmental disorder known as Fraser 
syndrome and F8, which encodes coagulation factor VIII (Hoefele et al., 2013; Choi et al., 
2015). Given that the function of these genes did not appear to be disease relevant, none of 
the above loci were prioritised for follow-up. The focus of the investigation moved to the 
individual families.  
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Table 5.5.1.1. Candidate genes emerging from the analysis of Asian dominant cases 





PolyPhen2 PROVEAN SIFT Mutation Taster CADD2 
38GPP1/2 
41GPP1/2 
F8 p.Lys399Glu 7053 Probably Damaging Damaging Deleterious Polymorphism 17.7 
(chr X) p.Ser1974Pro  Probably Damaging Damaging Tolerated Disease Causing 16.6 
38GPP1/2 
8GPP1/2 
HKR1 p.Glu410Lys 1977 Possibly damaging Damaging Deleterious Disease Causing 20.6 
(chr 19) p.Gly531Arg  Probably Damaging Damaging Deleterious Disease Causing 15.3 
23GPP1/2 
8GPP1/2 
MEGF11 p.Arg771His 3132 Probably Damaging Neutral Deleterious Disease Causing 31 
(chr 15) p.Gly723Arg  Probably Damaging Damaging Deleterious Disease Causing 33 
38GPP1/2 
23GPP1/2 
FRAS1 p.His3347Gln 12024 Probably Damaging Damaging Deleterious Disease Causing 18.8 
(chr 4) p.Thr2991Met  Probably Damaging Damaging Deleterious Disease Causing 15.4 
1 Gene size refers to the length of the coding region 2The CADD algorithm returns a quantitative prediction, and scores above 15 are considered 
pathogenic.
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5.5.1.2 Analysis of pedigree 23GPP 
While numerous deleterious changes emerged from the analysis of families 8GPP, 
41GPP, and 38GPP, the list of candidate genes was much shorter in pedigree 23GPP, where 
the two affected cases were more distantly related (Table 5.5.1.2.1).  
Based on the variants’ pathogenic potential, the most promising candidate in family 23 
was CYP1A1 (Table 5.5.1.2.2). Of note, this gene codes for a monooxygenase which regulates 
the AhR pathway, a signalling cascade that has been implicated in the progression of psoriasis 
(Di Meglio et al., 2014).  
To further investigate CYP1A1 as a candidate gene, two lines of enquiry were pursued. 
First the p.Arg511Leu allele was screened in six additional members of family 23GPP 
(23PV1-6, Figure 5.5.1.2.1) who were affected by plaque psoriasis. In parallel, the entire 
coding region was screened in an Asian patient cohort including 86 cases of Indian (n=17), 
Malay (n=48), and Chinese (n=21) descent (Table 2.2.5 in Methods).    
The analysis of family 23GPP did not detect p.Arg511Leu in any additional 
individuals. Meanwhile, screening of the Asian cohort identified four unrelated subjects 
carrying p.Arg511Leu, p.Arg455Gln, and p.Pro492Arg alleles (Table 5.5.1.2.3).  However, a 
survey of the datasets recently released by the 1000 Genomes Consortium, revealed that the 
p.Arg511Leu change has an average frequency of 1.9% in Indian populations and is 
especially common among the Telegu (MAF: 2.9%), one of the ethnic groups that is 
genetically closer to the Indians who settled in Malaysia (Wong et al., 2014). Thus, the 
prevalence of the variant exceeds the 1.5% pathogenicity threshold that was used throughout 
the study. Moreover, a burden test indicated that there was no statistical difference in the 
representation of CYP1A1 pathogenic variants between cases and controls (Table 5.5.1.2.4). 
Taken together, these findings indicated that CYP1A1 is unlikely to be a disease causing gene. 
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Table 5.5.1.2.1. Number of rare, deleterious changes segregating in the Asian pedigrees. 
8GPP 41GPP 38GPP 23GPP 
CADD>30 CADD>20 CADD>15 CADD >30 CADD>20 CADD>15 CADD >30 CADD>20 CADD>15 CADD>30 CADD>20 CADD>15 
4 28 34 6 23 31 5 36 41 2 6 9 
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Table 5.5.1.2.2. Deleterious changes emerging from the analysis of pedigree 23GPP. 
Gene Size1 
[bp] 
AA change Pathogenicity Predictions 
PolyPhen2 PROVEAN SIFT Mutation Taster CADD2 
CYP1A1 (chr15) 1536 p.Arg511L Probably damaging Damaging Deleterious Disease causing 32.0 
ZNF516 (chr18) 3489 p.Pro117Ser Probably damaging Damaging Deleterious Disease causing 26.9 
PLCH1 (chr3) 5079 p.Thr653Met Probably damaging Damaging Deleterious Disease causing 26.5 
EPHA8 (chr1) 3015 p.Arg837W Probably damaging Damaging Deleterious Disease causing 22.4 
TAS2R3 (chr7) 948 p.Asn24Ser Probably damaging Damaging Deleterious Disease causing 18.2 
ARHGEF16 (chr1) 2127 p.Ile405Ser Probably damaging Damaging Deleterious Disease causing 16.7 
IGSF10 (chr3) 7869 p.Arg1009Cys Probably damaging Damaging Deleterious Disease causing 15.5 
FRAS1 (chr4) 12024 p.Thr2991Met Probably damaging Damaging Deleterious Disease causing 15.4 
MEGF11 (chr15) 3132 p.Arg771H Probably damaging Neutral Deleterious Disease causing 31.0 
OR51G1 (chr11) 963 p.Cys248Ser Possibly damaging Damaging Tolerated Disease causing 15.8 
1 Gene size refers to the length of the coding region 2The CADD algorithm returns a quantitative prediction, and scores above 15 are 
considered pathogenic; AA, amino acid 
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Figure 5.5.1.2.1. Screening of the p.Arg511Leu allele of CYP1A1 in pedigree 23GPP. Black symbols represent GPP, while grey symbols refer to 
family members who were only affected by PV. Wt stands for wild type. 
 
 
               181 
Table 5.5.1.2.3 Deleterious changes detected in CYP1A1 
Sample 
ID 
Ethnicity Amino acid 
change 
Pathogenicity Predictions 











Probably Damaging Deleterious Damaging Disease Causing 32.0 
60GPP1 Chinese p.Arg455Gln Probably Damaging Deleterious Damaging Disease Causing 36.0 
64GPP1 Chinese p.Pro492Arg Possibly Damaging Deleterious Damaging Disease Causing 19.9 
1The Control datasets used in the study are described in section 2.2.5 2The CADD algorithm returns a quantitative prediction, and 
scores above 15 are considered pathogenic. 
               182 
  
Table 5.5.1.2.4. Frequency distribution of rare and deleterious CYP1A1 alleles. 
Ethnicity Allele counts in Cases Allele counts in Controls2 P value 
alt/all   % alt/all                                    %
Malay 1/961 1.04 2/192 1.04 0.5 
Chinese 2/42 4.8 7/416 1.68 0.22 
Indian 2/34 5.9 17/878 1.94 0.15 
1As the association analysis was performed on unrelated cases, only one of the GPP 
patients from family 23 was included in the dataset. 2Details of the control cohorts 
can be found in section 2.2.5. Abbreviations are as follows: alt, alternative allele 
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5.5.2 Analysis of the European cohort 
The analysis of European cases revealed six candidate genes, each harbouring rare 
deleterious alleles in three unrelated patients (Table 5.5.2.1). Among these, DNAH12 and 
ARFGAP2 were prioritised, because of the high CADD scores generated by the variants 
(Table 5.5.2.2). 
The same deleterious change in DNAH12 (p.Gly1895Ser; rs189965161) was found in 
three patients, affected by ACH (S0657, S0661) and GPP (T003673). Therefore, the locus 
was selected for follow-up in an extended cohort including 92 British pustular psoriasis cases 
(7 ACH, 4 GPP, and 81 PPP patients). However, no further individuals carrying 
p.Gly1895Ser were detected, arguing against the notion that the allele may be a recurring 
mutation. 
Three variants with pathogenic potential (p.Asn103Ser, p.Val320Met, p.Gly519Ser) 
were detected in ARFGAP2. Interestingly, this gene has been implicated in protein transport 
between the Golgi complex and the endoplasmic reticulum, which is reminiscent of AP1S3 
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Table 5.5.2.1. Genes harbouring mutations in multiple European cases 
N. of cases CADD>15 CADD>20 
3 n=4 n=2 
2 n=30 n=21 
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Table 5.5.2.2. Candidates emerging from the dominant analysis of European cases 











DNAH12 p.Gly1895Ser 12146 Probably Damaging Deleterious Damaging Disease Causing 25.5 
(chr 3) p.Gly1895Ser  Probably Damaging Deleterious Damaging Disease Causing 25.5 




ARFGAP2 p.Asn103Ser 2976 Benign Deleterious  Damaging Disease causing 21.8 
(chr 11) p.Val320Met 
 
Possibly damaging  Tolerated Damaging Disease causing 22.4 




FBN3 p.Asp2278His 8427 Probably damaging Deleterious Damaging Disease causing 15.2 
(chr 19) p.Gly1311Ala 
 
Probably damaging Deleterious Damaging Disease causing 19.9 
 




MPEG1 p.Thr73Ala 2148 Probably damaging Deleterious Damaging  Disease causing 19.0 
(chr 11) p.Thr73Ala 
 
Probably damaging Deleterious Damaging Disease causing 19.0 
  p.Pro405Thr   Probably damaging Deleterious Damaging Disease causing  20.5 




MYOM2 p.Gly1107Ala 4395 Probably damaging Deleterious Damaging Disease causing  16.9 
(chr 8) p.Pro568Leu 
 
Possibly damaging Deleterious Damaging Disease causing  22.0 
 




RBMXL1 p.Tyr234Cys 1170 Probably damaging Deleterious Damaging Disease causing   19.0 
(chr 1) p.Tyr234Cys 
 
Probably damaging Deleterious Damaging Disease causing  19.0 
  p.Arg43Cys   Probably damaging Deleterious Damaging Disease causing   20.0 
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The ARFGAP2 exons harbouring deleterious changes were screened in the British 
dataset mentioned above, which included the three individuals who had been originally 
whole-exome sequenced.  The presence of the p.Asn103Ser, p.Val320Met and p.Gly519Ser 
variants was verified and the p.Gly519Ser allele was also detected in another 2 unrelated 
individuals. Next, the whole coding region of ARFGAP2 (16 exons) was Sanger sequenced, 
and a further two changes with deleterious potential (p.Arg255Gly and p.Phe466Tyr) were 
uncovered (Table 5.5.2.3). Thus, a total of 5 mutations were observed in 7 unrelated 
individuals. Of note, all of these changes affected evolutionarily conserved residues (Figure 
5.5.2.1). A burden test demonstrated that this was a significant finding, as the frequency of 
pathogenic alleles was markedly increased in cases compared to controls (3.80% vs. 0.76%; P 
= 1.8 x10-5) (Table 5.5.2.5).  
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Sample ID Amino Acid 
Change  
 
Pathogenicity Predicitons Cases 


















22.3 3/184 1.63 




22.2 1/184 0.54 
ACH S0658 p.Val320Met 
(rs373135315) 




22.4 1/184 0.54 
PPP T008962 p.Arg255Cys 
(rs138040761) 




22.2 1/184 0.54 
ACH S0655 p.Asn103Ser 
(rs117324352) 
Deleterious Deleterious Neutral Disease 
causing 
21.8 1/184 0.54 
1The CADD algorithm returns a quantitative prediction and scores above 15 are considered pathogenic. 
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                                         Asn103      Arg255   Val320        Phe466      Gly519 
Human            QLRCMQVGGNANATAFFRQHGCTANDANTKYNSR…EKLREEQ..HSVLSEMQVIE…SSADLFGDG…MNSLQDRYGSY 
Gorilla          QLRCMQVGGNANATAFFRQHGCTANDANTKYNSR…EKLREEQ..HSVLSEMQVIE…SSADLFGDG…MNSLQDRYGSY 
Mouse            QLRCMQVGGNANATAFFRQHGCMANDANTKYTSR…EKLREEQ..HSVLSEMQVIE…SSADLFGNM…MNSLQDRYGS- 
Chicken          QLRCMQVGSNANATAFFRQHGCTTTDANAKYNSR…EKLREEQ..HSVLSEMQVIE…SSADLFGEA…MNSLQDRYGSY 
Turtle           ----MQVGSNANATAFFRQHGCTTTDANAKYNSR…EKLREEQ..HSVLSEMQVIE…SSADLFGEA…MNSLQDRYGSY 
Fugu             QLRCMQVGGNANATAFFRQHGCSTNDTNAKYNSR…EKLREEQ..HSVLSEMQVIE…SSADLFGDG…MNTIQDRYGSY 
 
 
Figure 5.5.2.1. Conservation status of the deleterious ARFGAP2 changes detected in cases 
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Table 5.5.2.4. Deleterious ARFGAP2 changes detected in controls  
 
AA Change rs ID Allele counts1 Pathogenicity prediction 
ExAC British 
exomes 
SIFT PolyPhen-2 PROVEAN Mutation taster CADD2 
p.Gly519Ser rs142683966 275 15 Tolerated Probably 
damaging 
Deleterious Disease causing 22.3 
p.Phe466Tyr - 1 0 Damaging Probably 
damaging 
Deleterious Disease causing 22.2 
p.Met435Val - 0 1 Damaging Probably 
damaging 
Deleterious Disease causing 26.6 
p.Arg406Gln rs200794218 17 0 Damaging Probably 
damaging 
Neutral Disease causing 35.0 
p.Arg406Trp rs35950498 58 1 Damaging Probably 
damaging 
Deleterious Disease causing 35.0 
p.Arg406Gly rs35950498 20 0 Damaging Probably 
damaging 
Deleterious Disease causing 26.8 
p.Arg255Cys rs138040761 2 0 Damaging Probably 
damaging 
Deleterious Disease causing 22.2 
p.Arg255Gly rs138040761 1 0 Damaging Possibly 
damaging 
Deleterious Disease causing 22.4 
p.Asn103Ser rs117324352 129 12 Damaging Benign Deleterious Disease causing 21.8 
p.Arg5Lys - 1 1 Damaging Benign Deleterious Disease causing 18.9 






     
1Details of the control cohorts can be found in section 2.2.5 2The CADD algorithm returns a quantitative prediction and scores above 15 are 
considered pathogenic.  AA, amino acid; ExAC, Exome Aggregation Consortium. P values were calculated with Chi-square tests (Methods 
2.10.2). 
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Table 5.5.2.5. Frequency distribution of rare and deleterious ARFGAP2 changes  
Allele counts in Cases Allele counts in Controls P value 
alt/all   % alt/all                                    %
7/184 3.80 534/69,900 0.76 1.8 x10-5 
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5.5.3 Comparison of the Asian and European datasets  
In the final stage of the analysis, the list of rare alleles with pathogenic potential was 
compared across the European and Asian datasets. This failed to reveal any genes that was 
mutated in both population. 
Given the association findings described in the previous section, the ARFGAP2 gene was 
examined in more detail. A p.Asp346Asn substitution affecting a conserved residue was 
found in cases 38GPP1 and 38GPP2 (Figure 5.5.3.1; Table 5.5.3). The change did not meet 
our pathogenicity criteria, as it was only classified as deleterious by three out of five 
algorithms. However, an inspection of the ARFGAP2 locus on the Ensembl genome browser 
revealed the presence of a shorter transcript isoform (ENST00000426335, Refseq ID: 
NM_001242832), which lacks exon 5 and encodes a protein that is likely to be adversely 
affected by the p.Asp210Asn variant (Table 5.5.3). To verify the expression profile of this 
shorter transcript, real-time PCR experiments were undertaken using isoform specific primers. 
These demonstrated that the shorter transcript was present in skin and immune cells. Thus, the 
p.Asp210Asn change is likely to have a deleterious effect on ARFGAP2 activity in disease 
relevant cell types. 
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Table 5.5.3. Effects of ARFGAP2 changes on the proteins encoded by the two gene transcripts 
Gene Sample ID Transcript1 AA Change Pathogenicity Predictions 
PROVEAN SIFT PolyPhen-2 Mutation Taster CADD2 
ARFGAP2 38GPP1/2 Full length 













 S0660 Full length 













 S0658 Full l length 













 S0655 Full length 














1Refseq ID are as follow: full length transcript NM_032389 (protein: ENSP00000434442); isoform lacking exon 5 NM_001242832 (protein: 
ENSP00000400226);  2The CADD algorithm returns a quantitative prediction and scores above 15 are considered pathogenic. AA, amino 
acid. 
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                Asp346/210 
Human           ..DLFDDVGTFA.. 
Gorilla         ..DLFDDVGTFA.. 
Mouse           ..DLFDDVGTFA.. 
Chicken         ..DLFDDVGTFA.. 
Turtle          ..DLFDDVGTFA.. 
Fugu            ..DMFDEP-GFT.. 
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Figure 5.5.3.2. Relative expression of ARFGAP2 full length transcript (NM_032389, 
indicated with black bars) and the isoform lacking exon 5 (NM_001242832, indicated 
with grey bars) in disease relevant cell types. All transcript levels are normalised to 
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5.6 Discussion 
Despite the identification of disease alleles within IL36RN, CARD14 and AP1S3, 
the majority of pustular psoriasis cases remain unaccounted for (Setta-Kaffetzi et al., 
2014; Mahil et al., 2015; Sugiura et al., 2014). Thus, the aim of this study was to 
uncover additional genetic determinants for the disease, by means of whole-exome 
sequencing. 
In order to maximise the likelihood of discovering novel genes, a homogeneous 
patient cohort was ascertained on the basis of severe disease presentation. In the absence 
of quantifiable markers, severity was assessed by surrogate measures such as age of 
onset and systemic involvement. To further reduce the confounding effect of genetic 
heterogeneity, the cases were allocated to different analysis groups, based on ethnicity 
and predicted mode of disease inheritance. 
 Despite these precautions, substantial genetic heterogeneity was observed, 
which complicated the design of follow-up studies.  
 
5.6.1 Analysis of recessive cases 
Patients born from consanguineous unions are likely to harbour autozygous 
disease alleles. This allows geneticists to prioritise homozygous variants during the 
filtering process and quickly exclude large portions of the genome. While this is 
undoubtedly a great advantage, ascertaining probands from communities with high rates 
of parental relatedness can cause other problems.  
If the patient originates from an isolated population, their genome will be 
enriched for variants that are not found in reference datasets, which will confound the 
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identification of genuine mutations. The disease allele may also prove to be unique to 
the population in question, so that the inclusion of autozygous pedigrees in gene 
discovery studies may increase the heterogeneity of the study resource. Here, no genes 
showed recessive (homozygous or compound heterozygous) deleterious variants in 
more than one case. Of note, a number of assumptions were built in the filtering strategy 
that could have affected the identification of candidate genes. 
First of all, it was postulated that the disease is caused by rare mutations, so that 
all variants with a MAF > 1.5% were filtered out. Given that the frequency of IL36RN 
mutations is nearly 2% in some Asian population (Hussain et al., 2015), other members 
of the lab have more recently repeated the analysis of the recessive group by increasing 
the MAF threshold to 5%. This still revealed no genetic overlaps between the pedigrees, 
indicating that the negative results were not due to an incorrect estimation of the 
mutation frequency.  
Importantly, structural rearrangements were analyzed alongside nucleotide 
changes, but all the copy number variants (CNV) that appeared in multiple cases proved 
to be artifacts, which could not be verified upon manual inspection of reads with IGV. 
Moreover, no intersection was detected between CNVs and single base changes. Thus, 
it is unlikely that the disease was caused by the large genomic rearrangements detected 
in the examined cases. Of note, WES is less efficient as WGS in the detection of CNVs, 
(Singleton, 2011), so that we cannot exclude the possibility that a pathogenic structural 
change may have been missed. 
 In individuals that were the offspring of consanguineous marriages, it was 
further assumed that two copies of the disease allele were inherited alongside SNP 
haplotypes that were identical by descent. Although this is an entirely reasonable model, 
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other scenarios (e.g. the possibility of de-novo inheritance in one or both pedigrees) 
were not examined and cannot be discounted.  It is also important to bear in mind that 
the analysis was limited to homozygous regions spanning at least 2Mb. While this 
threshold is consistent with that used in other studies of consanguineous pedigrees 
(Alsalem et al., 2013; McQuillan et al., 2008), the possibility that bialellic mutations 
may have been located in smaller regions cannot be excluded. It is interesting, however, 
that reducing the size of homozygous regions to 1.5Mb would not have revealed 
additional candidates in the Indian family. 
Another critical factor to bear in mind is the sequencing depth, which in some 
cases (2GPP1 and 38GPP2, see Table 5.2.1), fell below our proposed benchmark of 20x 
coverage for 90% of CCDS transcripts. The issue of coverage is particularly important 
for two homozygosity blocks spanning 5 and 17 Mb on chromosome 10, which were 
shared by both patients born into consanguineous marriages. In fact, fifteen protein 
coding genes lying in these regions were not adequately covered in at least one of the 
two affected individuals. Of note, two of these loci are known to partake in immune-
responses. KIF5B encodes a protein that is crucial for the polarization of lytic granules 
in Natural Killer cells, an immune cell type that has been detected in the inflammatory 
infiltrate of psoriatic lesions (Dunphy et al., 2011; Tuli et al., 2013). MAP3K8 encodes a 
serine/threonine protein kinase that regulates NF-B signalling as well as IL-1 and 
TLR-4 mediated activation of the Extracellular-regulated-kinase (ERK) pathway (Hedl 
et al., 2015). Of interest, a MAP3K8 SNP associated with inflammatory bowel disease 
was shown to up-regulate IL-1 production in pattern-recognition receptor activated 
macrophages (Hedl et al., 2015). Thus, it will be important to Sanger sequence these 
two genes, to exclude the possibility that a shared disease allele may have been missed. 
In the subsequent phase of the analysis, the consanguineous pedigrees were individually 
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examined, looking for autozygous diseases alleles.  
There was significant background consanguinity in the Roma pedigree, since the 
number of homosygous changes lying in homozygousity regions markedly exceeded 
that detected in the Indian case (31 vs. 17). Of note, six autozygous variants found in the 
Roma patient were predicted to be deleterious by multiple alogorithms. Most mapped to 
genes involved in cell cycle control (ARHGAP11A and EVI5) (Xu et al., 2013; Lim et 
al., 2013), cell motility (FMN1) (Dettenhofer et al., 2013), and metabolism (SLC45A4) 
(Bartölke et al., 2014), but two were in genes (GLI2 and NR3C2) that partake in 
immune response. GLI2 is a hedgehog responsive transcription factor which attenuates 
T-cell receptor-signaling by inhibiting NF-B and AP-1 activity (Furmanski et al., 
2015). NR3C2 encodes a mineralocorticoid hormone activated transcription factor, that 
regulates the activation of macrophages and NK-cells (Bene et al., 2014).  
Overall, the high number of autozygous changes and the lack of detailed 
functional information for some of the mutated loci hindered the prioritisation of 
candidate genes. Thus none of the above loci was screened in further affected 
individuals.  
As all relatives of the Roma patient refused to participate in the study, the only 
way to narrow down the candidate list in the future could be to generate additional 
sequence data from unrelated individuals who are likely to harbour recessive disease 
alleles. Of note, an agreement to share data has been reached with Dr Asma Smahi 
(Hospital Necker, Paris), who has exome sequenced a number of GPP patients born into 
consanguineous marriages. In parallel, the lab is working on ascertaining further 
recessive cases through international collaborations. Thus, the variant profile of the 
Roma case will be further analysed as soon as additional data is available. 
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In the Indian sample, the filtering of the variant profile narrowed down the list of 
possible candidates to three loci: STOX1, DOCK8 and MAPKBP1. 
STOX1 was excluded from the list of possible disease genes as the analysis of a 
recently released Indian dataset, indicated that the critical variant was in fact a common 
polymorphism. This demonstrated the importance of accessing frequency data for 
ethnicity-matched controls, to avoid the confounding effect of population-specific 
SNPs. Thus, resources such as the ExAC dataset (including >60,000 individuals 
sampled from multiple ethnic groups) or smaller population specific samples (e.g. the 
Dutch controls sequenced by Francioli et al., 2014), will be crucial to the identification 
of disease genes in whole genome/whole exome-sequencing studies.  
The mutations originally observed in DOCK8 and MAPKBP1 were not detected 
in any other individual from the follow-up resource. Thus the screening of these 
candidates was not pursued any further. While this decision was based on the 
observation that the vast majority of GPP mutations are recurrent (Setta-Kafetzi et al., 
2013; Setta-Kafetzi et al., 2014; Jordan et al., 2012), the possibility that disease-causing 
changes may reside elsewhere in DOCK8 or MAPKBP1 cannot be excluded, especially 
as the two genes have immune related functions. DOCK8 encodes a guanine nucleotide 
exchange factor and is a disease gene for autosomal recessive hyper-IgE syndrome, an 
immune deficiency characterised by recurrent infections, eosinophilia and high 
incidence of allergic manifestations (Aydin et al., 2015). MAPKBP1 encodes a scaffold 
protein, which down-regulates TRAF2- and NOD2 dependent NF-B signaling in 
epithelial tissues (Yamaguchi et al., 2009; Lecat et al., 2012). It has to be emphasized, 
however, that the follow-up cohort for these two loci included almost a hundred 
pustular psoriasis cases, and that the DNA segments that were sequenced were over 400 
base pair long. The fact that no damaging variants were found in these conditions 
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suggests that DOCK8 and MAPKBP1 are unlikely to be disease genes for pustular 
psoriasis.  
 
5.6.2 Analysis of dominant cases 
In the dominant group, the variant profiles were allocated to two different pools 
(Asian and European) based on the patient ethnicity.  
The analysis of the Asian dataset identified four genes - F8, HKR1, MEGF11, 
FRAS1-, which harboured mutations in more than one pedigree. Of note, family 23GPP 
had the most power to uncover disease-causing changes, given that the two affected 
individuals were the farthest related. Since the best candidate for this pedigree 
(CYP1A1) was excluded because of the high allele frequency of the putative mutation, 
the four genes mentioned above could be ranked, based on whether they were mutated 
in pedigree 23GPP. This would suggest that the best candidates are FRAS1 and 
MEGF11, where the latter could be further prioritised because of the higher CADD 
scores generated by putative mutations. MEGF11 is involved in the mosaic arrangement 
of neurons in the retina; however, the possibility that it is also expressed in the skin or 
in immune cells cannot be excluded (Kay et al., 2015). Thus, the locus may be worthy 
of further consideration.  
In the European cohort, 6 genes harboured deleterious changes in three unrelated 
cases. As the probands were all isolated cases, candidate genes were simply prioritised 
on the basis of the pathogenic potential and recurrence of putative mutations. On this 
basis, two loci (DNAH12 and ARFGAP2) were selected for follow-up.  
DNAH12 encodes a heavy chain dynein that participates both in axoneme 
motility and has been tentatively implicated in intracellular transport (Vaisberg et al., 
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1996). Although three unrelated individuals were found to carry a p.Gly1895Ser 
substitution by exome sequencing, the screening of this change in a European dataset 
failed to uncover any further cases harbouring the same variant. Thus the DNAH12 
locus is unlikely to contribute to disease onset. 
ARFGAP2 encodes a GTPase activating protein, which participates in the early 
secretory pathway by enhancing the enzymatic activity of ADP-ribosylation factor 1 
(ARF1) (Kartberg et al., 2010). Most importantly, one of the mechanisms mediating the 
effect of ARF1 on intracellular transport is the activation of the AP-1 clathrin adaptor 
complex (Meyer et al., 2005). This is noteworthy, as the AP1S3 gene encodes one of the 
AP-1 subunits (Setta-Kafetzi et al., 2014). Thus, the function of ARFGAP2 in vesicular 
trafficking makes it an attractive candidate gene.  
Here, the follow-up of the ARFGAP2 locus generated some promising results. 
One of the three mutations captured by exome sequencing (p. Gly519Ser) proved to be 
recurrent, while two further deleterious variants were identified. A burden test showed 
that the combined frequency of deleterious alleles was significantly higher in European 
patients compared to controls (P=1.8 x10-5). Of note, a sixth change with pathogenic 
potential was observed in pedigree 38GPP (p.Asp346Asn). Interestingly, this base 
change was only predicted to have an adverse effect on the protein encoded by an 
ARFGAP2 isoform that lacks exon 5. Although, the presence of this transcript in disease 
relevant cell types was confirmed by real-time PCR, the isoform was much less 
abundant than the full-length transcript, so that the pathogenicity of the p.Asp346Asn 
allele will need to be validated with additional studies of protein conservation and three-
dimensional structure homology modelling.  
It also has to be noted, that the result of the ARFGAP2 follow-up did not reach 
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exome-wide significance (P<2.5*10-6, Kiezun et al., 2012), nor were functional studies 
performed to support the pathogenic potential of this locus. Further genetic 
investigations will now be undertaken by another member of the group, with the aim to 
validate the pathogenic role of the locus and lay the foundations for the functional 
characterization of disease alleles.  
 
5.6.3 Conclusions 
 Overall, the present data highlights the difficulty of applying whole-exome 
sequencing to the study of a disease that is clinically and genetically heterogeneous. It 
also emphasizes the importance of accessing ethnically matched control data. In this 
context, the identification of ARFGAP2 as a promising candidate gene seems to suggest 
that the analysis of unrelated but carefully selected cases could be more powerful than 
the characterisation of single, moderately informative pedigrees. Thus, the most 
important step in a contemporary gene identification study is the selection of patients 
for whole-exome sequencing, which requires thorough phenotyping by expert 
dermatologists. In the future, gathering information on possible disease triggers (e.g. 
infections or pregnancy), risk factors (e.g. smoking) and response to treatment will 
allow a better stratification of pustular psoriasis and facilitate the identification of new 
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6 FINAL DISCUSSION 
6.1 The genetic overlap between plaque and pustular psoriasis 
Autoimmune diseases are caused by the abnormal activation of the immune 
system, which can result in systemic or organ-specific inflammation.  
Psoriasis is an example of this phenomenon. Although it is primarily a skin 
disorder, it is mediated by abnormal activation of innate and adaptive responses, with a 
clear pathogenic involvement of Th17 lymphocytes (Lynde et al., 2014).  
Psoriasis vulgaris, the most common subtype of the disease, is a complex, 
multifactorial disorder, which affects 2 % of the population worldwide. Conversely 
generalized pustular psoriasis is a rare, but very severe clinical variant (Mahil et al., 
2015).  Given that the frequency of PV among GPP patients (~50%) highly exceeds that 
in the general population (Mahil et al., 2015), the question has been raised as to whether 
the two conditions share common genetic determinants. 
While the major susceptibility locus for PV (HLA-Cw*0602) is not associated 
with pustular forms of the disease (Mahil et al., 2015), this study demonstrated that 
IL36RN alleles do not confer an increased risk of plaque psoriasis. This conclusion, 
which was reached through the Sanger sequencing of >200 disease cases and the re-
analysis of two large-scale studies, is unlikely to be confounded by lack of statistical 
power. 
Thus, it would appear that the major genetic determinants of PV and GPP show 
mutual exclusion, which argues against the notion that the same genes could underlie 
both phenotypes. 
Interestingly, these differences in genetic architecture point to distinctive 
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pathogenic pathways. HLA-C is an important mediator of antigen presentation, so that 
the association with HLA-Cw*0602 is in keeping with the notion that PV is mainly a T-
cell mediated disorder (Harden et al., 2015). Conversely, IL36RN encodes an anti-
inflammatory molecule that is highly expressed in keratinocytes, where it regulates the 
activity of three innate cytokines (IL-36α/β/γ) (Gabay and Towne, 2015). Generalised 
pustular psoriasis is therefore more likely to be an autoinflammatory condition, caused 
by the abnormal activation of innate, rather than adaptive immunity. In fact, the acute 
and episodic presentation of GPP is reminiscent of autoinflammatory disorders such as 
the cryopyrin associated syndromes, which manifest with recurrent fevers accompanied 
by flares of neutrophilic skin inflammation (Holzinger et al., 2015). 
The distinction between GPP and PV is also in keeping with the results of recent 
studies, indicating that IL-1 and IL-36, rather than IL-17 and IL-23, are the dominant 
cytokines in the GPP transcriptome (Johnston et al., 2015). Thus it would be tempting to 
propose that GPP is an IL-1/IL-36 mediated autoinflammatory disease while PV is an 
IL-23/IL-17 driven autoimmune disorder. While this is an attractive dichotomy, other 
experimental data suggest that the distinction may not be as clear cut and indicate a 
degree of overlap in the pathogenic pathways underlying the two conditions (Figure 
6.1.1 and Figure 6.1.2).   
For instance, it is well known that IL-36γ and IL-36α are markedly over-
expressed in the skin lesions of psoriatic patients (Carrier et al., 2011; Gabay and 
Towne, 2015), where they are upregulated by IL-17, rather than IL-36Ra deficiency 
(Carrier et al., 2011; D’Erme et al., 2015). In fact, a recent study has identified IL-36γ 
as a biomarker of disease activity and response to treatment in plaque psoriasis (D’Erme 
et al., 2015). 
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The analysis of CARD14 reported in this study also suggests an overlap between 
the pathogenesis of PV and GPP. Although the data presented in Chapter 4 showed that 
penetrant CARD14 mutations are rare in PV, this does not detract from the fact that 
common CARD14 alleles have been repeatedly associated with the disease (Mahil et al., 
2015). As my work identified an association between the p.Asp176His allele and GPP, 
the abnormal activation of NF-B downstream of CARD14 would appear to be another 
pathway underlying the pathogenesis of plaque and pustular psoriasis. 
More broadly, these results indicate that further studies of PV susceptibility 
genes may be warranted in GPP, to fully dissect the genetic and pathogenic overlap 
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Figure 6.1.1. Current understanding of the pathogenesis of psoriasis vulgaris 
When exposed to injury or infection, keratinocytes release DNA and/or RNA, as well as 
the antimicrobial peptide LL37. LL37-self nucleic acid complexes are then recognized 
by pDCs through TLR9 and by mDCs through TLR7/8, mDC cells migrate to the lymph 
nodes and activate Th1, Th17, and Th22 lymphocytes. Indeed, polymorphisms that 
affect antigen presentation to T cells (HLA-Cw6) and Th17 cell activation are strongly 
associated with PV susceptibility. T-lymphocyte subsets re-circulate to the skin, and the 
cytokines they release further activate keratinocytes, generating a feedback-loop 
between innate and adaptive immunity. These events are supported by neutrophils and 
macrophages, attracted towards the epidermis though KC derived chemokines. This 
further highlights the role of KC in psoriasis. KC, keratinocyte; pDC, plasmacytoid 
dendridic cell; mDC, myeloid dendridic cell; AMP, antimicrobial peptide. 
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Figure 6.1.2. Current understanding of the pathogenesis of generalised pustular 
psoriasis  
Following exposure to inflammatory stimuli (e.g. infections), mutation in IL36RN, 
AP1S3 or CARD14 up-regulate IL-36 secretion by keratinocytes. IL-36 molecules act 
both in an autocrine and paracrine fashion on KC and dendridic cells. Activated KC 
release chemokines that attract both neutrophils and macrophages towards the epidermis 
while DCs activate Th17 cell subsets, driving a positive feedback-loop between 
keratinocytes and T-cells. Abbreviations are as follows: KC, keratinocyte; pDC, 
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6.2 Identification of pustular psoriasis susceptibility genes  
Whole-exome sequencing of patients with pustular psoriasis revealed the 
presence of substantial genetic heterogeneity. This was observed even though the cases 
had been carefully selected, so as to be as homogeneous as possible in terms of their 
clinical phenotype.   
The analysis of likely dominant cases highlighted ARFGAP2 as a possible 
disease gene. After the completion of this study, the locus was followed-up by other 
members of the Capon lab. This revealed ARFGAP2 alleles with deleterious potential in 
a total of five unrelated cases of Malay descent. While this is an interesting observation, 
the enrichment of damaging alleles in cases vs. controls was not statistically significant, 
possibly owing to the small size of the control Malay resource. Thus, the status of 
ARFGAP2 as a pustular psoriasis gene remains to be validated.  
The analysis of the recessive cases was confounded by suboptimal coverage of 
the target exome, in one of the two individuals who were examined by next generation 
sequencing. This issue is currently being addressed by the group through a careful 
examination of the sequence gaps, with a special focus on a block of homozygosity on 
chromosome 10, which was shared by the two individuals who were exome-sequenced.  
This re-analysis has revealed an interesting candidate among the genes that were 
poorly covered. cAMP response element modulator (CREM) encodes a transcription 
factor that is highly expressed in T cells and has been implicated in both innate and 
adaptive immune regulation (Rauen et al., 2011; Verjans et al., 2015). The gene is 
currently being Sanger sequenced to explore the possibility that mutations at this locus 
may have been missed.  
  For the future, the group is committed to further exome sequencing studies, with 
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the expectation that the analysis of larger patient numbers will enhance the likelihood of 
detecting novel disease genes, despite the presence of genetic heterogeneity. Of note, 
Generalised Pustular Psoriasis has been successfully nominated for inclusion in the 
100,000 genomes project (McGrath, 2016). Thus it, is anticipated that sequence data 
will be available for at least 30 unrelated cases by the end of 2018. Of note this will be 
generated by whole-genome, rather than whole-exome sequencing, which will resolve 
the issue of uneven coverage of target regions. 
  In the meantime, there is scope for re-analysing the available data at selected 
candidate regions, where mutations would be worthy of follow-up even if they had been 
observed in one or two cases. Thus, the variant profiles are currently been filtered for 
mutations that affect genes implicated in other autoinflammatory disorders.  
Of note, current research in our lab indicates that AP1S3 mutations affect IL-36α 
production, by disrupting the immune regulatory function of autophagy. These 
interesting results highlight IL-36α as a key player in the pathogenesis of pustular 
psoriasis and suggest that future studies could focus on genes that regulate the 
production and biological activity of this cytokine. Thus, genetic screens of IL-36 
signalling modulators would shed new light on IL-36 biology, while also identifying an 
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Appendix II: Primers used in the study 
 
 
Table II a: Primers used for PCR and Sanger sequencing 
 
Primer ID Target Region Sequence 5' to 3' 
Tannealing 
[°C] 
ARFGAP2 Ex1-2 F ARFGAP2 
Exon1-2 
AGATCGGACTCCAATCACCC 66 
 ARFGAP2 Ex1-2 R GAATTCAGAGCGGCCCAAG 




ARFGAP2 Ex3 R TGACCAGTTTCGAAGTTTTCAG 




ARFGAP2 Ex4-5 R CTAGGCCTACCCAGCAGGA 




ARFGAP2 Ex 6-7 R CAGGCAGTAGGACCTCTGAA 




ARFGAP2 Ex8 R GGTAAGTGGTAAGGTCAAGGAGT 




ARFGAP2 Ex9-10R GCATCCCAAACTGCTAGGAA 




ARFGAP2 Ex11R TTGTCCTTGTACCTAGGGAGA 




ARFGAP2 Ex12R GTTCTTCTAGACAGTGCTGCC 
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ARFGAP2 Ex16R CAAGGGCTGGTACTGACCAT 




ARHGAP11A Ex4R TTGGAGTATACTCCTCATAG 




ARHGAP11A Ex5R CCAACTTTCTAACAGTTGCC 




ARHGAP11A Ex6R CCAAAAAGGCACATACCACA 




ARHGAP11A Ex7R TGCCTACAATTTTGGGTTCA 









ARHGAP11A E12R GTTACAACACATGTACTCTGC 




ARHGEF16 R GGAGGAGAAGGTCACAAGCA 
CARD14 Ex 2 CARD14 Exon 2 
 
ATG GCC ACT GGA ATG CTT C 
63 
CARD14 Ex 2 CAG GAC GAG AAG AGA CCC C 
CARD14 Ex 3 CARD14 Exon 3 
 
ACC CAG CAG AAC CCA GAA A 
64 
CARD14 Ex 3 AAG GGG GAG TAG GGC AAA T 
CARD14 Ex 4 CARD14 Exon 4 
 
TGC TCA CCT GCT CAC CTA C 
66 
CARD14 Ex 4 AAG GAG TTC CAG GGA GAT GG 
CARD14 Ex 5 CARD14 Exon 5 
 
TTC AGT CTC GAG GCA GGA AG 
63 
CARD14 Ex 5 AAC CAC CTG TCA GAA ACC CC 
CARD14 Ex 6 CARD14 Exon 6 
 
AAG ACT GCA TCC GTC CAC A 
63 
CARD14 Ex 6 AAT TAT GTG AGC TCG GCG TG 
CARD14 Ex 7 CARD14 Exon 7 AGA ACT GTC TCC CTC CCT C 66 
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CARD14 Ex 7  TGT GGA CCG AGG AAA GAG AC 
CARD14 Ex 8 CARD14 Exon 8 CAC TGC ACA TGT GAA CAC GA 
63 
CARD14 Ex 8 TCG CTC ATC ACA GTG ACA CT 
CARD14 Ex 9 CARD14 Exon 9 CTG GAA GCT GAC GAG AGG AA 
63 
CARD14 Ex 9 CGT ACC AAC CTC TTC CCT GT 
CARD14 Ex 10-11 CARD14 Exon 
10-11 
TGT GTC CTT CTT TCC CCT CC 
65 
CARD14 Ex 10-11 TAT CTG CCC TTT CCC TGG AG 
CARD14 Ex 12-13 CARD14 Exon 
12-13 
AGA TCT GTG AAG AAG GGG CT 
66 
CARD14 Ex 12-13 TGA AGT CTG CCT GGG TCA C 
CARD14 Ex 14-15 CARD14 Exon 
14-15 
TGC AGG CAG TGG TCC TAC 
63 
CARD14 Ex 15-15 CGC CCA CCC TCT ATT GCT 
CARD14 Ex 16-17 CARD14 Exon 
16-17 
AAA GCT CTG GAG ACT GGC AT 
63 
CARD14 Ex 16-17 TTT GAA GGG GTG CAG AGG AG 
CARD14 Ex 18-19 CARD14 Exon 
18-19 
ACA CAC CTC AGG CTG TTC TC 
63 
CARD14 Ex 18-19 CCC AGC CCC ATG ATT CTT GA 
CARD14 Ex 20-21 CARD14 Exon 
20-21 
TGG AAT TCTAGG TGCTGG GG 
64 
CARD14 Ex 20-21 GGT CGG TCCCTG TAC CTTTA 
CARD14 Ex 22 CARD14 Exon 
22 
 
AAATTCAGC TCTGCC CAGCTCC  
63 CARD14 Ex 22 TCC CAA AGT TGT GCG GAA AC 
CARD14 Ex 23 CARD14 Exon 
23 
 
TGT CAT CAC TAC CCT AGC CA 
63 CARD14 Ex 23 GCC TCA TGT GCC AAG GAG 










CYP1A1Ex3-4F CYP1A1Exon 3- AGAGAAGCTGGGACAACAGC 67 























DNAH12 varEx38R TGTACAATTTTAAACACTGAGCA 









EPHA8 R TCCACAGAGCTGATGACCTG 




HLA-C S R GGTCGCAGCCATACATCCA 




IL36RN- Exon1-R CACAATTTCCCAGCTGCAAT 




IL36RN- Exon2-R GCTTAGAGCCTGGTTTGTGC 




IL36RN- Exon3-R CAAAGCTGCCATCAACAGAA 





























IGSF10 R CATTGAGCACTGTGGCTGAG 




IQGAP2 R GGGTCAAATCCTCCTCCTTC 









FRAS1 R TCTGTAGAGGGAGATCATTTGC 




PLCH1 R CAAGATGGTGGCATAGTGAGA 




RELT R ATCCTTCAGGGGAGCAACAT 




RNF207 R CAAGAGGTAGGGCTCTGCG 




STOX1 R GCCTTTTCTTAACCCCCTCTT 




TAS2R3 R CCCTGAATCATGTGTGTTGG 




VNN2 R GAGGCATTCATTTCTCTGCACT 
ZNF516 F ZNF516 Exon 3 GAAGCCCTACAAGTGTCCCT 58.5 (10% 
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ZNF516 R  CTTCTTACGCTCGAACTGGC DMSO) 
All primers were purchased from Eurofin Genomics. 
Table II b: Primers used for Sanger Sequencing only 
Primer ID Target Region Sequence 5' to 3' 
        CARD14s 1F / T7F  T7 TAATACGACTCACTATAGGG 
        CARD14s 1R  CARD14sh in pcDNA 3.1 TCCAGAATGTCCTTCTCC 
     CARD14s 1ibF  CARD14sh in pcDNA 3.1 ACTTGCTGGATTTGCTGAA 
   CARD14s 1ibR CARD14sh in pcDNA 3.1 TTCAGCAAATCCAGCAAGT 
    CARD14s 2F CARD14sh in pcDNA 3.1 TCCTGTGAGCTGGAATTG 
   CARD14s 2R  CARD14sh in pcDNA 3.1 TAATCCAGGTGTGGGTCG 
   CARD14s 3F CARD14sh in pcDNA 3.1 GAGCTGGTGGACAGCTTC 
     CARD14s 3R/BGH R CARD14sh in pcDNA 3.1 TAGAAGGCACAGTCGAGG 
CMVextra1        pCMV promoter in pcDNA 3.1 GGACTTTCCTACTTGGCAGT 
BGHextra1  BGH site in pcDNA 3.1 CTTCTAGTTGCCAGCCATC 
All primers were purchased from Eurofin Genomics. 
Table II c: Primers used for real-time PCR 
Primer ID Target gene Sequence 5' to 3' 
ARFGAP2 Q F main  ARFGAP2 full length 
transcript  
TCACTCCCCAGAGAAGAAGG 
ARFGAP2 Q R 
main 
ARFGAP2 full length 
transcript  
CAGGCCACTGCTCTCTGTAGA 
ARFGAP2 Q F 2nd ARFGAP2 isoform lacking 
exon 5 
ATGGCACTGATCCCCCTGC 
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ARFGAP2 Q F 2nd ARFGAP2 isoform lacking 
exon 5 
TCTGTGTTGGGGCCATGCT 
All primers were purchased from Eurofin Genomics. 
 
Table II d: Primers used for microsatellite genotyping 
Primer ID Target  Sequence 5' to 3' 
Chr6 Micros F AFM142xh6 
(D6S273) 
5'FAM-GCAACTTTTCTGTCAATCCA 
Chr6 Micros R ACCAAACTTCAAATTTTCGG 
 
Appendix III: Web resources 
Application Website 
Basic Local Alignment Search 
Tool (BLAST)  
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
Beijing Meidi TCM Skin 
Disease Hospital 
http://www.skindiseasehospital.org 




COILs  http://embnet.vital-it.ch/software/COILS_form.html 
Combined Annotation 
Dependent Depletion (CADD) 
http://cadd.gs.washington.edu/ 
dbSNP  http://www.ncbi.nlm.nih.gov/SNP/ 
Ensembl http://www.ensembl.org/index.html 
               249 




Genetic Power Calculator http://pngu.mgh.harvard.edu/~purcell/gpc 
Graphpad http://graphpad.com/quickcalcs/contingency1.cfm 
ImageJ http://imagej.nih.gov/ij/ 










Mutation Taster http://www.mutationtaster.org/ 
Ncoils http://manpages.ubuntu.com/manpages/precise/man1/nc
oils 




Psoriasis Medication http://psoriasismedication.org 
Sanger Method sequencing http://www.slideshare.net/suryasaha/sequencing-the-
next-generation 
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SIFT/PROVEAN http://sift.jcvi.org/ 
Singapore Sequencing Indian 
Project (SSIP) 
http://www.statgen.nus.edu.sg/~SSIP/ 
Sroogle  http://sroogle.tau.ac.il/ 
STRAP http://www.bioinformatics.org/strap/ 
The Exome Aggregation 
Consortium (ExAC) Browser 
http://exac.broadinstitute.org/ 
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PUBLICATIONS ARISING FROM THIS THESIS 
 
 
impact on the ability of these cells to
sense the local antigenic microenviron-
ment and regulate cutaneous immune
responses. It is also not clear why
certain therapeutic interventions, but
not others, are associated with a restora-
tion of LC motility. It may be that anti-
TNF and anti-IL-12/23 therapies result in
a resetting of normal epidermal func-
tion, including LC mobilization. These
data demonstrate the utility of the
ex vivo explant model and provide
evidence that aberrant LC mobilization
is a function of the psoriatic process,
rather than a predisposing phenotype.
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Loss of IL36RN Function Does Not Confer Susceptibility
to Psoriasis Vulgaris
Journal of Investigative Dermatology (2014) 134, 271–273; doi:10.1038/jid.2013.285; published online 18 July 2013
TO THE EDITOR
Recessive mutations of the gene encod-
ing the interleukin-36 receptor antago-
nist (IL36RN) have been associated with
generalized pustular psoriasis, palmar-
plantar pustulosis, and acrodermatitis
continua of Hallopeau (Marrakchi
et al., 2011; Onoufriadis et al., 2011;
Setta-Kaffetzi et al., 2013). As patients
suffering from these pustular conditions
often present with concomitant psoriasis
vulgaris (PV), it has been proposed that
IL36RN deficiency may also contri-
bute to PV susceptibility (Marrakchi
et al., 2011). This hypothesis is sup-
ported by the observation that mice
lacking il36rn show exacerbated symp-
toms of imiquimod-induced psoriasiform
dermatitis and enhanced infiltration of
inflammatory cells in the dermis and
the epidermis (Tortola et al., 2012). The
elevated expression of IL-36 cytokines
in psoriatic skin (Carrier et al., 2011;
Johnston et al., 2011) is also consistent
with the notion that abnormal IL-36
signaling has an important role in the
establishment of cutaneous inflamma-
tion (Supplementary Figure 1 online).
On the basis of the above findings,
it has recently been suggested that
IL-36 blockade could be an innovativeAccepted article preview online 21 June 2013; published online 18 July 2013
Abbreviations: IL36RN, interleukin-36 receptor antagonist gene; PV, psoriasis vulgaris
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approach for the treatment of PV
(Tortola et al., 2012). However, the
pathogenic role of IL-36 cytokines
has mostly been investigated in the
context of animal models (Blumberg
et al., 2010; Carrier et al., 2011;
Tortola et al., 2012), and the notion
that IL36RN deficiency contributes to
the onset of human PV has yet to be
demonstrated. Here, we have explored
this hypothesis by investigating whether
IL36RN loss-of-function alleles are
associated with PV.
We reasoned that the segregation of
deleterious sequence variants would
result in familial recurrence of PV
and ascertained 349 unrelated patients
with a positive family history of the
disease (174 male and 175 female
individuals; see also Table 1). We also
examined 14 independent cases of
erythrodermic psoriasis (10 male and
4 female individuals), based on the
hypothesis that penetrant mutations
would more likely result in a severe
clinical presentation. All patients were
recruited through St John’s Institute
of Dermatology and Glasgow Western
Infirmary. The study was conducted
in accordance with the declaration
of Helsinki, and ethical approval
was obtained from Guy’s and
St Thomas Local Research Ethics
committee. All participants granted
their written informed consent.
The four IL36RN coding exons and
proximal promoter region were sequen-
ced using primers and cycling condi-
tions described elsewhere (Onoufriadis
et al., 2011; Setta-Kaffetzi et al.,
2013). Nucleotide changes were iden-
tified using the Sequencher software
(Genecodes).
Sanger sequencing identified six com-
mon polymorphisms with minor allele
frequencies exceeding 5%. None of
these changes resulted in an amino-
acid substitution and none of the vari-
ants was significantly overrepresented in
cases compared with controls (Supple-
mentary Table 1 online). To exclude the
possibility that these findings may be
due to lack of statistical power, we
reexamined the IL36RN markers ana-
lyzed in a previous genome-wide asso-
ciation study of 2,600 psoriatic cases
and 5,700 controls (Strange et al.,
2010). By integrating experimental and
imputed data (see Supplementary
Methods online), we obtained geno-
types for 130 single-nucleotide poly-
morphisms spanning the IL36RN locus
and 10 kb of flanking regions. None
of these markers generated a P-value
o0.05, indicating that common IL36RN
variants are unlikely to confer significant
increases in disease risk.
None of the examined patients har-
bored recessive alleles with pathogenic
potential (i.e., homozygous or com-
pound heterozygous changes resulting
in non-synonymous substitutions or
protein truncation). Three affected indi-
viduals were heterozygous for rare non-
synonymous substitutions. Two carried
a known p.Ser113Leu (rs144478519)
change and one previously unreported
p.Thr77Ile variant. The latter substitu-
tion was classified as benign by the SIFT
(Kumar et al., 2009) and PolyPhen-2
(Adzhubei et al., 2010) pathogenicity
prediction tools and therefore was not
analyzed any further. Conversely, the
p.Ser113Leu allele is known to be
damaging, as it has been repeatedly
detected in patients with pustular
psoriasis (Onoufriadis et al., 2011;
Setta-Kaffetzi et al., 2013). As data pre-
viously generated by our group sugges-
ted that this mutation may have a
pathogenic effect even in the hetero-
zygous state (Navarini et al., 2013;
Setta-Kaffetzi et al., 2013), we investi-
gated its segregation in the families
of the two critical patients. In both
cases, we found that the p.Ser113Leu
substitution was not co-inherited with
the disease (Supplementary Figure 2
online). We also observed that the
frequency of p.Ser113Leu in our
patient resource (2/726 chromosomes
or 0.27%) was comparable to that
seen in 2,222 exomes sequenced
in-house (15/4,444 chromosomes
or 0.34%). Thus, the p.Ser113Leu
change is unlikely to contribute to PV
susceptibility.
Data generated in animal models
indicate that IL-36 cytokines are likely
to have a pathogenic role in the
establishment of skin inflammation.
Transgenic mice overexpressing il36a
in basal keratinocytes present with a
psoriasiform phenotype (IL-23-depen-
dent hyperkeratosis accompanied by
infiltration of neutrophils and lympho-
cytes into the dermis) that is exacerbated
by il36rn knockout (Blumberg et al.,
2007). It has also been demonstrated
that IL-36R blockade resolves the
inflammatory changes of human psoria-
tic skin transplanted onto immune-
deficient mice (Blumberg et al., 2010),
whereas loss of il36rn exacerbates
the pathology of imiquimod-induced
psoriasiform dermatitis (Tortola et al.,
2012).
Despite the interest generated by
these findings, the effect of IL36RN
deficiency on the establishment of PV
has not been investigated. Here, we
addressed this issue through the genetic
analysis of an extended clinical resource
including 363 patients affected by famil-
ial and/or severe disease. We found that
none of the examined cases harbored
recessive IL36RN mutations. Although
two patients were heterozygous for the
pathogenic p.Ser113Leu mutation, this
change did not segregate with the dis-
ease in the relevant families and was not
overrepresented among case chromo-
somes. Our patient resource was suffi-
ciently powered to uncover variants
occurring at a frequency 40.25% and
detect associations with alleles of mode-
rate to strong effect (Supplementary
Figure 3 online). Although the preva-
lence and the odds ratios documented
for the p.Ser113Leu allele are within
these parameters (Navarini et al., 2013;
Setta-Kaffetzi et al., 2013), our analysis
might have missed the pathogenic
contribution of rarer alleles of modest
effect. Nonetheless, it is reasonable to
conclude that in the British population
Table 1. Disease recurrence in the familial PV resource
Number of affected individuals in the pedigree
45 5 4 3 2 Total
No. of families 15 11 33 121 169 349
Abbreviation: PV, psoriasis vulgaris.
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loss of IL36RN activity is not associated
with a significant increase of PV risk.
As our study was focused on IL36RN,
we cannot exclude the possibility that
mutations in functionally related genes
(e.g., IL36A, IL36B, and IL36G) may be
associated with the disease. Thus, our
findings warrant further genetic investi-
gations into the role of IL-36 cytokines
in human PV.
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Plectin Mutations Underlie Epidermolysis Bullosa Simplex
in 8% of Patients
Journal of Investigative Dermatology (2014) 134, 273–276; doi:10.1038/jid.2013.277; published online 18 July 2013
TO THE EDITOR
Epidermolysis bullosa simplex (EBS) is a
mechanobullous genodermatosis char-
acterized by an intraepidermal split
through the cytoplasm of basal keratino-
cytes, which is mainly caused by domi-
nant-negative mutations in the genes
encoding keratins 5 and 14 (Coulombe
et al., 1991; Lane et al., 1992). Mutation
analysis of KRT5 and KRT14 in a
large biopsy-confirmed EBS population
in the Netherlands, however, revealed
that in 25% of unrelated cases no
mutations could be identified in these
genes (Bolling et al., 2011). A similar
percentage of EBS cases with wild-type
KRT5 and KRT14 genes was reported
for the EBS population in the United
Kingdom (Rugg et al., 2007). A missense
mutation, Arg2000Trp, in PLEC, enco-
ding the hemidesmosomal protein
plectin, which connects the basal kera-
tins to the hemidesmosomal plaque, was
associated in cases with dominant EBS
of hands and feet (EBS-Ogna) (Koss-
Harnes et al., 2002; Kiritsi et al., 2013).
In this study, we investigated the
frequency of PLEC mutations in biopsy-
proven EBS probands that lacked muta-
tions in KRT5 and KRT14. The study was
performed according to the Declaration
of Helsinki principles, and informed
consent was obtained from the patients.
PLEC mutation analysis was performed
in 16 Dutch probands with a biopsy-
proven EBS in which mutations in KRT5
and KRT14 had been excluded. PCR
amplification of all exons and adjacent
intronic sequences of PLEC (GenBank
NM_000445) was performed using pri-
mers located in the flanking introns.
Primers resulting in overlapping PCR
products were used for the large exonsAccepted article preview online 17 June 2013; published online 18 July 2013
Abbreviation: EBS, epidermolysis bullosa simplex
MC Bolling et al.
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Our patients could continue their therapy either by avoiding
leucovorin or by rapid desensitization (with adequate installa-
tions, standardized protocols, and expert personnel).
Up to 3 patients suffered overlooked milder symptoms during
previous administrations. Helping patients identify and commu-
nicate these symptoms may prevent unnecessary risks.
In conclusion, we describe an important number of confirmed
HSRs to leucovorin during a 1-year period.We show how patients
reacting to leucovorin may also react to L-isomer calcium foli-
nate. We believe that protocols studying FOLFOX/FOLFIRI
HSRs should be undergone by drug allergy experts, and include
systematic skin testing and DPTwith folinic acid, to avoid infra-
diagnosis and its resulting risks. Moreover, we report the first
intravenous rapid desensitization to leucovorin in a reactive pa-
tient (confirmed by DPT).
We are indebted to Dr Federico Longo-Mu~noz and Dr Reyes Ferreiro-
Monteagudo, from the Medical Oncology Department, and Dr Marina
Sanchez-Cuervo, from the Pharmacy Department, for their colaboration and
clinical expertise. We thank all the participants in the multidisciplinary
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IL36RN mutations define a severe autoinflam-
matory phenotype of generalized pustular
psoriasis
To the Editor:
Autoinflammatory diseases are a heterogeneous group of
disorders mediated by abnormal activation of the innate
immune system, resulting in recurrent episodes of systemic and
organ-specific inflammation.1 In recent years, the pace of
autoinflammatory disease gene discovery has undergone a
dramatic acceleration with the emergence of novel autoinflamma-
tory phenotypes, highlighting the need to establish reliable
diagnostic criteria through the analysis of extended case series.1
Generalized pustular psoriasis (GPP) is a rare autoinflammatory
conditionpresentingwith recurrent episodesof skin pustulation that
are often accompanied by systemic inflammation (acute-phase
response with neutrophilia) and concurrent psoriasis vulgaris
(PV).2 We and others demonstrated that a proportion of GPP cases
carry recessive mutations of IL36RN, the gene encoding the IL-36
receptor antagonist.3,4 This anti-inflammatory protein modulates
the activity of IL-36 a, b, and g, a group of IL-1 family cytokines
that have repeatedly been shown to be overexpressed in psoriatic
lesions. Importantly, studies of animal models and human primary



















Case 1 Negative Negative Positive: urticaria 1.87 Positive: urticaria Negative
Case 2 Negative Negative Positive: general urticaria,
rhinoconjunctivitis




Case 3 Negative Negative Positive: chills, back pain,
elevated blood
pressures, fever
2.46 Not performed Negative
Case 4 Negative Negative Positive: general urticaria,
eyelid angioedema
4.85 Not performed Negative
Case 5 Negative Negative Positive: chills, chest
pain, facial erythema
1.23 Positive: chills, facial
erythema
Negative
ST concentrations used for oxaliplatin were 5 mg/mL and 0.5 mg/mL.1 For irinotecan (20 mg/mL; 2 mg/mL), leucovorin (10 mg/mL; 1 mg/mL), and calcium levolinate (10 mg/
mL; 1 mg/mL) were empirically obtained: full-strength solution according to manufacturer instructions and diluted further in normal saline to 1:10, and these concentrations were
tested in 10 control patients to prove them nonirritant.
ST, Skin test.
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cell cultures indicate that IL-36 molecules induce the activation of
keratinocytes and antigen-presenting cells, thus propagating skin
inflammation in patients with psoriasis.5
Although these discoveries have shed new light on the
pathogenesis of GPP, the rarity of the disease has thus far hindered
a robust definition of the symptoms associated with deficiency of
IL-36 receptor antagonist (DITRA), so that reliable indications for
IL36RN screening are still lacking. Here we sought to address this
issue by ascertaining an extended patient resource. We examined
233 cases (see Tables E1-E3 in this article’s Online Repository at
www.jacionline.org) recruited in accordance with the principles
of the Declaration of Helsinki and with ethical approval from
the relevant committees of participating institutions. This data
set originated from 3 sources: (1) 177 cases were ascertained
through a systematic literature search based on the terms
‘‘IL36RN’’ and ‘‘generalized pustular psoriasis’’ (see Fig E1 in
this article’s Online Repository at www.jacionline.org); (2) 45 pa-
tients received diagnoses from the coauthors of this study, accord-
ing to established criteria2; and (3) 11 cases were initially
ascertained by the International Registry of Severe Cutaneous
Adverse Reaction Consortium. After an in-depth case review,
the consortium expert committee proposed the presentation to
be consistent with GPP. Thus the key inclusion criterion underly-
ing the 3 ascertainment streams was a clinical diagnosis of GPP.
The subsequent identification of patients with systemic flares
was based on the criteria established by the American College
of Chest Physicians (leukocytosis and fever >388C).6
To delineate the phenotypic spectrum associated with DITRA,
we first determined the frequency of IL36RN mutations in our
cohort. We found that 49 (21.0%) of 233 cases carried recessive
IL36RN alleles (see Table E1). Because information on age of
onset, systemic involvement, and PV concurrence was available
for 99.6%, 72.1%, and 86.7% of cases, we compared these fea-
tures in patients bearing recessive IL36RN mutations (n 5 49)
and in those without pathogenic alleles at this locus (n 5 166,
see Table E1 and the Methods section in this article’s Online
FIG 1. A-C, Subjects with recessive IL36RN alleles have earlier disease onset (Fig 1,A), more frequently have
systemic inflammation (Fig 1, B), and less frequently have PV (Fig 1, C) compared with IL36RN-negative
subjects. D and E, Although the prevalence of systemic inflammation remains high among cases with a
single mutation (Fig 1, D), these subjects present with significantly delayed disease onset compared with
those with recessive alleles (Fig 1, E). ns, Not significant; SI, systemic inflammation, which was defined
according to the American College of Chest Physicians criteria (leukocyte count >12 3 109/L and fever
>388C)6. **P < .01, ***P < .001, and ****P < 1026.
TABLE I. Frequency distribution of heterozygous IL36RN alleles
Origin
Allele counts (%)
P value ORCases Control subjects
British 2/22 (9.1%) 2/568 (0.3%) .008 28.3
Chinese 4/72 (5.6%) 8/394 (2.0%) .10 2.8
Japanese 3/66 (4.5%) 0/178 (0%) .019 19.7
Malay 5/110 (4.5%) 0/192 (0%) .006 20.1
OR, Odds ratio.
J ALLERGY CLIN IMMUNOL
APRIL 2015
1068 LETTERS TO THE EDITOR
Repository at www.jacionline.org). We found that IL36RN-posi-
tive subjects manifested a strikingly more severe clinical pheno-
type characterized by an earlier age of onset (176 2.4 vs 336 1.5
years, P5 5.93 1027) and a markedly increased risk of systemic
inflammation (83.3% vs 55.6%, P5 1.53 1023; Fig 1, A and B).
We also observed a very significant reduction in the prevalence of
PV in the IL36RN-positive cohort (36.1% vs 68.7%, P 5 5.0 3
1024; Fig 1, C), validating the results of a small Japanese study.7
We previously reported 6 patients with GPP bearing single
heterozygous IL36RNmutations.8 In keepingwith this observation,
we observed 18 cases (including the subjects we had originally
described) with a single disease allele. To validate the significance
of these findings, we compared the frequency of monoallelic
IL36RNmutations in cases versus population-matched control sub-
jects. We found that heterozygous disease alleles were consistently
enriched among cases, with statistically significant P values
(P<.02; false discovery rate< 0.05) observed inmost ethnic groups
(Table I).We also performed ameta-analysis of our case-control re-
sources, which demonstrated that monoallelic IL36RN mutations
confer a very substantial increase in disease risk (weighted pooled
odds ratio, 7.32; 95% CI, 3.02-17.7; P5 1.13 1025).
We next compared disease severity in subjects carrying 1 or 2
mutations. We focused our analysis on age of onset and systemic
inflammation because PV concurrence is not considered a reliable
indicator of GPP severity.2 We observed a high prevalence of
systemic inflammation (>80%) in both patient groups (Fig 1,
D), but we noted that the mean age of onset in IL36RN heterozy-
gotes exceeded by 2-fold that of patients with biallelic mutations
(36 6 5.5 vs 17 6 2.4; P 5 6.0 3 1024; Fig 1, E).
The aim of our study was to investigate the correlation between
IL36RN mutation status and the clinical presentation of GPP to
aid the definition of diagnostic criteria for the stratification of
patient cohorts. We found that IL36RN alleles define a GPP
phenotype characterized by early onset, high risk of systemic
inflammation, and low prevalence of PV. Of note, these
conclusions were drawn by comparing the IL36RN-positive data
set with a heterogeneous cohort that was solely defined by the
lack of IL36RNmutations. As further disease genes are identified
and systematically genotyped, the designation of more
homogeneous patient subgroups will become possible, allowing
the development of formal diagnostic algorithms.
We recognize that our study design, which combined the
analysis of newly recruited cases with a literature review, might
have been vulnerable to ascertainment bias. However, we note
there was no significant variability in the frequency of IL36RN
mutations across data sets (see Table E4 in this article’s Online
Repository at www.jacionline.org), indicating that our inclusion
criteria were sufficiently robust to allow the ascertainment of a
reasonably homogeneous resource.
Our analysis demonstrated a gene dosage effect whereby GPP
onset is significantly delayed in subjectswithmonoallelicmutations.
Intriguingly, we found that these subjects were still at high risk of
systemic inflammation. Thus heterozygous patients might require a
longer or more intense exposure to environmental triggers to
manifest overt disease. Once an abnormal immune response is
initiated, however, thepresenceof awild-type IL36RN allele doesnot
appear sufficient to prevent the onset of systemic inflammation. This
suggests that abnormal cytokine signaling might be propagated by
molecules acting downstream of IL36RN. Further ex vivo analyses
will be required to validate this model and define the cytokines that
sustain abnormal inflammatory responses in patients with GPP.
In conclusion, we have defined a clinical triad (early onset,
systemic inflammation, and absence of concurrent PV) that could
be used to prioritize patients with GPP for IL36RN screening.
Importantly, pilot studies indicate that a proportion of patients
with IL36RN mutations could be treated with the IL-1 antagonist
anakinra.9,10 Therapeutic agents that specifically target the IL-36
receptor are also being developed.11 Thus our work is expected to
facilitate the identification of patients who might benefit from
personalized treatment with IL-1 or IL-36 blockers.
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Is there a risk using hypoallergenic cosmetic
pediatric products in the United States?
To the Editor:
Health care providers wisely advise the parents of children with
atopic dermatitis (AD) to apply emollients to treat xerotic and
inflamed skin. So-called hypoallergenic products are typically
recommended because patients with AD have an elevated risk of
contact allergy to fragrances, surfactants, and preservatives.1-3
This is likely explained by more frequent allergen exposure via
topical products in combination with an impaired skin barrier
facilitating allergen penetration.4
Chronic exposure to contact allergens in cosmetics increases
the risk of not only allergic contact dermatitis (ACD) but also
AD.5 Repeated cutaneous exposure to skin sensitizers initially
leads to ACD characterized by TH1 inflammation, but then a
gradual shift toward TH2 inflammation, resulting in AD.
4 In addi-
tion, AD skin has a specific initial propensity to TH2 program-
ming following exposure to contact allergens in contrast to the
normal TH1 programming in non-AD skin.
6
Anecdotally, we have observed a lack of correlation between
marketing terms highlighting hypoallergenicity or dermatologist/
pediatrician-recommended status and the actual content of contact
allergens in topical products. We therefore evaluated the allergen
content of 187 unique pediatric cosmetics marketed in the United
States as hypoallergenic. Inclusion criteria were products mar-
keted as pediatric and ‘‘hypoallergenic,’’ ‘‘dermatologist recom-
mended/tested,’’ ‘‘fragrance free,’’ or ‘‘paraben free.’’
Products from 6 different retailers in and around Redlands,
California, were purchased or photographed in September 2013.
The ingredients, name, brand, type, and advertising term for each
product were recorded. To identify contact allergens, the in-
gredients were compared with allergens in the North American
Contact Dermatitis Group standard screening tray using a
customized search algorithm programmed into Matlab 7.4
(Mathworks, Natick, Mass).
We found that 167 (89%) of the 187 products contained at least
1 contact allergen, 117 (63%) 2 or more, and 21 (11%) 5 or more
(Table I). The average number of allergens in each product was
2.4 (95% CI, 2.05-2.51). The most prevalent single allergen was
cocamidopropyl betaine, found in 45 (24%) followed by prop-
olis/beeswax in 35 (19%), phenoxyethanol in 33 (18%), tocoph-
erol in 25 (13%), and DMDM hydantoin in 24 (13%) (Table II).
Of note, 11.2% of the products contained methylisothiazolinone.
By allergen category, the most prevalent sensitizers were preser-
vatives 108 (58%) and fragrances 55 (29%).











allergens (n) 95% CI*




66 78.8 (52) 50.0 (33) 21.2 (14) 9.1 (6) 3.0 (2) 73.8-83.8
Fragrance free 52 80.8 (42) 55.8 (29) 30.8 (16) 17.3 (9) 11.5 (6) 75.3-86.2
Hypoallergenic 135 88.2 (119) 65.2 (88) 42.2 (57) 23.7 (32) 11.1 (15) 85.2-90.9
Paraben free 72 88.9 (64) 56.9 (41) 29.2 (21) 18.1 (13) 5.6 (4) 85.2-92.6
NA, Not applicable/available.
*95% CI reflects the CI for % with 1 or more allergen.
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METHODS
Mutation screening
The IL36RN coding region was screened by using primers and conditions
reported elsewhere.E1 In those instances in which Sanger sequencing
uncovered a single disease allele, the possibility that the second
mutation might be accounted for by the insertion/deletion of an entire
exon was excluded by amplifying the entire IL36RN gene region, as
previously described.E2 Nucleotide changes were considered deleterious if
(1) experimentally derived evidence was available in the literature or
(2) a high-confidence pathogenicity prediction was returned by using at least 4
of the following programs: SIFT,E3 PolyPhen-2,E4 Provean,E5 MutPred,E6 and
MutationTaster.E7 The sequence of the IL36RN transcript ENST00000393200
was used as a reference in all bioinformatics analyses.
Statistical tests
Differences in the frequency distribution of dichotomous clinical findings
(presence/absence of PVor systemic inflammation) and mean ages of disease
onset were assessed with the Fisher exact test and Student unpaired t test,
respectively. Both were implemented with the online tools available at
http://graphpad.com/quickcalcs/.
The combined frequency of heterozygous IL36RN alleles was compared in
cases versus control subjects by using the Fisher exact test. Control allele
frequencies were determined in the following resources: 284 British subjects
sequenced by the 1000 Genomes Project (n5 89) and TwinsUK (n5 195), 89
Japanese and 197 Han Chinese subjects sequenced by the 1000 Genomes
Project, and 96 subjects sequenced by the Singapore Sequencing Malay
Project.E8-E10 The meta-analysis of multiple case-control data sets was
implemented with Review Manager 5.2.E11 P values of less than .05 were
deemed statistically significant.
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Activating CARD14 Mutations Are Associated with
Generalized Pustular Psoriasis but Rarely Account for
Familial Recurrence in Psoriasis Vulgaris
Dorottya M. Berki1, Lu Liu2, Siew-Eng Choon3, A. David Burden4, Christopher E.M. Grifﬁths5,
Alexander A. Navarini6, Eugene S. Tan7, Alan D. Irvine8,9, Annamari Ranki10, Takeshi Ogo11, Gabriela Petrof2,
Satveer K. Mahil1, Michael Duckworth2, Michael H. Allen2, Pasquale Vito12, Richard C. Trembath13,
John McGrath2, Catherine H. Smith2, Francesca Capon1,14 and Jonathan N. Barker2,14
Caspase recruitment family member 14 (CARD14, also known as CARMA2), is a scaffold protein that mediates
NF-κB signal transduction in skin keratinocytes. Gain-of-function CARD14 mutations have been documented in
familial forms of psoriasis vulgaris (PV) and pityriasis rubra pilaris (PRP). More recent investigations have also
implicated CARD14 in the pathogenesis of pustular psoriasis. Follow-up studies, however, have been limited, so
that it is not clear to what extent CARD14 alleles account for the above conditions. Here, we sought to address
this question by carrying out a systematic CARD14 analysis in an extended patient cohort (n= 416). We observed
no disease alleles in subjects with familial PV (n= 159), erythrodermic psoriasis (n= 23), acral pustular psoriasis
(n= 100), or sporadic PRP (n= 29). Conversely, our analysis of 105 individuals with generalized pustular psoriasis
(GPP) identiﬁed a low-frequency variant (p.Asp176His) that causes constitutive CARD14 oligomerization and
shows a signiﬁcant association with GPP in Asian populations (P= 8.4× 10− 5; odds ratio= 6.4). These data indicate
that the analysis of CARD14 mutations could help stratify pustular psoriasis cohorts but would be mostly
uninformative in the context of psoriasis and sporadic PRP.
Journal of Investigative Dermatology (2015) 135, 2964–2970; doi:10.1038/jid.2015.288; published online 13 August 2015
INTRODUCTION
Caspase recruitment family member 14 (CARD14, also known
as CARMA2) is a conserved scaffold protein that mediates
TRAF2-dependent activation of NF-κB signaling (Scudiero
et al., 2011). The gene is most prominently expressed in
the skin, as transcript levels are high in keratinocytes and
moderately abundant in dermal endothelial cells (Fuchs-Telem
et al., 2012; Harden et al., 2014). Conversely, CARD14 mRNA
is virtually undetectable in T-lymphocytes and monocytes,
suggesting that the gene is speciﬁcally required for the
maintenance of skin immune homeostasis (Fuchs-Telem
et al., 2012; Harden et al., 2014). In keeping with this
notion, gain-of-function CARD14 mutations have been linked
to a number of inﬂammatory dermatoses.
Disease alleles resulting in enhanced NF-κB signaling were
ﬁrst described in two multi-generation pedigrees where
psoriasis vulgaris (PV) segregated as an autosomal dominant
trait (Jordan et al., 2012b). Three further activating mutations
were subsequently reported in individuals with familial
pityriasis rubra pilaris (PRP), a papulosquamous condition
phenotypically related to psoriasis (Fuchs-Telem et al., 2012).
Finally, the analysis of a small Japanese resource identiﬁed
a tentative association between a CARD14 variant
(p.Asp176His) and a generalized pustular psoriasis (GPP), a
rare neutrophilic dermatosis that often presents with systemic
upset and concurrent PV (Sugiura et al., 2014).
Of note, the follow-up to the ﬁndings originally obtained in
familial PV has been very limited, with a single survey of
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seven North-African pedigrees published in the literature
(Ammar et al., 2013). Likewise, studies of CARD14 in
PRP have mostly been restricted to cohorts recruited in the
Middle East (Eytan et al., 2014), and the association between
p.Asp176His and generalized pustular psoriasis has yet to be
validated, as it was only supported by marginal statistical
signiﬁcance. Thus, large gaps remain in our understanding of
the phenotypes that are caused by CARD14 mutations, and it
is not clear whether the genetic analysis of this locus might
aid disease stratiﬁcation.
Here, we have sought to address this issue by investigating
an extended and an ethnically diverse patient resource.
We found that CARD14 alleles are unlikely to account for a
signiﬁcant proportion of familial PV or sporadic PRP cases.
Conversely, we demonstrated that the p.Asp176His variant
has a substantial impact on protein function and is strongly
associated with generalized pustular psoriasis in the Chinese
and Japanese populations.
RESULTS
CARD14 mutations do not have a signiﬁcant role in the
pathogenesis of familial PV, sporadic PRP, or acral pustular
psoriasis
As all CARD14 mutations described to date cluster to exons 3
and 4 (Fuchs-Telem et al., 2012; Jordan et al., 2012b; Eytan
et al., 2014; Sugiura et al., 2014), we initially focused
our genetic screening on this region. We sequenced the two
exons in a total of 416 patients, affected by acral pustular
psoriasis (APP; n=100), erythrodermic psoriasis (n= 23),
familial PV (n= 159), GPP (n= 105), or PRP (n= 29)
(Table 1, Supplementary Table 1 online). Importantly, our
calculations showed that all data sets had adequate power
(480%) to detect mutations accounting for 45% of disease
cases (Figure 1). In fact, the power of the familial PV, APP, and
GPP samples exceeded 95% (Figure 1). This is in keeping
with previous analyses of the APP and GPP cohorts, which
allowed us to identify a number of low-frequency mutations
(Setta-Kaffetzi et al., 2013; Setta-Kaffetzi et al., 2014).
Despite the evidence for adequate power, we could not
detect any deleterious alleles among patients affected by APP,
familial PV, or erythrodermic psoriasis (Tables 2A and 2B). In
fact, the only coding change observed in these data sets was a
p.Ser200Asn substitution, which was identiﬁed in two cases
of APP and four patients affected by familial PV (Table 2A).
This variant was, however, classiﬁed as benign by multiple
pathogenicity prediction algorithms. Moreover, its frequency
in APP (1.0%) and familial PV subjects (1.25%) did not
exceed that observed in European controls (1.3%, according
to the data generated by the Exome Aggregation Consortium).
The screening of the PRP sample revealed a single
change with pathogenic potential (p.Gln136Lys; Table 2A).
However, this was observed in a patient who under-
went parallel investigations of the GJB4 gene to explore a
differential diagnosis of erythrokeratoderma. Given that a
damaging p.Cys169Trp change was identiﬁed in GJB4, it was




Acral pustular psoriasis1 100 34M, 66F North-European
Erythrodermic psoriasis 23 18M, 5F North-European
Familial psoriasis vulgaris 159 78M, 81F North-European
Generalised pustular
psoriasis
105 34M, 71F North-European
(n= 12 )
Chinese (n= 24 )
Malay (n=52)
Indian (n= 17)











Abbreviations: F, Female; M, Male.






















Figure 1. Power calculations. A binomial calculation calculator was used to estimate the power to detect CARD14 mutations accounting for variable proportions
of disease cases. This demonstrated that sequencing exons 3 and 4 in the various patient cohorts would have480% power to uncover mutations found in45%
of disease cases.
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not possible to reach a ﬁrm conclusion as to which variant
was causing the disease phenotype.
Importantly, sequencing of the entire CARD14 coding
region in a representative patient subset (n= 82; Supplemen-
tary Table 2 online) did not identify any additional changes
with deleterious potential. Thus, our ﬁndings indicate that
CARD14 disease alleles are unlikely to account for a signi-
ﬁcant proportion of familial PV, sporadic PRP, or APP cases.
The CARD14 p.Asp176His variant is associated with generalized
pustular psoriasis in the Chinese and Japanese populations
The analysis of the generalized pustular psoriasis resource
identiﬁed three unrelated subjects of Chinese descent, who
carried a deleterious p.Asp176His substitution (Figure 2a;
Table 2A; Supplementary Table 3 online). Of note, one of the
patients had inherited the variant from a maternal aunt, who
was also affected by GPP. Although the change occurs at low
frequency in the Chinese population, we found that it was
more common in GPP cases compared with controls (6.2%
vs. 1.0%, P= 0.03; Table 3). As these observations mirror
those previously reported in a small Japanese data set (Sugiura
et al., 2014), we undertook a meta-analysis of the two studies.
To maximize statistical power, we increased by 4-fold the size
of the Japanese control resource by obtaining frequency data
for an additional 322 individuals (104 subjects sequenced by
the 1000 Genomes Project and 218 screened in-house). This
validated the association with the p.Asp176His substitution
(P=0.008) and showed that the Japanese and Chinese data
sets were genetically homogeneous (I2:0%). The subsequent
meta-analysis of the two studies also demonstrated that the p.
Asp176His change confers a very substantial increase in
disease risk (odds ratio: 6.4; 95% conﬁdence interval: 2.5–
16.1; P= 8.4× 10−5).
As p.Asp176His occurs on the background of a single
haplotype in the Japanese population (Sugiura et al., 2014),
we typed four tagging single nucleotide polymorphisms in our
mutation bearing patients, in order to establish whether
they carried the same ancestral chromosome. We found that
three subjects were homozygous and one likely heterozygous
for the same intragenic haplotype that was described in the
Japanese individuals carrying the p.Asp176His variant
(Supplementary Table 4 online). Thus, our data strongly
support the notion that the spread of the mutation across East
Asia is the result of a founder effect.
Sequencing of the entire CARD14 coding region in a
representative patient subset (n= 15) did not uncover any
further disease alleles, indicating that the association with
GPP is speciﬁc to the p.Asp176His change.
Table 2A. Rare coding variants detected in the study resource







p.Met119Arg (novel) PRP (n= 1) Tolerated Benign Neutral Disease
Causing
Pathogenic Damaging NEUTRAL





p.Glu168Lys (novel) GPP (n= 1) Tolerated Benign Neutral Polymorphism Pathogenic Neutral NEUTRAL
p.Asp176His
(rs144475004)









Tolerated Benign Neutral Polymorphism Likely Benign Neutral NEUTRAL
p.Ala216Thr (novel) GPP (n= 1) Tolerated Benign Neutral Polymorphism Likely
Pathogenic
Neutral NEUTRAL
1Although the CADD algorithm does not return qualitative pathogenicity predictions, scores 415.0 are generally considered as evidence of pathogenicity.
The only variant that is likely to be disease causing (p.Asp176His) is highlighted in bold.
2Variants were classiﬁed as pathogenic if they were predicted to be deleterious by at least four algorithms.
Table 2B. Rare splicing variant detected in the study resource
Change (rs ID) Patient phenotype
Pathogenicity prediction
Max entropy SROOGLE Senepathy MutationTaster CADD score1 CONSENSUS2
c.2569+4T4C (rs146678380) APP (n=1) Neutral Neutral Neutral Disease Causing Neutral NEUTRAL
Abbreviations: APP, acral pustular psoriasis; GPP, generalized pustular psoriasis; PRP, pityriasis rubra pilaris; PV, psoriasis vulgaris.
1Although the CADD algorithm does not return qualitative pathogenicity predictions, scores 415.0 are generally considered as evidence of pathogenicity.
The only variant that is likely to be disease causing (p.Asp176His) is highlighted in bold.
2Variants were classiﬁed as pathogenic if they were predicted to be deleterious by at least four algorithms.
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The p.Asp176His variant is a deleterious allele associated with
constitutive CARD14 oligomerization
To investigate the functional consequences of the p.Asp176His
substitution, we ﬁrst used bioinformatics to assess its potential
effect on the coiled-coil (CC) domain encoded by exons 3
and 4. We found that the change from a negatively charged
aspartic acid to a basic histidine signiﬁcantly reduces the
likelihood of CC formation (Figure 2b). This effect is compar-
able with the predicted impact of p.Leu156Pro and
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Figure 2. The p.Asp176His substitution causes spontaneous CARD14 oligomerization. (a) Chromatogram showing the p.Asp176His (c.526G4C) change,
which is predicted to disrupt coiled-coil (CC) formation (b). (c) Western blotting of total cell lysates shows comparable amounts of wild-type and mutant
CARD14. (d and e) Western blotting and densitometric analysis of soluble proteins shows reduced accumulation of CC mutants (p.Glu138Ala, p.Pro156Leu,
p.Asp176His) compared with wild-type CARD14 and the non-CC mutant p.Gly117Ser. (f and g) Western blotting and densitometric analysis of insoluble proteins
shows enhanced aggregation of CC mutants compared with wild-type CARD14 and p.Gly117Ser. All densitometry data are expressed as mean± SD of at
least two independent experiments. Comparable results were obtained when the levels of soluble (or insoluble) protein were normalized to total CARD14,
rather than β-actin. *Po0.05; ***Po0.001; ****Po0.0001. WT, wild-type.
Table 3. Genetic analysis of the p.Asp176His variant
Allele counts (%)
Ethnicity Cases Controls P value
Japanese 4/42 (9.5%) 14/844 (1.7%) 0.008
Chinese1 3/48 (6.2%) 4/400 (1.0%) 0.030
Meta-analysis 8.4×10−5
1As the association analysis was carried out on unrelated cases, the aunt of
patient T014369 was excluded from the data set.
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associated with PRP and psoriasis (Fuchs-Telem et al., 2012;
Jordan et al., 2012b).
Of note, the CC domain of CARD11 (a well-characterized
CARD14 paralogue) keeps the protein in an inactive confor-
mation, which, in the absence of inﬂammatory stimuli,
precludes auto-oligomerization and downstream signal trans-
duction (Lamason et al., 2010). In fact, gain-of-function muta-
tions within the CC of CARD11 cause spontaneous protein
aggregation and constitutive activation of NF-κB signaling,
leading to the onset of diffuse large B-cell lymphoma (Lenz
et al., 2008).
To investigate the possibility that the p.Asp176His
substitution may also promote protein oligomerization, we
transfected HEK293 cells with wild-type or mutant FLAG-
CARD14 and monitored recombinant protein levels with an
anti-FLAG antibody. Although western blotting of whole-cell
extracts showed comparable transfection efﬁciencies for the
two constructs (Figure 2c), the analysis of soluble proteins
demonstrated that the p.Asp176His change was associated
with a signiﬁcant decrease in the levels of free CARD14 (Figure
2d and e). This suggested that the mutant protein was forming
insoluble oligomers. To validate this hypothesis, we used the
anti-FLAG antibody to analyze the insoluble fraction of the cell
extracts. As predicted, we found that CARD14 aggregates were
signiﬁcantly more abundant in the cells that had been
transfected with the p.Asp176His cDNA (Figure 2f and g).
Interestingly, a similar effect was noted for the constructs
harboring the p.Leu156Pro and p.Glu138Ala disease alleles
(Figure 2d, e, f, and g). Thus, our ﬁndings indicate that the
pathogenic potential of the p.Asp176His change is comparable
with that of previously validated mutations.
DISCUSSION
In the last few years, CARD14 mutations have been asso-
ciated with a range of inﬂammatory skin disorders, including
familial psoriasis and clinically related conditions such as PRP
and generalized pustular psoriasis (Fuchs-Telem et al., 2012;
Jordan et al., 2012b; Sugiura et al., 2014). Although these
ﬁndings have highlighted CARD14 as a key regulator of skin
immune homeostasis, their applicability to clinical practice
has been limited. Very little information is available on
mutation frequencies in different conditions or ethnic groups,
so that it is unclear whether CARD14 screening would aid the
diagnosis or stratiﬁcation of inﬂammatory dermatoses. Here,
we sought to address this issue by analyzing a sizeable and a
well-characterized patient resource, recruited in Europe and
East Asia.
We ﬁrst examined a familial PV cohort including 4150
unrelated cases. Despite the signiﬁcant power of this data set,
we could not identify previously unreported disease alleles or
detect any of the mutations reported in previous studies (Jordan
et al., 2012a; Jordan et al., 2012b). Although it could be argued
that our deﬁnition of the phenotype allowed the inclusion of
many affected sib-pairs who were unlikely to suffer from
monogenic psoriasis, our resource also comprised 51 families
with four or more affected individuals (Supplementary Table 1
online). Thus, our results indicate that Mendelian forms of
psoriasis are likely to be genetically heterogeneous, with
CARD14 mutations accounting for a small minority of cases.
The subsequent analysis of the PRP cohort generated
similarly negative results, validating the emerging notion that
CARD14 mutations do not contribute to sporadic forms of the
disease (Eytan et al., 2014). Although the idea that CARD14
has a role in the pathogenesis of PV and PRP is supported by
observations of gene overexpression in patient skin and by the
results of genome-wide association studies (Tsoi et al., 2012;
Eytan et al., 2014), our ﬁndings indicate that screening this
locus for deleterious mutations is unlikely to help the
stratiﬁcation of patient resources.
The analysis of the GPP data set demonstrated a signiﬁcant
association with a non-conservative amino acid substitution
(p.Asp176His) that is only found in Asian populations.
The functional characterization of this nucleotide change
indicated that it is likely to affect CC formation, leading to the
loss of CARD14 auto-inhibition and spontaneous protein
oligomerization. Although we did not formally demonstrate
that these abnormalities result in enhanced transcription of
NF-κB target genes, this outcome is supported by several lines
of evidence. First of all, it has been shown that CARD11
oligomerization levels strongly correlate with increased
NF-κB activation (Lenz et al., 2008). Second, the effect of
p.Asp176His on CC formation is comparable with that of
p.Leu156Pro and p.Glu138Ala, which have been extensively
characterized and linked to abnormal NF-κB signaling in vitro
and ex vivo (Fuchs-Telem et al., 2012; Jordan et al., 2012b;
Harden et al., 2014). Finally, a systematic analysis of rare
CARD14 variants has shown that overexpression of
p.Asp176His mutant constructs results in increased NF-κB
reporter activity (Jordan et al., 2012a). Thus, our ﬁndings
validate p.Asp176His as a deleterious gain-of-function allele.
Of interest, Mossner et al. (2015) have very recently
observed the p.Asp176His mutation in two APP cases
recruited in Estonia. As the p.Asp176His substitution was
not detected in any of the European data sets sequenced by
the 1000 Genomes Project, it is not surprising that the variant
did not appear in our APP cohort. In fact, its presence among
Estonian patients is likely to reﬂect the distinctive population
history of the Baltic countries. In this context, the analysis of
p.Asp176His in Asian data sets will be required to conﬁrm the
association with APP and provide further evidence for a
genetic overlap between generalized and localized pustular
psoriasis (Setta-Kaffetzi et al., 2013).
Although the evidence presented here strongly supports a
pathogenic role for p.Asp176His, no association with GPP
was observed in a recent analysis of a Han Chinese resource
(Qin et al., 2014). It is interesting, however, that none of the
cases that were examined had been screened for mutations in
IL36RN, the major genetic determinant of GPP (Onoufriadis
et al., 2011). Conversely, both our study and the analysis
carried out by Sugiura et al. (2014) were restricted to IL36RN-
negative cases. Thus, our results support the notion that the
sequential screening of disease genes will enhance the power
to detect pathogenic mutations and facilitate the stratiﬁcation
of GPP cohorts.
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MATERIALS AND METHODS
Subjects
This study was undertaken in accordance with the principles
of the Declaration of Helsinki and with the approval of the
ethics committees of all participating institutions. Patients affected
by PV, erythrodermic psoriasis, GPP, and APP (including both
Acrodermatitis Continua of Hallopeau and Palmar Plantar Pustulosis)
were ascertained as described elsewhere (Berki et al., 2014; Hussain
et al., 2015). PRP was diagnosed on the basis of established criteria
(Judge et al., 2004). All patients with pustular psoriasis had been
previously screened for IL36RN and AP1S3 mutations, so as to
exclude any subjects carrying disease alleles at known loci
(Onoufriadis et al., 2011; Setta-Kaffetzi et al., 2014). Individuals
who were affected by PV and had at least one ﬁrst-degree relative
with the same disease were considered cases of familial PV
(Supplementary Table 1 online). The demographics of the various
patient cohorts are summarized in Table 1.
Allele frequency data for 208 unrelated Chinese controls were
initially collated from the 1,000 Genome Project (CHB and CHS data
sets) (Abecasis et al., 2012). To match the genetic make-up of
cases, eight individuals with IL36RN mutations were subsequently
excluded from the association analysis. Allele frequency data for
422 independent Japanese controls were obtained from the 1,000
Genome Project (JPT data set, n= 104), the work published by
Sugiura et al. (n= 100) (Sugiura et al., 2014), and from the analysis of
218 healthy individuals, recruited at the National Cerebral and
Cardiovascular Center in Osaka (Japan) and genotyped in house by
Sanger Sequencing. None of the above individuals carried IL36RN
mutations. Allele frequency data for the European population were
obtained by mining the data generated from the Exome Aggregation
Consortium (http://exac.broadinstitute.org/).
All study participants granted their written informed consent.
Sanger sequencing and pathogenicity predictions
Primers were designed to amplify all CARD14 coding exons
and exon–intron junctions, as well as the genomic regions
spanning haplotype tagging single nucleotide polymorphisms
(Supplementary Table 5 online). Sequenced PCR products were
loaded on an ABI3730xl DNA Analyzer (Applied Biosystems,
Waltham, MA), and nucleotide changes were detected using
Sequencher 4.10.1 (Gene Codes Corporation, Ann Arbor, MI). The
pathogenic potential of non-synonymous sequence variants occur-
ring with a minor allele frequency o2% was assessed with the
following programs: SIFT (Kumar et al., 2009), PolyPhen-2 (Adzhubei
et al., 2013), PROVEAN (Choi et al., 2012), MutationTaster (Schwarz
et al., 2010), CADD (Kircher et al., 2014), Align GVGD (Mathe et al.,
2006), SROOGLE (which was also used to compute Senepathy
scores) (Schwartz et al., 2009), and MaxEntScan (Yeo and Burge,
2004). The impact of damaging nucleotide changes on CC
domains was further investigated with the NCOILS 1.0 software
(Lupas et al., 1991).
Site-directed mutagenesis, cell culture, and transfection
The previously described CARMA2-sh construct (Scudiero et al.,
2011) was used as a template for site-directed mutagenesis, as it
encodes the CARD14 isoform with the highest expression in the skin
(Jordan et al., 2012b). Reactions were prepared using the
QuikChange Lightning Site Directed mutagenesis Kit (Agilent, Santa
Clara, CA) and the primers listed in Supplementary Table 6 online.
The integrity of all constructs was veriﬁed by Sanger sequencing of
the CARD14/CARMA2 coding region, FLAG tag, CMV promoter, and
BGH poly-adenylation signal. HEK293 cells were grown in DMEM
and supplemented with 1% penicillin/streptomycin and 10% fetal
calf serum (all from Life Technologies, Carlsbad, CA). Cells were
seeded on 12-well plates at a concentration of 2.5× 105 per ml and
transfected with the indicated constructs, using Lipofectamine 2000
(Life Technologies). All cultures were harvested 48 hours after
transfection.
Western blotting and densitometry
Whole-cell protein extracts were prepared by treating cells with a
denaturing lysis buffer (5% SDS, 200Mm Tris-HCl pH 6.8, 1 mM
EDTA, 1.5% β-Mercaptoethanol, 8M Urea, and 1× Complete
Protease Inhibitor Cocktail (Roche, Basel, Switzerland)). For the
analysis of the soluble and insoluble fractions, cells were initially
incubated with a non-denaturing buffer (50 mM Tris-HCl pH 7.4,
50mM NaCl, 5 mM EDTA, 10% Glycerol, 1% NP40, and 1×
Complete Protease Inhibitor Cocktail)and centrifuged for 15minutes
at 13,000 r.p.m., at 4 °C. The supernatant was then stored as a
soluble fraction, whereas the pellets containing the insoluble protein
aggregates were lysed with the denaturing lysis buffer. Following
PAGE and transfer to nitrocellulose membranes, blots were probed
with 1:2,500 mouse monoclonal anti-FLAG (Sigma-Aldrich, St Louis,
MO) and 1:1,000 rabbit polyclonal anti β-actin (Cell Signaling
Technology, Beverly, MA) antibodies. Autoradiography ﬁlms were
scanned, and densitometric analysis was undertaken with the Image J
software (Schneider et al., 2012).
Statistical analyses
Power calculations were implemented with the binomial
probability calculator available at stattrek.com/online-calculator/
binomial.aspx. The frequency of the p.Asp176His substitution
was compared in cases versus controls with Fisher’s exact test.
The meta-analysis of two association studies was undertaken by
using the RevMan 5.2 software (Cochrane Collaboration T, 2012) to
calculate a weighted pooled odds ratio and Z score. The
densitometry data were analyzed with GraphPad Prism 6.0
(GraphPad Software, La Jolla, CA) by one-way analysis of variance
followed by the Dunnett’s post-test. P valueso0.05 were considered
statistically signiﬁcant.
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